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“A person with a new idea is a crank until the idea succeeds.”
Mark Twain
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Abstract
Making sense out of data is one of the biggest challenges of our time. With the emergence of
technologies such as the Internet, sensor networks or deep genome sequencing, a true data explosion
has been unleashed that affects all fields of science and our everyday life. Recent breakthroughs, such
as self-driven cars or champion-level Go player programs, have demonstrated the potential benefits
from exploiting data, mostly in well-defined supervised tasks. However, we have barely started to
actually explore and truly understand data.
In fact, data holds valuable information for answering most important questions for humanity:
How does aging impact our physical capabilities? What are the underlying mechanisms of cancer?
Which factors make countries wealthier than others? Most of these questions cannot be stated as
well-defined supervised problems, and might benefit enormously from multidisciplinary research
efforts involving easy-to-interpret models and rigorous data exploratory analyses. Efficient data ex-
ploration might lead to life-changing scientific discoveries, which can later be turned into a more im-
pactful exploitation phase, to put forward more informed policy recommendations, decision-making
systems, medical protocols or improved models for highly accurate predictions.
This thesis proposes tailored Bayesian nonparametric (BNP) models to solve specific data ex-
ploratory tasks across different scientific areas including sport sciences, cancer research, and eco-
nomics. We resort to BNP approaches to facilitate the discovery of unexpected hidden patterns
within data. BNP models place a prior distribution over an infinite-dimensional parameter space,
which makes them particularly useful in probabilistic models where the number of hidden param-
eters is unknown a priori. Under this prior distribution, the posterior distribution of the hidden pa-
rameters given the data will assign high probability mass to those configurations that best explain the
observations. Hence, inference over the hidden variables can be performed using standard Bayesian
inference techniques, therefore avoiding expensive model selection steps.
This thesis is application-focused and highly multidisciplinary. More precisely, we propose an
automatic grading system for sportive competitions to compare athletic performance regardless of
age, gender and environmental aspects; we develop BNP models to perform genetic association
and biomarker discovery in cancer research, either using genetic information and Electronic Health
Records or clinical trial data; finally, we present a flexible infinite latent factor model of international
trade data to understand the underlying economic structure of countries and their evolution over time.
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Resumen
Uno de los principales desafı´os de nuestro tiempo es encontrar sentido dentro de los datos. Con
la aparicio´n de tecnologı´as como Internet, redes de sensores, o me´todos de secuenciacio´n profunda
del genoma, una verdadera explosio´n digital se ha visto desencadenada, afectando todos los campos
cientı´ficos, ası´ como nuestra vida diaria. Logros recientes como pueden ser los coches auto-dirigidos
o programas que ganan a los seres humanes al milenario juego del Go, han demostrado con creces
los posibles beneficios que podemos obtener de la explotacio´n de datos, mayoritariamente en tareas
supervisadas bien definidas. No obstante, apenas hemos empezado con la exploracio´n de datos y su
verdadero entendimiento.
En verdad, los datos encierran informacio´n muy valiosa para responder a muchas de las pregun-
tas ma´s importantes para la humanidad: ¿Co´mo afecta el envejecimiento a nuestras aptitudes fı´sicas?
¿Cua´les son los mecanismos subyacientes del cancer? ¿Que´ factores explican la riqueza de ciertos
paı´ses frente a otros? Si bien la mayorı´a de estas preguntas no pueden formularse como proble-
mas supervisados bien definidos, e´stas pueden ser abordadas mediante esfuerzos de investigacio´n
multidisciplinar que involucren modelos fa´ciles de interpretar y ana´lisis exploratorios rigurosos. Ex-
plorar los datos de manera eficiente abre potencialmente la puerta a un sinnu´mero de descubrimientos
cientı´ficos en diversas a´reas con impacto real en nuestras vidas, descubrimientos que a su vez pueden
llevarnos a una mejor explotacio´n de los datos, resultando en recomendaciones polı´ticas adecuadas,
sistemas precisos de toma de decisio´n, protocolos me´dicos optimizados o modelos con mejores ca-
pacidades predictivas.
Esta tesis propone modelos Bayesianos no-parame´tricos (BNP) adecuados para la resolucio´n es-
pecı´fica de tareas explorativas de los datos en diversos a´mbitos cientı´ficos incluyendo ciencias del
deporte, investigacio´n contra el ca´ncer, o economı´a. Recurrimos a un planteamiento BNP para fa-
cilitar el descubrimiento de patrones ocultos inesperados subyacentes en los datos. Los modelos
BNP definen una distribucio´n a priori sobre un espacio de para´metros de dimensio´n infinita, lo cual
los hace especialmente atractivos para enfoques probabilı´sticos donde el nu´mero de para´metros la-
tentes es en principio desconocido. Bajo dicha distribucio´n a priori, la distribucio´n a posteriori de
los para´metros ocultos dados los datos asignara´ mayor probabilidad a aquellas configuraciones que
mejor explican las observaciones. De esta manera, la inferencia sobre el espacio de variables ocultas
puede realizarse mediante te´cnicas esta´ndar de inferencia Bayesiana, evitando el proceso de seleccio´n
de modelos.
xiii
Esta tesis se centra en el a´mbito de las aplicaciones, y es de naturaleza multidisciplinar. En
concreto, proponemos un sistema de gradacio´n automa´tica para comparar el rendimiento deportivo
de atletas independientemente de su edad o ge´nero, ası´ como de otros factores del entorno. Desar-
rollamos modelos BNP para descubrir asociaciones gene´ticas y biomarcadores dentro de la investi-
gacio´n contra el ca´ncer, ya sea contrastando informacio´n gene´tica con la historia clı´nica electro´nica
de los pacientes, o utilizando datos de ensayos clı´nicos; finalmente, presentamos un modelo flexi-
ble de factores latentes infinito para datos de comercio internacional, con el objetivo de entender la
estructura econo´mica de los distintos paı´ses y su correspondiente evolucio´n a lo largo del tiempo.
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1
Introduction
1.1 Motivation
We are living an exciting new era of science characterized by massive amounts of data. Every second,
2.9M emails are sent, 73 products are ordered on Amazon, and 20 minutes of video are uploaded
to Youtube.1 According to IBM, healthcare data double every 24 hours, from which around 80% is
unstructured, waiting to be analyzed [166]. Recent advances in the field of deep learning have proved
efficient in exploiting such huge amounts of data, bringing solutions to well-defined supervised tasks.
Nonetheless, we are still far from getting the utmost out of data, specially in unsupervised scenarios,
by exploring it and extracting valuable insights from reality so far unknown.
This is specially manifest in the field of medicine: although tons of data are available for each
patient, most diagnoses and treatments still remain untailored to the needs of each individual. A much
bigger gain might be expected if we manage to turn data into meaningful, interpretable knowledge
first. This thesis contributes to this endeavor by focusing on probabilistic methods and inference
algorithms for data exploration.
1Source: http://www.globaldots.com/big-data-promise-hype-challenges/
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CHAPTER 1. INTRODUCTION
Three important obstacles need to be addressed in order to extract valuable information from
data. First of all, relationships between observations are typically highly complex. Take for instance
biological mechanisms causing a certain disease or sociological factors affecting in a presidential
election. To analyze such data, we need flexible and easy-to-interpret models able to extract the es-
sential information. Here, we focus on probabilistic graphical models, i.e., generative models which
represent the input distribution of the data using latent variables. The use of latent variables allow
us to abstract from reality and to understand statistical dependencies in an easy manner.2 Graphical
models are thus particularly suitable for collaboration across fields, as they allow for a bi-directional
communication between domain experts and machine learning researchers, e.g., for model design
and validation. These models have additionally the potential of delivering previously known infor-
mation together with novel aspects of the data that were so far unknown. If a model is interpretable,
that is, if a model can provide explanations or easy-to-understand information concerning its behav-
ior, researchers will trust more its predictions [104, 175].
The second problem refers to having small data within big data. Observations never have the ex-
act same contextual properties. In healthcare applications, disease evolution or drug effects strongly
depend on individual characteristics, to the point that most major drugs are known to be effective
in only 25 to 60 percent of patients, and more than 2 million cases of adverse drug reactions occur
annually in the United States, including 100,000 deaths [218]. Small data also appear in the shape
of outliers (e.g., patients suffering from rare diseases), or just due to missing observations. Fur-
thermore, privacy and ethical concerns might difficult gathering huge amounts of data, e.g., we will
never be able to run clinical trials of arbitrary sizes. Bayesian approaches address this issue through
integration to compute posterior estimates, eliminate nuisance variables or missing data, and average
models for prediction [11]. Within this framework, dependency structures can be incorporated to
efficiently share information across varying observations.
The last challenge is that the number and complexity of statistical hypotheses grow with data,
due to the so-called “curse of dimensionality” [18]. As a consequence, most exploratory studies in
empirical sciences are not easy to replicate, once simulation conditions are slightly different. The
growing number of statistical hypotheses might lead to a rising amount of false positives, e.g., artifact
discoveries due to either chance or undesirable confounding factors. To address this problem, ma-
chine learning approaches should be able to generalize to unseen observations, without over-fitting.
We may address this problem by incorporating tools from classical statistical methods, including
assessment of statistical significance, multiple hypothesis testing or confounder correction [216].
2Synthetic samples can also be generated to validate the model and analyze its properties.
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1.2 Scientific Aims and Perspective
This doctoral thesis deals with Bayesian nonparametric (BNP) models for data exploration. The
Bayesian framework is particularly appealing in its ability to capture uncertainty of inferred parame-
ters and avoid overfitting. Moreover, the nonparametric property refers to the ability of such models
to automatically adapt their complexity depending on the amount of available data [61]. The number
of latent variables is potentially unbounded, a priori unknown, and is also learned from the data.
Another interesting aspect concerns the discrete nature of the random measures underlying BNP
models, which make them sparse, and thus, naturally easy to interpret.
Ultimately, our objective is to develop BNP models and their corresponding inference algorithms
to help experts in other fields get valuable insights from their data, in applications that have a strong
impact on society. This research is application-driven, in the sense that we first understand the
needs and challenges in a certain field and then try to give solutions through model abstractions. To
reach that goal, we might need to improve existing models or design new ones, together with their
respective inference algorithms. These resulting models might then generalize to other interesting
applications which we did not consider in a first place. In short, we find inspiration for new models
and inference approaches in real important problems for society.
Data exploratory purposes. Data exploration comes in different forms in the machine learning
community: Principal component analysis and factor analysis are linear methods that provide non-
sparse solutions with strong Gaussianity assumptions. Local-linear embedding [181], Isomap [205]
and Gaussian process latent variable models [111] learn non-linear manifolds in high dimensional
spaces with non-sparse features; non-negative matrix factorization [91] provides a low dimensional
sparse representation of the data. Also, BNP models can be used for clustering [50] and sparse feature
analysis [72], in which the underlying latent dimension is unknown. There are many applications
that have benefited from data exploratory analyses, including market basket analysis [38], computer
vision [220], genomics [27, 107, 28], social sciences [132], and psychiatry [182].
Although the flexibility of BNP models makes them particularly attractive for experts in other
fields, obtaining interpretable results might be an even stronger requirement. In this thesis, we refer
to interpretability as the “ability to explain or to present novel information in understandable terms
to a human” [41]. Most BNP models are described as general priors [188, 125, 72] that might not
give easy-to-interpret solutions if applied blindly, even if they provide accurate predictions. In order
to additionally obtain interpretable results, e.g., meaningful structures for data exploration, we need
to specify the priors and likelihood in a way that points towards the sought explanation by including
11
CHAPTER 1. INTRODUCTION
our prior knowledge and generative assumptions of the data in an adequate manner.
In this way, the first insights of the obtained results should not be foreign to us. This makes
models trustworthy for experts in other fields that do not know about machine learning or statistics,
so other conclusions that were not common knowledge can be taken as plausible. At this stage we are
able to formulate hypotheses that can be tested with future data and can provide previously unknown
insights about the given problem. Such procedure avoids the frequent black-box flavor found in
other methods, facilitating collaboration across fields. Examples of such interdisciplinary efforts
using BNP models can be found in psychiatry [182], genetics [222], biostatistics [46], computer
vision [64], econometry [144] or musicology [174]. In this thesis, we are interested in practical data
exploration applications of BNP models that specially benefit from their flexibility. This thesis puts
special focus on model design and encoding of appropriate assumptions, which are crucial to bring
an interpretable solution for each problem at hand.
1.3 Contributions
This thesis is multidisciplinary, bringing novel solutions to deal with real-world problems in the fields
of sport sciences, cancer research and economics. Throughout this thesis, we address the following
points:
(A) improve model interpretability via prior and likelihood design, e.g., imposing structure or spar-
sity in the solution space.
(B) increase model flexibility and ability to share information across samples through the imple-
mentation of dependent models.
(C) get replicable results by combining Bayesian approaches with classical statistical methods.
The contributions of this thesis have also been or will be partially published in [159, 157, 160,
154, 158, 210, 208, 161]. These correspond to extensions of existing BNP models across diverse
research areas, with application to the problems of fairness in athletic competitions, biomarker and
genetic association discovery in cancer research, and analysis of the economic structure of countries
via their export portfolios.3 We summarize our contributions below.
Fairness in Athletic Competitions
In order to study the impact of age, gender and environment on runner performance, we present
a dependent infinite mixture model for density estimation of stratified data [159]. The novelty of
3Our contribution in [156] is out of scope of this thesis.
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this work relies not only on the application, but also on the technical steps (non-trivial structural as-
sumptions) to obtain interpretable results and share information across athletes. Our analysis delivers
valuable information for sport science experts, as well as a fair system to compare runners, regardless
of their age and gender, that could be directly incorporated in regular sport events. The presented
methodology is general to compare group densities in applications having a certain evolutionary or
competitive trait, such as in pediatrics (e.g., comparison of children population according to weight
and height), social sciences (e.g., analysis of gender impact on actual salary income across coun-
tries), or epistemology (e.g., assessment of environment effect on scientific output). This work has
additionally led to the development of computational structures using Hadoop and Spark to speed
up inference [155],4 and opened a new research line on non-linear regression problems [157], as
described in Section 3.6.
Meaningful Discoveries in Cancer Research
Drug effect assessment through biomarker discovery in clinical trials. We propose a general
BNP approach for biomarker discovery and subpopulation characterization in clinical trials. Our
model has been used to help expert oncologists understand conditions for drug effectiveness. It
also incorporates statistical techniques to account for false positives, and it separates drug effects
from natural prognostic factors by sharing information among patients in a structured manner. We
demonstrate the usefulness of our novel approach on a randomized phase II case-control study of a
cutting-edge immunotherapy treatment against liver cancer, in collaboration with Roche Diagnostics.
Not only did our method find already well-known statistically significant biomarkers, but it also
discovered new ones that could not be found with previous approaches, opening the door to the
development of a new drug for a subgroup of liver cancer patients [158]. The proposed model is
an extension of the general latent feature model [210], for which we have also contributed with
further empirical validation analyses [208] and a user-friendly C++ software release with wrappers
for Matlab and Python (an R package is currently under development) on Github.5
Finding genetic associations with clinical features for enhanced diagnosis. In order to under-
stand cancer mechanisms and their interactions with patients’ phenotypes and environment, we an-
alyze cancer-patients data from the Memorial Sloan-Kettering Cancer Center in New York. The
database contains information from electronic health records and detailed genetic data obtained
through deep genome sequencing. We look for associations between gene mutations and clinical
4This research line is out of scope of this thesis.
5Available at https://github.com/ivaleraM/GLFM.
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features in cancer by first finding an appropriate nonparametric representation of the patient popu-
lation via latent features, and then performing classical statistical tests on subsequent partitions of
patients. The proposed BNP model allows for a joint analysis of multiple cancer types, and is able
to deal with phenotype heterogeneity, small cohort size, epistatic and pleiotropic effects6, as inspired
by [154]. The proposed model is compared against classical alternatives, including linear mixed
models where clinical features were tested for associations against the mutated genes [160].
Analysis of World Trade
Finally, we propose a BNP approach to analyze international trade. Our objective is to understand
economic growth of countries, i.e., which factors make countries wealthier than others, and how
these countries acquire such capabilities over time, with the ultimate goal of issuing economic policy
recommendations. We first propose a flexible scheme for the static scenario, that incorporates relaxed
prior assumptions on the activation of features in the latent space, in agreement with reality [161].
The relaxed prior allows each country to exhibit wider variations in the number of active features (re-
flecting rich vs poor countries), as well as more flexible a priori distributions in the global activation
of features (accounting for simple vs specific capabilities). Second, we propose a dynamic extension
to analyze the temporal evolution of countries’ economies over time. We incorporate a Markovian
structure over the features to account for time-varying feature activations for each country.
1.4 Organization
The remainder of this thesis is organized as follows. In Chapter 2 reviews the basics behind BNP
models. In particular, we introduce the stochastic processes that will be used as building blocks along
this thesis: the Dirichlet process (DP), and the Beta process (BP). The rest of the chapters are devoted
to our contributions. Chapter 3 describes a dependent BNP model for marathon modeling. Chapter 4
and 5 develop BNP approaches for data exploratory analyses in the context of personalized medicine
for cancer research. In Chapter 4, we focus on the clinical trials scenario, and bring a powerful
tool to characterize subpopulations and identify valuable biomarkers to help expert oncologists in
their research. In Chapter 5, we propose a joint hierarchical model for both clinical records and
genetic data, in order to identify novel genetic associations with clinical features across different
types of cancer. Chapter 6 develops static and dynamic Poisson factor analysis (PFA) schemes to
understand the economic structure of countries via international trade. Finally, Chapter 7 is devoted
to the conclusions and future lines of research.
6This work received a Spotlight Talk Award at the 9th Annual Machine Learning Symposium in New York, 2015.
14
2
Overview of Bayesian Nonparametrics
2.1 Introduction
Data in the real world typically involves some source of uncertainty. This uncertainty may come
from noisy measurements, incomplete information, or from the finite size of datasets [62]. Proba-
bility theory has proven to be effective for understanding such data in terms of degrees of belief 1,
establishing a consistent framework for quantification and manipulation of uncertainty. Models that
incorporate random variables and probability distributions to quantify degrees of certainty are called
probabilistic Bayesian models, and are at the foundation of pattern recognition. Such models con-
stitute an important tool in all areas of science as a way to develop statistical algorithms for making
predictions and learning hidden structures from data [18].
Bayesian approaches consider model parameters as unobserved random variables instead of de-
terministic values. The Bayesian paradigm allows to incorporate a priori knowledge of the world and
desirable constraints over the solution space through the prior, as well as to account for uncertainty
in the estimation of model parameters [11]. Within Bayesian models, latent variable models consist
1An alternative interpretation of probability is the frequentist point of view, where the probability of an event corre-
sponds to the limit of its relative frequency in a large number of trials.
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of hidden and observed variables, where the hidden variables encode underlying patterns in our data
(typical applications include clustering, feature modeling, and topic modeling). Such models have
had a major impact on numerous applied fields, including computational biology, economics, natural
language processing, social network analysis, and computer vision [20].
Latent variable models rely on the Bayes theorem. Let X design the observed data, and Θ be
the set of unobserved variables. The Bayes theorem provides an elegant way to relate data-based
evidence, encoded in the likelihood p(X|Θ) with prior assumptions on the latent variables via the
prior p(Θ). The Bayes theorem can be stated as:2
p(Θ|X) = p(X|Θ)p(Θ)
p(X)
, (2.1)
where p(Θ|X) is the posterior distribution, i.e., the conditional distribution of the latent variables
given the observed data, and p(X) is the evidence or marginal distribution of the data under this
model [18]. The posterior distribution can be used to explore, summarize, and form predictions
about the data [20]. When the number of observations tends to infinity, the likelihood term p(X|Θ)
dominates over the prior.3 In that respect, a prior can be understood as a “constraint” over the solution
space whose influence might become weaker the more data we see.
This thesis focuses on latent variable models developed according to the “Box’s loop” probabilis-
tic pipeline [20], illustrated in Figure 2.1. This is an iterative loop process for data analysis, which
consists of three fundamental stages: model formulation, inference, and model criticism. According
to this scheme, we should first formalize our assumptions into a simple model to fit knowledge do-
main of the problem at hand, including hidden structure which we believe exists in the data. Second,
we can use an inference algorithm to approximate4 the posterior distribution and analyze the data
under the assumptions encoded through the priors and likelihood. Finally, we should assess whether
the analysis succeeds or fails, i.e., revise whether the model gives accurate predictions or insights
that are consistent with current expert knowledge, and repeat the cycle if required.
Why nonparametrics? Most machine learning problems consist in learning an appropriate fixed
set of parameters within a model class given the training data. Typically, practitioners fit several
models with a different number of parameters, and use a separate validation set to determine the
most adequate number of parameters. Determining appropriate model classes is referred to as model
2Note that the Bayes theorem is a general expression for any two random variables. We here further incorporate an
asymmetric interpretation of the theorem, which lies at the foundation of Bayesian statistics.
3This does not mean that the posterior distribution will be consistent, i.e., that its mean will tend to the true values.
Additional conditions would be necessary for this to hold.
4Computing the posterior analytically turns out to be intractable most of the time, so we need an approximation.
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Figure 2.1: Box’s loop probabilistic pipeline for research. First, we formalize the problem, and include
appropriate assumptions based on expert knowledge. Second, we perform inference to learn the posterior
distribution of the hidden variables. We can then use the posterior, i.e., apply the model, to make predictions
and explore the data. Third and last, we revise the model using expert knowledge, accounting for weaknesses
and strengths, eventually repeating the Box’s loop if necessary.
selection in the literature [18]. Model selection is of fundamental concern for machine learning
practitioners, not only for avoidance of over-fitting and under-fitting, but also for discovery of the
appropriate causes and structures underlying data. Some examples of model selection and adaptation
include: selecting the number of clusters in a clustering problem, the number of latent features
in a matrix factorization problem, or the complexity (degrees of freedom) of a certain function in
nonlinear regression.
Addressing model selection by fitting multiple models of varying complexity is computationally
expensive. Nonparametric models constitute an alternative approach where model complexity is also
learned from data. While parametric models are fully characterized by a fixed number of parameters,
the number of parameters in nonparametric models grows with the amount of training data [135].
Nonparametric approaches are memory-based, in the sense that the amount of stored information
into the model is proportional to the number of observations. For instance, the k-nearest neighbors
method is nonparametric in the sense that it classifies the unseen instance based on the k points in
the training set which are nearest to it (we need to store the whole training set for classification).5
Also, fitting a Gaussian mixture model (GMM) with a fixed number of Gaussians is a parametric
approach for density estimation. A nonparametric version would be the Parzen window estimator,
which centers a Gaussian at each observation, and hence uses one mean parameter per observa-
5Note that nonparametric refers to the nature of the method, it does not mean that the method has no parameters, e.g.,
the k-nearest neighbors has one parameter k.
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tion [18]. Nonparametric methods have become popular in classical (non-Bayesian) statistics [215].
Another well-known example is the support vector machine [33], which has been widely applied to
handle classification and regression problems. In model design, there is often a trade-off between
flexibility and computational/storage costs. An example of such is the use of inducing points in
the inference of Gaussian processes (GPs). Although a GP is a nonparametric prior over the space
of functions, inducing points play the role of “local summaries” of the function and help limit the
memory of the model, making it possible to scale inference to higher datasets [165].
2.2 Intuition behind Bayesian Nonparametric Models
Bayesian nonparametric (BNP) models made their debut in the 70s, with the seminal papers of Fer-
guson [53] and Antoniak [12] among others,6. Although mathematically elegant, inference was too
problematic at that time, so BNP models did not pick up much attention in the community until the
90s, thanks to the introduction of Markov chain Monte Carlo (MCMC) methods [59]. Around ten
years later, variational inference made its appearance in the field [102], and allowed BNP models
to further scale to higher amounts of data, making them even more popular in the 2010s [21, 42].
Recent advances in the field of deep learning have taken the main interest of the machine learning
community, putting BNP models in the background. Although powerful, the spread of BNP models
is still moderate, for computational complexity still remains an important drawback. Several lines of
research address this issue, both from the perspective of MCMC approaches (by including adaptive
subsampling or stochastic gradient dynamics) [11] or scaling up variational inference techniques via
noisy stochastic gradients [90].
BNP models combine the benefits of Bayesian methods with the flexibility of nonparametric
approaches [61]. Instead of specifying a closed-form model, BNP techniques place probability mass
on an infinite range of models and let the inference procedure select those configurations that best
fit the data, in order to provide competitive predictions or density estimations [143]. Thus, BNP
models provide a useful tool for problems in which the number of unknown hidden variables is itself
unknown and can be learned using standard Bayesian inference techniques. Given our prior beliefs,
the posterior in a parametric model is constrained to a closed family, whereas BNP models allow
for more flexible shapes in the posterior distribution. Although a BNP model is characterized by an
infinite-dimensional parameter space, only a finite subset of the available parameters is used for any
given finite dataset. This subset will generally grow with the dataset size.
6De Finetti’s theorem (which will be described later) dates from the 30s [35] but this was not fully exploited in the
context of BNP approaches until decades later.
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An illustrative example. In order to get a better intuition for BNP models, let us consider a finite
GMM and its non-parametric Bayesian counterpart. For simplicity, we will assume unknown mixture
means and known covariance matrix, e.g., Σ = σxI where I refers to the identity matrix. Let X =
[x1,x2, . . . ,xN ]
> be the input matrix for N input observations xn ∈ RD×1, where n = 1, . . . , N .
A finite GMM of K clusters assumes the following likelihood distribution:
p(x1,x2, . . . ,xN |Φ) =
K∑
k=1
pikN (µk, σxI), Φ = {(pik,µk)Kk=1}, (2.2)
where Φ refers to the set of hidden variables, µk is the k-th cluster parameter (mean vector), and
pik is the mixture weight for cluster k. Given X, our aim is to learn the distribution of Φ. Inferring
the joint posterior distribution p(Φ|X) directly is an intractable problem which cannot be solved
analytically. To address such issue, a common practice is to introduce an auxiliary cluster assignment
variable zn for each observation xn that indicates the mixture to which xn belongs, e.g., p(xn|zn) =
N (µzn , σxI). Equation 2.2 can then be rewritten as:
p(x1,x2, . . . ,xN |Φ) =
N∏
n=1
p(xn|zn,µ1:K), Φ = {(pik,µk)Kk=1, (zn)Nn=1}, (2.3)
If we now assume a prior distribution over Φ, we can write the complete joint probability as
p(x1,x2, . . . ,xN ,Φ) =
( N∏
n=1
p(xn|zn,µ1:K)p(zn|pik)
)( K∏
k=1
p(µk)
)
p(pi), (2.4)
and formulate a sequential generative process for X such that p(X|Φ) is given by (2.2) or (2.3),
pi ∼ Dirichlet(a1, . . . , aK) (2.5)
∀k = 1, . . . ,K
µk ∼ N (µ0,Σ0) (2.6)
∀n = 1, . . . , N
zn ∼ Categorical(pi) (2.7)
xn|zn ∼ N (µzn , σxI). (2.8)
pi refers to the vector of mixture weights [pi1, . . . , piK ], µ0, Σ0 and a = {a1, . . . , aK} are the model
hyperparameters, e.g. prior parameters for the distribution of latent variables, and the Categorical
19
CHAPTER 2. OVERVIEW OF BNP
Figure 2.2: Graphical representation for a ﬁnite GMM. Nodes in a circle are random variables, grey nodes
are observed ones, and white nodes are unobserved variables. Model (hyper)parameters are not circled. An
inﬁnite GMM has the same graphical representation but replacing k = 1 . . .∞.
distribution is equivalent to a Multinomial distribution with number of draws equal to one. In this
example, we have two types of latent variables: global variables (πk and μk for each k-th clus-
ter) and local variables (one cluster assignment zn for each observation xn). Figure 2.2 shows the
corresponding graphical representation for a ﬁnite GMM with K clusters.
In contrast, a non-parametric GMM allows for a potentially unbounded number of clusters K,
and can be obtained by using an inﬁnite-dimensional distribution over the parameter space, i.e.,
by replacing (2.5) and (2.6) jointly by a stochastic process called the Dirichlet process (DP). The
generative formulation in this case is given by:7
G =
∞∑
k=1
πkδμk ∼ DP(α,H) (2.9)
∀n = 1, . . . , N
θn ∼ G (2.10)
xn|θn ∼ N (θn, σxI), (2.11)
where θn is the observation-speciﬁc cluster mean vector corresponding to observation n (using the
previous cluster assignment variables, θn = μzn), and G is a random measure corresponding to a
realization of the DP which can be written as an inﬁnite sum of sticks or atoms of weights πk at
locations μk , where k = 1, . . . ,∞ and
∑∞
k=1 πk = 1. A DP is a stochastic process parameterized
by a concentration parameter α and base measure H (further details can be found in Section 2.3.1).
Figure 2.3 shows a draw example G ∼ DP(α,H), where H deﬁnes a distribution for the atom
locations, e.g., in our particular example H .= N (μ0,Σ0), and α plays the role of an “inverse
variance” parameter, such that small values of α result in fewer sticks with high weights, whereas
bigger values of α “spread” the probability mass all over, resulting in a bigger number of sticks with
7Formal deﬁnitions will be provided in Section 2.3, we here provide an intuition for introducing BNP models.
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Figure 2.3: A draw example G from a Dirichlet process. We only depict the sticks with highest weights,
although the number of sticks in inﬁnite. Drawing G is equivalent to independently drawing each μk ∼ H ,
and π from a certain stick-breaking process, which will be introduced in 2.3.1.
smaller weights. Given G, the generative process consists of sampling one local variable θn for each
data point xn. Since G is discrete with probability one, θn will take repeated values in proportion
to π, resulting in different clusters of observations. Even if the number of atoms in G is inﬁnite, a
dataset is ultimately ﬁnite, and thus, the number of non-empty clusters (locations μk for which ∃j
s.t. θj = μk) will be bounded. In a streaming application, sampling an observation-speciﬁc variable
θ∗ for a new observation x∗ could either return a cluster mean from which we have already sampled
before, or a completely new cluster with some probability πnew that is proportional to α.
Generally speaking, the central idea behind BNPs is the replacement of classical ﬁnite-dimensional
prior distributions with general stochastic processes, allowing for a potentially inﬁnite number of pa-
rameters, i.e., an open-ended number of degrees of freedom in the model [203]. Thus, BNP models
rely on random measures to induce an inﬁnite-dimensional distribution over the parameter space,
which we will deﬁne more rigorously in the next section.
2.3 Random Measures
A random measure M can be understood as a stochastic process indexed by a sigma algebra. Let
(Φ,FΦ) be a measurable space, where Φ is a set, and FΦ is a σ-algebra over Φ, for instance Φ is
the real line and FΦ refer to the Borel sets. A random measure deﬁnes a distribution over measures
on that measurable space; it corresponds to a collection of random variables M(A) ∈ [0,∞), one
for each set A ∈ FΦ. The expectation of a random measure is called the mean measure, which we
denote by ν(A) .= E[M(A)].
Completely randommeasures. A completely random measure (CRM) refers to a random measure
such that the masses G(A1), G(A2), . . . assigned to disjoint subsets A1, A2, . . . ∈ FΦ by a draw
G from the CRM are independent random variables [105]. The class of CRM includes important
stochastic processes such as the Beta process (BP), Gamma Process, Poisson Process, and the stable
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subordinator, which are often used as priors on a wide range of applications. A recent review of
CRMs and their applications can be found in [117]. A CRM on some space(Φ,FΦ) is characterized
by a positive Le´vy measure8 ν(dφ, dpi) on the product space Φ × R+, with associated product σ-
algebra FΦ⊗FR+ . CRMs have a useful representation in terms of Poisson processes on this product
space. Let Π = {(φk , pik) ∈ Φ × R+}1k=1 be a Poisson process on Φ × R+ whose rate measure
is given by the Le´vy measure ν(dφ, dpi). We denote this as Π ∼ PP(ν). A CRM can then be
represented as an infinite sum of weighted atoms or sticks,
G =
1∑
k=1
pikδ  k ∼ CRM(ν), (2.12)
where (φk)1k=1 is the set of atom locations, and (pik)
1
k=1 is the set of atom weights, which do not
necessarily sum to one. If
∑1
k=1 pik = 1 holds, this CRM is then referred to as normalized random
measure. Further details on CRMs can be found in [105].
Normalized random measures. Given a completely random measure G ∼ CRM(ν), we can
construct a normalized random measure P based on an underlying probability measure on Φ as
follows
P =
1∑
k=1
pik∑1
j =1 pij
δ
 k
∼ NRM(ν). (2.13)
The most common example of normalized random measure is the DP, which can be obtained by
normalization of the Gamma Process. Distributions over probability measures are of great impor-
tance in Bayesian statistics and machine learning, and normalized random measures have been used
in many applications including topic modeling, image segmentation, or monitoring of genetic popu-
lations [200, 204].
Exchangeability and De Finetti’s theorem Random measures are at the heart of BNP models via
the De Finetti’s theorem. Indeed, the theorem establishes a link between random measures and the
so-called exchangeability property of the data. An infinitely exchangeable sequence of observations
x1,x2, . . . ,xN is a sequence whose probability is invariant under finite permutations ρ of the first N
elements, for all N ∈ N [54], i.e.,
p(x1,x2, . . . ,xN ) = p(x
(1) ,x (2) , . . . ,x (n) ), ∀N ∈ N. (2.14)
8In probability theory, a Le´vy process is a stochastic process with independent, stationary increments, which can be
viewed as the continuous-time analog of a random walk [105].
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According to De Finetti’s theorem, any infinitely exchangeable sequence x1,x2, . . . ,xN can be writ-
ten as a mixture of i.i.d. samples as follows:
p(x1,x2, . . . ,xN ) =
∫
φ
N∏
n=1
Q(xn|φ)P (dφ), ∀N ∈ N, (2.15)
where Q(·|φ) is a family of conditional distributions and P is a random measure over Φ called the
De Finetti mixing measure (or directing measure).
For instance, if P is a discrete random measure drawn from a DP, and Q(·|φ) .= N (φ, σxI), we
recover the example of the Gaussian mixture model described in Section 2.2. Also, if P is a DP,
and Q(·|φ) is the discrete probability distribution described by the probability measure φ, we obtain
a distribution over exchangeable partitions known as the Chinese restaurant process (CRP) [6]. As
another example, if P is a BP and Q(·|φ) is a Bernoulli process, we obtain a distribution over ex-
changeable binary vectors; such construction defines the so-called Indian buffet process (IBP) [206].
In the following, we describe the two basic random measures that will be used along this thesis, to-
gether with their corresponding collapsed processes: the DP and the BP, giving rise to the CRP and
IBP respectively.
2.3.1 Dirichlet Process
The Dirichlet process (DP) is a stochastic process whose realizations are random infinite discrete
probability distributions [53]. Let G0 be a probability random measure on the measurable space
(Φ,FΦ). A random probability measure G over (Φ,FΦ) is said to be a DP if, for any finite measur-
able partition (A1, A2, . . . , Ar) of Φ, the random vector
(
G(A1), G(A2), . . . , G(Ar)
)
is distributed
as a finite-dimensional Dirichlet distribution of the form(
G(A1), G(A2), . . . , G(Ar)
)
∼ Dirichlet
(
αG0(A1), αG0(A2), . . . , αG0(Ar)
)
.
(2.16)
We then write G ∼ DP(α,G0), where G0 is referred to as the base measure (which is the expected
value of the process) and α ∈ R+ is the concentration parameter, which plays the role of an inverse
variance. Thus, the weak distribution of a DP, i.e., the set of all its finite-dimensional marginals
follow a Dirichlet distribution. The first two cumulants of the DP are given by
E[G(A)] = G0(A), and Var[G(A)] =
G0(A)(1−G0(A))
α+ 1
. (2.17)
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An explicit representation of a drawG  DP(α,G0) from a DP can be written as
G =
1X
k=1
pikδ  k , (2.18)
where pik are the atom weights, and φk 2  are atom locations defined in the parameter space [188].
The representation in (2.18) shows that draws from a DP are atomic (discrete) with probability one.
As illustrated in Section 2.2, Eq. 2.18 defines an infinite mixture model, i.e., a mixture model
with a countably infinite number of clusters. However, since the weights pik decrease exponentially
quickly, only a small number of clusters will be used to describe the data a priori. In fact, the
expected number of mixtures grows logarithmically with the number of observations. In the DP
mixture model, the actual number of clusters describing the data is not fixed, and can be automatically
inferred from the data using the usual Bayesian posterior inference framework. The DP mixture
model has been widely studied in the literature [12, 50, 124].
In the following, we describe other closely-related processes and explicit representations of the
DP, including the stick-breaking process and culinary metaphor of the CRP. Explicit representations
of stochastic processes directly describe a random draw from the stochastic process, rather than
describing its distribution.
Stick-Breaking Representation
The discrete random measureG in (2.18) is uniquely determined by two infinite sequences, fpi kgk2N
and fφ kgk2N . As stated in [188], the stick-breaking representation of the DP generates these two
sequences by drawing φk  G0 independently, and by drawing a set of auxiliary variables (vk )1k=1
such that
vk  Beta(α, 1), and pik = vk
k  1Y
‘=1
(1   v‘ ). (2.19)
Note that the sequence of atom weights fpi kgk2N constructed by (2.19) satisfies
P 1
k=1 pik = 1 with
probability one. We write   GEM(α) if  is a random probability measure over the positive
integers defined by 2.19 (GEM stands for the authors Griffiths, Engen and McCloskey) [153].
Figure 2.4 illustrates a sequential construction of the sequence fpi kgk2N . Starting with a stick of
unit length, at each iteration k = 1, 2, . . . ,1, a piece of relative length vk is “broken off” (relative
to the current length of the stick).
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1
. . .
k = 1
k = 2
k = 3
π1
π2
π3
Figure 2.4: Illustration of the stick-breaking construction for the DP. Drawing G ∼ DP(α,G0) is equiva-
lent to drawing π ∼ GEM(α) and φk ∼ G0, ∀k = 1, . . . ,∞ independently.
Chinese Restaurant Process
The CRP is typically found in the literature of DPs. This process deﬁnes a distribution on inﬁnite
partitions of the data [6], and takes the name from a standard culinary metaphor that vividly illustrates
how the DP operates [204]. In this metaphor, the atom locations φk are referred to as “dishes” in a
restaurant, and observations that are clustered together are viewed as customers sitting on the same
table, therefore eating from the same dish. In this generative process, customers enter the restaurant
one at a time, and they can either sit on an existing table, with probability proportional to the number
of previous customers that are already sitting on that table, or open a new table, with probability
proportional to α. In the latter case, they also sample a new dish from the prior, i.e., φknew ∼ H .
The implicit representation of the DP, which is closely-related to the CRP, is the Po´lya urn
scheme [19]. Let θ1, . . . , θN be a sequence of i.i.d. random variables distributed according toG. That
is, all variables θn are conditionally independent given G, and hence exchangeable. The successive
conditional distribution of θn given θ1, . . . , θn−1 takes the form
θn|θ1, . . . , θn−1, α,G0 ∼
i−1∑
=1
1
i− 1 + αδθ +
α
i− 1 + αG0. (2.20)
This expressions shows that θn has non-zero probability of being equal to one of the previous draws.
This leads to a “rich gets richer” effect, in which the more often a point is drawn, the more likely it is
to be drawn in the future. Let {φk}Kk=1 denote a sequence containing the unique values of variables
θn. By deﬁning mk as the number of values θn which are equal to φk, we can rewrite (2.20) as
θn|θ1, . . . , θn−1, α,G0 ∼
K∑
k=1
mk
i− 1 + αδφk +
α
i− 1 + αG0. (2.21)
Note that, despite this “richer gets richer” effect, the probability of θn being drawn from G0 (and
hence being different to all previous values) is always positive, and proportional to α.
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Eqs. 2.20 and 2.21 can be interpreted as a Po´lya urn model, in which a ball θn is associated with
a color φk. The balls are drawn from the urn equiprobably. When a ball is drawn, it is placed back
in the urn together with a new ball of the same color. In addition, with probability proportional to α,
a new atom (color) is created by drawing from G0, and a ball of that new color is added to the urn.
Alternatively, this process can also be illustrated using the same culinary metaphor as for the CRP.
According to this metaphor, we consider a Chinese restaurant with an inﬁnite number of tables. Each
θn corresponds to a customer who enters the restaurant, while the distinct values φk correspond to the
tables at which the customers sit. The n-th customer sits at the table φk with probability proportional
to the number of customers mk already seated there (in which case we set θn = φk), or sits at a new
table with probability proportional to α (therefore increasing K by one, drawing then φK ∼ G0, and
setting θn = φK).
Finally, let us explicitly relate the Po´lya urn scheme to the CRP. For that, let us now introduce
auxiliary random variables z1, z2, . . . ,∞ to indicate the assigned atom index of each random draw,
e.g., θn = φzn = φ

k. Compared to the Po´lya urn scheme in which we considered the conditional
distribution of the actual color of each new drawn ball, we now consider the color index indicating
that color. In other words, the CRP describes the sequential probability of each cluster assignment
variable,
zn|z1, . . . , zn−1, α,G0 ∼
K∑
k=1
mk
i− 1 + αδk +
α
i− 1 + αδknew . (2.22)
where k = 1, . . . ,K correspond to the atom indexes of the already observed clusters (colors that have
already appeared in the Po´lya urn model or non-empty tables in the CRP), and knew corresponds to a
completely new index. The iterative process in Eq. 2.22 deﬁnes a distribution over inﬁnite partitions.
See Figure 2.5 for a sketch of the CRP.
INDIAN BUFFET PROCESS
...
2
10
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93
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Figure 2: A partition induced by the Chinese restaurant process. Numbers indicate customers (ob-
jects), circles indicate tables (classes).
it is identical to the extended Polya urn scheme introduced by Blackwell and MacQueen 1973).
Imagine a restaurant with an infinite number of tables, each with an infinite number of seats.2 The
customers enter the restaurant one after another, and each choose a table at random. In the CRP
with parameter α, each customer chooses an occupied table with probability proportional to the
number of occupants, and chooses the next vacant table with probability proportional to α. For
example, Figure 2 shows the state of a restaurant after 10 customers have chosen tables using this
procedure. The first customer chooses the first table with probability αα = 1. The second customer
chooses the first table with probability 11+α , and the second table with probability
α
1+α . After the
second customer chooses the second table, the third customer chooses the first table with probability
1
2+α , the second table with probability
1
2+α , and the third table with probability
α
2+α . This process
continues until all customers have seats, defining a distribution over allocations of people to tables,
and, more generally, objects to classes. Extensions of the CRP and connections to other stochastic
processes are pursued in depth by Pitman (2002).
The distribution over partitions induced by the CRP is the same as that given in Equation 5. If
we assume an ordering on our N objects, then we can assign them to classes sequentially using the
method specified by the CRP, letting objects play the role of customers and classes play the role of
tables. The ith object would be assigned to the kth class with probability
P(ci = k|c1,c2, . . . ,ci−1) =
{ mk
i−1+α k ≤ K+
α
i−1+α k = K+1
where mk is the number of objects currently assigned to class k, and K+ is the number of classes for
which mk > 0. If all N objects are assigned to classes via this process, the probability of a partition
of objects c is that given in Equation 5. The CRP thus provides an intuitive means of specifying a
prior for infinite mixture models, as well as revealing that there is a simple sequential process by
which exchangeable class assignments can be generated.
2.4 Inference by Gibbs Sampling
Inference in an infinite mixture model is only slightly more complicated than inference in a mixture
model with a finite fixed number of classes The standard algorithm used for inference in infinite
Figure 2.5: Illustration of the Chinese restaurant process. Circles correspond to tables in the restaurant,
while numbers correspond to customers sitting on tables.
Hierarchical Dirichlet Process
The hierarchical Dirichlet process (HDP) is a well-known BNP prior which is useful for modeling
grouped data [204]. The HDP is a distribution over a set of random probability measures. The
process deﬁnes a set of random probability measures Gj (one for ach group of data), and a global
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random probability measureG. The global measure G is distributed as a DP with concentration
parameter γ and base probability measure G0, i.e., G ∼ DP(γ,G0). Hence, it can be written as
G =
∞∑
k=1
ρkδφk . (2.23)
The random measures Gj are conditionally independent given G, and they are distributed as DPs
with concentration parameter α and base probability measure G, i.e., Gj ∼ DP(α,G). Since G is
a discrete probability measure with support at the points {φk}k∈N , each probability measure Gj has
support on the same set of points and, therefore, we can write
Gj =
∞∑
k=1
pijkδφk . (2.24)
In other words, the atom weights9 pijk are different for each group j, but the atom locations are shared
across groups j.
Let (A1, A2, . . . , Ar) be a measurable partition of Φ. Since Gj ∼ DP(α,G) for each j, we have
by definition that the random vector
(
Gj(A1), Gj(A2), . . . , Gj(Ar)
)
is distributed as
(
Gj(A1), Gj(A2), . . . , Gj(Ar)
)
∼ Dirichlet
(
αG(A1), αG(A2), . . . , αG(Ar)
)
.
(2.25)
This will be useful to establish the connection between the weights pijk and the weights of the global
measure, ρk. Note that Eq. 2.24 defines an infinite mixture model for each group of observations j.
Furthermore, all groups share the atom locations φk (which do not depend on j), and they also share
statistical strength on the weights pijk.
2.3.2 Beta Process
A BP is a CRM which is often used as a Bayesian nonparametric prior for sparse collections of binary
features [206]. BPs are defined on an abstract measurable space (Φ,FΦ) and have the property that
the mass of any particular atom lies in the interval [0, 1]. The BP can be constructed based on a
random measure Π ∼ PP(ν) of a Poisson Process defined on (Φ × [0, 1],FΦ × F[0,1]), where ν
refers to its mean measure ν(dφ, dpi) = αpi−1(1 − pi)(α−1)dpiP (dφ) [145]. The first dimension of
9We use the notation pi = [pi1, pi2, . . .] to refer to the atom weights of the global probability measure G, and pij =
[pij1, pij2, . . .] to refer to the atom weights of each group-level probability measure Gj .
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the Poisson Process corresponds to atom location, and the second dimension to atom weight.
A draw G from a BP is a countably innite collection of weighted atoms in a space with
probability one, whose weights lie in the interval[0; 1] [117]. The distribution on these weights
is governed by two parameters (similarly to the DP): a concentration parameter > 0 and a base
measureH , and we writeG  BP( ; H ). But in contrast to the DP which provides a probability
measure, the total measureG() 6= 1 with probability one. Beta processes are often used in a
hierarchical prior as parameters for a Bernoulli process (BeP), which we will denote asX jG 
BeP(G) . When the BP is marginalized out, we obtain the IBP [206].
Stick-Breaking Construction
The stick-breaking construction of the BP in [202] is an useful representation for some inference al-
gorithms. In this construction, a sequence of independent Beta-distributed random variablesf vkgk2 N
are used to obtain the atom weightsf  kgk2 N. These are generated according to
vk  Beta( ; 1);  k =
kY
‘ =1
v‘ ; (2.26)
resulting in a decreasing sequence of probabilities k . This construction can be understood with the
stick-breaking process illustrated in Figure 2.6. Starting with a stick of length 1, at each iteration
k = 1 ; 2; : : :, a piece is broken off at a pointvk relative to the current length of the stick. The
variable k corresponds to the length of the stick just broken off , and the other piece of the stick is
discarded.
1
. . .
k = 1
k = 2
k = 3
⇡1 = v1
⇡2 = ⇡1v2
⇡3 = ⇡2v3
Figure 2.6:Illustration of the stick-breaking construction for the BP.
Indian Buffet Process
The IBP is a stochastic process dening a probability distribution over equivalence classes of sparse
binary matrices with a nite number of rows and an unbounded number of columns [72]. Although
the number of columns is potentially innite, only a nite number of those will contain non-zero
entries due to the nite nature of the observed data. Another important property of IBP-generated
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matrices is that they are exchangeable both in rows and columns. The IBP can be derived taking
the limit as K → ∞ of a finite binary matrix Z ∈ {0, 1}N×K , whose elements znk are distributed
according to:
pik ∼ Beta(α/K, 1), znk ∼ Bernoulli(pik), (2.27)
where pik is the probability of observing a non-zero value in column k, zn• is the n-th row for
sample n and z•k is the k-th column of matrix Z. We say that a feature k is active for sample n if
znk = 1. When K →∞, the above process is equivalent to the IBP. We denote:
Z ∼ IBP(α), (2.28)
where α is the concentration parameter controling the a priori activation probability of new features.
The expected number of active features per row is distributed according to Poisson(α) and the actual
number K of features with non-zero elements is distributed as Poisson
(
α ·∑Ni=1 (1i ) ). The param-
eter α has thus an effect on both, the a priori number of columns in Z and degree of sparseness of
the matrix, e.g., a bigger value for α results in a higher number of expected latent features and more
active features per row a priori.
As discussed previously, the underlying De Finetti’s representation of the IBP is a mixture of
BePs directed by a BP as follows:10
G ∼ BP(1, α,H) (2.29)
Zn· ∼ BeP(G), (2.30)
where G is the directing measure, and H is the probability base measure for the BP [206]. The IBP
can also be directly obtained by combining the previously described stick-breaking construction with
an infinite collection of Bernoulli-distributed random variables (one for each atom) as:
vk ∼ Beta(α, 1), pik =
k∏
i=1
vi,
znk ∼ Bernoulli(pik). (2.31)
Similarly to the culinary metaphor for the CRP, there exists a sequential stochastic process
that defines a conditional distribution p(znk|Z−nk) which can be illustrated using a new culinary
metaphor that gives the name to this stochastic process. Imagine an Indian restaurant whose buffet
10Eq. 2.29 and 2.30 employ a common slight misuse of notation by ignoring the features’ position of the beta and
Bernoulli processes.
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consists of infinitely many dishes arranged in a line. N customers enter the restaurant sequentially.
The first customer starts at the left of the buffet and takes a serving from each dish, stopping after a
Poisson(α) number of dishes, as his plate becomes overburdened. The n-th customer moves along
the buffet and samples dishes in proportion to their popularity, serving himself with probability mkn ,
where mk is the number of previous customers who have sampled dish k. Having reached the end
of all previously sampled dishes, the n-th customer then tries a Poisson(αn ) number of new dishes.
This construction give us Z matrices whose features are ordered decreasingly according to their fea-
ture activation probability, although any feature permutation will have the same probability given
the exchangeability property over columns. The actual distribution over the equivalence matrix Z is
independent of the arrival order of customers entering the restaurant [202].
2.4 Inference Methods
The main computational problem in BNP modeling (as in most of Bayesian statistics) is computing
the posterior distribution. For most interesting models, the posterior is computationally not tractable
(not available in closed form), thus requiring inference algorithms to compute an approximation. The
two most popular inference approaches are MCMC and variational inference techniques.
MCMC methods refer to iterative algorithms in which groups of latent variables are sampled
given all the rest (such distributions are called the conditional distributions). This approach has
asymptotic theoretical guarantees: it consists in defining a Markov chain on the different states of
the hidden variables whose asymptotic distribution (equilibrium distribution) is known to converge
to the posterior distribution. Samples obtained from this Markov chain will eventually correspond
to samples from the posterior as the number of iterations tends to infinity [177]. A simple form of
MCMC sampling is Gibbs sampling, where the Markov chain is constructed by considering the con-
ditional distribution of each hidden variable given the rest of hidden variables and the observations.
The CRP construction is particularly amenable to Gibbs sampling inference, as obtaining these con-
ditional distributions is straightforward. A detailed survey of Gibbs sampling for inference in DP
mixture models can be found in [140]. Gibbs sampling for the IBP is described in [72].
In contrast, variational inference resorts to transforming the inference problem into an optimiza-
tion task [102]. The idea here is to approximate the posterior distribution by a simpler family of dis-
tributions and searching for the member of that family that is closest to it (according to the Kullback-
Leibler divergence). This is also equivalent to maximizing a certain lower bound on the marginal
distribution of the data, called the “Evidence Lower Bound” (ELBO). Unlike MCMC methods, vari-
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ational inference algorithms are not guaranteed to recover the posterior, but they are typically faster
than MCMC, and convergence assessment is straightforward. These methods have been applied to
DP mixture models [21] and IBP latent feature models [42].
2.5 Summary
In this chapter, we have given a gentle introduction to Bayesian nonparametric and intuition, in-
cluding concepts such as exchangeability, De Finetti’s theorem, completely random measures and
normalized random measures. We have presented the basic building blocks (stochastic processes)
which will be used within this thesis, i.e., the Dirichlet process, and the Beta process, as well as the
additional processes resulting from integrating the De Finetti’s mixing random measure in a Dirichlet
process and a hierarchical Beta process–Bernoulli process construction: the Chinese restaurant pro-
cess and the Indian buffet process. Finally, we have given an overview of the most common inference
approaches to fit BNP models, i.e, to approximate the posterior distribution. The remaining chapters
are devoted to our contributions.
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3
Atom-Dependent Dirichlet Process
for Marathon Modeling
This chapter presents a novel application of Bayesian nonparametrics (BNPs) for density estimation
of stratified data, with application to data from marathon runners. In particular, we make use of the
dependent Dirichlet process (DDP) [125], which is a powerful tool that encompasses the Dirichlet
process (DP) and the hierarchical Dirichlet process (HDP). However, the DDP is very general and
it cannot be directly applied to data without additional constraints. Here, we specify a way to tie
the parameters across groups using a Gaussian process (GP) [172], thus making the DDP a practical
prior for our problem at hand. Additionally, we rely on the HDP to model intermediate running
times for each runner, uncovering different running patterns within athletes. This model is also used
to predict the finishing time in the race. Finally, we relate the proposed model to the literature of
infinite mixture of experts (IMoE) in the context of non-linear regression [171].
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3.1 Introduction
Fairness is becoming an important requirement for certain machine learning (ML) systems to have,
some examples include non-gender-biased recommendation systems or unbiased decision-systems
regarding racial discrimination. Our objective in this chapter is to compare in a fair manner the
finishing time of runners having different age and gender. Currently, most popular marathons award
entry to participants by their best marathon in the previous 12 months. For example, in Boston it is
the only way that a participant can gain entry to the race, while other paths are available in New York,
Chicago or London.1 Our objective is to propose a methodology that can be used to equalize entry
requirements for different marathons, which vary considerably for one event to the next, as there
is no widely accepted standard method to specify them. Furthermore, the world master of athletics
(WMA) has an age-grading system for equalizing the finishing time according to the age and gender
of athletes.2 They lobby for this measure to be taken into consideration for selecting the winners
of each race, even though that procedure is based on world records, i.e., outliers that may not be
very representative, or even realistic, for most races. Our method also provides an alternative way to
reward runners fairly regardless of their age and gender.
Our approach consists in adapting a single-p dependent Dirichlet process (sp-DDP) to cluster
the finishing time for each runner according to his/her age and sex [125]. We propose a Gaussian
process to control how the clusters (representing marathon finishing time) change from one group to
the next (different ages or gender). We find that the means of these clusters are directly comparable
to the marathon entry requirements and the age-graded tables from the WMA. Additionally, direct
comparisons for any finishing time are straightforward, since we find a full distribution for all ages
and both genders. The sp-DDP can simultaneously deal with different races and/or the same race
on different years, providing a unified ranking for all the races that may differ on elevation profile,
temperature or humidity.
3.2 Dependent Dirichlet Processes
The DDP is a generalization of the DP that can be applied for clustering of groups of data [124]. For
each group j, we have an infinite mixture model of the form
Gj =
∞∑
k=1
pijkδφjk , (3.1)
1Complete information for each marathon event can be found in their respective web pages.
2World Master of Athletics webpage: http://www.mastersathletics.net/.
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where Gj is a group-specific random measure, and the atom weights pijk and atom locations φjk
follow stochastic processes on the covariate space j. In the following, we will describe two particu-
larizations of the DDP that we use throughout this chapter: the HDP and the sp-DDP.
Hierarchical Dirichlet process. The HDP, which was already introduced in Section 2.3.1, is a
particular DDP to cluster groups of data that share the exact same mixture components [204]. It
is equivalent to a set of DPs, one for each group of data, in which all DPs share the same base
distribution which is itself drawn from a DP. Mathematically, we first draw a base distribution from
a DP as G0 ∼ DP(γ,H), where G0 =
∑∞
k=1 vkδφk , and for each group j we draw a distribution
from a DP using G0 as the base distribution, i.e., Gj ∼ DP(α,G0). This construction ensures that
all the random measures Gj share the same atom locations given by G0, since G0 is itself a discrete
probability distribution. Since each atom corresponds to a cluster, cluster parameters φk are shared
across all groups. Each Gj admits a representation as
Gj =
∞∑
k=1
pijkδφk , (3.2)
where the atom locations φk do not depend on the group j. Furthermore, this method allows groups
to share statistical strength via the atom weights vk of the base distribution G0. Indeed, the vector of
weights for each group j can be obtained as pij ∼ DP(α,v).
In the corresponding culinary metaphor, the HDP can be explained with a Chinese restaurant
franchise (CRF), in which there is a collection of restaurants, and dishes are shared across restaurants.
However, the popularity of each dish, i.e., the corresponding atom weight, is different in each of the
restaurants [204].
Single-p dependent Dirichlet process. The sp-DDP is another DDP, which works in a comple-
mentary fashion to the HDP. In this case, atom weights are shared across groups while atom locations
are allowed to vary. In terms of the often used culinary metaphor for DPs [61], while the HDP shares
the dishes across restaurants but allows a different dish popularity in each of the restaurants, the
sp-DDP shares the dish popularity across restaurants but allows the dishes to vary slightly, in order
to better fit each group of customers (see Figure 3.1 for a comparative sketch). The latter would be
a peculiar CRF in which the popularity of tables is matched one-to-one across restaurants, with the
served dish in each linked table slightly customized in each restaurant (e.g., different ingredients,
cooking time or local taste).
In the sp-DDP, the latent measure for each group j can be expressed as
35
CHAPTER 3. ATOM-DEPENDENT DP FOR MARATHON MODELING
Figure 3.1: Comparison of two Dependent Dirichlet processes. The HDP is at the left, sp-DDP is at the
right. The first one shares atom locations, while the second one shares mixture weights.
Gj =
∞∑
k=1
pikδφjk , (3.3)
where the vector pi ∼ GEM(α) contains the mixture weights and φjk are the atom locations. The
sp-DDP does not specify how to tie the atom locations φjk across groups for each k. This step
is critical, as it conditions the performance of the model. We put forward in Section 3.3 another
stochastic process for this purpose.
3.3 Our Approach
3.3.1 Atom-Dependent Dirichlet Process Mixture Model
Our model is based on the sp-DDP prior, as it allows comparing the shape of different distributions
while keeping the corresponding quantiles fixed. In the context of the marathon, we use it to obtain
a fair comparison between groups of runners regardless of their age or gender. Runners are grouped
together according to their age and gender, yielding J different groups. In our infinite mixture
model, we cluster the runners of all groups with a potentially unbounded number of clusters. Each
cluster k presents a fixed percentage of runners given by pik, with a stochastic process linking the
atom locations, i.e., the mean finishing time. This construction has the potential to provide a direct
comparison for the finishing time in each group j. However, as the sp-DDP is a very general prior,
we need to define the likelihood and the stochastic process in a way that is insightful about the
marathoner’s finishing time.
We denote each marathoner finishing time as xji, where j = 1, . . . , J indexes the group and i
runs over marathoners, and we assume a Gaussian likelihood for the finishing time xji:
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xji|cji = k, µk, θj , σ2x ∼ N
(
xji|µk + θj , σ2x
)
. (3.4)
Here, µk denotes the global mean for cluster k, θj is the shift associated to group j, cji represents the
cluster assignment associated to observation xji, and σ2x is the variance of the Gaussian distributions.
Hence, we use a cluster-specific parameter µk to describe cluster k, but we allow deviations from
this value due to age or gender: this effect is modeled by θj .
The key aspect that makes the sp-DDP useful for comparing different age-gender groups is the
stochastic process that governs θj . We would like this value to vary smoothly across ages, and
therefore we choose a zero-mean Gaussian process prior for it:
θ ∼ N (0,Σθ) , (3.5)
where θ = [θ1, . . . , θJ ]>, and for the covariance function we use the standard choice, i.e., the squared
exponential kernel given by
(Σθ)`j = σ
2
θ · exp
(
−(`− j)
2
2ν2
)
+ κδ(`− j), (3.6)
where ` and j represent two different age groups, σ2θ accounts for the variance, ν controls the degree
of correlation between age groups ` and j, and κ is a jitter factor to avoid numerical instabilities.
We use an independent Gaussian process for each gender. There are other alternatives, see [172] for
a comprehensive introduction for valid covariance functions. In our case, the squared exponential
kernel is a smooth kernel (infinitely differentiable) that captures the correlation between the different
age groups. We place a Gaussian prior over the cluster means µk and an inverse gamma prior over
the variance σ2x, i.e.,
µk ∼ N
(
µ0, σ
2
0
)
, σ2x ∼ IG (a, b) , (3.7)
where µ0, σ20 , a and b are hyperparameters of the model. The value of σ
2
0 is assumed to be much
larger than σ2θ , so that the first one controls the overall finishing time for the clusters (hours), whilst
σ2θ controls the differences between groups due to different ages (minutes).
Finally, we place the following priors over the assignment variables cji and cluster weights pi:
cji|pi ∼ pi, pi|α ∼ GEM(α), (3.8)
which completes the specification of the generative model and GEM stands for the stick-breaking
prior by Griffiths, Engen and McCloskey, as defined in [152]. We refer to this sp-DDP prior, together
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Figure 3.2: Graphical representation of the basic ADDP mixture model. Grey circles represent observed
variables, white circles are hidden random variables. Plates refer to duplicated random variables.
with the likelihood model in Eq. 3.4 and the GP for θj , as the Atom-dependent Dirichlet process
(ADDP) mixture model. A graphical representation for the ADDP is depicted in Figure 3.2. This
model is similar to the ANOVA-DDP prior in [37]: in our case, we rely on a GP to control the de-
pendency between the shift variables θj , while the ANOVA-DDP prior relies on independent priors.
This allows for smooth variations of the cluster means with the age.
We assume a common variance σ2x for all the clusters, because it provides an ordering of the
clusters, which is necessary for comparing the finishing times. Allowing for different variances for
each component should provide a more accurate (in the sense of better density estimation) description
of the finishing times, but a less interpretable and less actionable representation, as runners assigned
to Gaussian components with different variances are not directly comparable. We have not placed a
joint prior for the cluster means and variances through the normal-inverse gamma distribution, since
separate priors might have better properties for density estimation [76] and allow for faster Gibbs
sampling inference.
3.3.2 Further Model Extensions
Age-gender interaction. The basic ADDP mixture model considers male and female runners in-
dependently, assuming independent shift delays θj between both genders j (i.e., we use a block-
diagonal covariance matrix). A natural extension of the model consists in introducing an additional
gender factor δ and some age-gender interaction factors ωj in order to capture the correlation be-
tween male and female athletes. In such model, the shift delays θj are shared for both men and
women, and j indexes different age groups instead of age-gender groups. We refer to this model as
the age-gender interaction ADDP model. The generative model can be written as follows:
xji|cji = k, gji, µk, θj , σ2x, δ, ωj ∼ N
(
xji|µk + θj + 1[gji = 1](δ + ωj), σ2x
)
, (3.9)
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cji|pi ∼ pi pi|α ∼ GEM(α) σ2x ∼ IG (a, b) (3.10)
µk ∼ N
(
µ0, σ
2
0
)
δ ∼ N (0, σ2g)
θ ∼ N (0,Σθ)
ω ∼ N (0,Σω)
(3.11)
where the indicator variables gji differentiate male (gji = 0) and female (gji = 1) runners, δ is the
gender effect, and ω = [ω1, . . . , ωJ ]> contains the age-gender interaction factors influencing the
likelihood of female runners. Additionally, σ2g and Σω are hyperparameters of the model.
Multiple races. We could apply the previous models to finishing times from different races or
years, but we might obtain unexpected results since different races can present unalike conditions
due to temperature, elevation profile, humidity, pull of runners, etc. In this section, we present an
useful extension that deals with different races all together and allows drawing comparisons between
these races. In order to deal with this, we extend the basic ADDP model using varying weights across
races. This leads to a hierarchical atom-dependent Dirichlet process (H-ADDP) model, in which
cluster weights are allowed to change across races, and cluster parameters are allowed to change
across age-gender groups. We refer to this model as the hierarchical H-ADDP model. Figure 3.3
shows a graphical representation of this extended model, with the following likelihood and priors:
xrji|crji = k, µk, θj , σ2x ∼ N
(
xrji|µk + θj , σ2x
)
, (3.12)
µk ∼ N
(
µ0, σ
2
0
)
,
θ ∼ N (0,Σθ) ,
σ2x ∼ IG (a, b) ,
crji|pir• ∼ pir•,
pir•|v, α ∼ DP(α,v),
v|γ ∼ GEM(γ),
(3.13)
where r indexes the different races, γ is the upper level concentration parameter, pir• = (pirk)∞k=1
are the mixture weights for race r, v = (vk)∞k=1 are the global weights for all races.
One simple way to interpret this model is by conditioning on a particular race or an age-gender
group. If we only have data from a single race, we recover our original ADDP model. If we only have
data from a single age-gender group, we recover an HDP, i.e., the cluster components are shared, but
the mixing proportions are different.
Cluster-dependent shifts. We now present another extension of the model concerning the shifts
θ. In the model described above, the delay θj only depends on the age and gender, which implies
that the shift is the same for all clusters k, no matter whether they are fast or slow runners. However,
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Figure 3.3: Graphical representation of the H-ADDP mixture model. Cluster weights change across races,
whereas cluster means change across age-gender groups.
we can also consider cluster-dependent shifts. This allows us to capture different shift evolutions
across age/gender depending on the speed of runners. That is, instead of having a single delay θj
for each group, we consider a different delay θjk for each cluster and group. Each vector θ•k =
[θ1k, . . . , θJk]
> follows its own Gaussian process with mean µθ and covariance matrix Σθ:
θ•k ∼ N (µθ,Σθ) . (3.14)
3.4 Results
In the following experiments, we apply the described models to the New York City marathon3 for
6 different years, between 2006 and 2011. This database consists of 249, 899 runners in total. We
additionally compare the NYC marathon data to the marathons of Boston4 and London5 for 2010
and 2011, including 117, 255 additional runners. In order to test the resulting models, we set aside
a test set with 20% of the participants for each race and age/gender group, ensuring that the age and
gender proportions are the same in both train and test sets.
Concerning the hyperparameters for the basic ADDP mixture model in Section 3.3, we have set:
σ2θ = 0.05, ν = 10, κ = 10
−6, a = 1, b = 1, µ0 = 5 and σ20 = 1. The value of µ0 and σ0 are set
so that 2-hour marathoners are within 3 standard deviations and 9-hour marathoners (typical cut-off
time) are not unheard of. The ratio between σθ and σ0 is approximately 1 to 4, so the former is of the
order of 15 minutes, while the latter is of the order of one hour. Therefore, σ0 controls the overall
finishing time, while σθ controls the differences among age groups. The values of a and b control the
variance of each Gaussian component and are set so that values of less than an hour, but not too small,
3NYC marathon data at http://www.tcsnycmarathon.org/about-the-race/results
4Boston marathon data at http://www.stat.unc.edu/faculty/rs/Bostonwebpage/readme.html
5London marathon data at http://www.virginmoneylondonmarathon.com/
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are more likely. ν was defined in Eq. 3.6 and controls the correlation between the mean finishing
time of runners having same gender and different ages, so that they do not deviate significantly. The
value of κ measures the error in the recorded time and in this case it prevents numerical instabilities.
In the age-gender interaction ADDP model, we choose the same hyperparameters as in the basic
ADDP model, and the additional hyperparameters are set as σ2g = 0.05 (which corresponds to the
same prior variance as for θj) and Σω = 12Σθ.
For the HDP model in Section 3.5.1, we set  = 0.2 km−1 and τ = 5000, because the differences
between the relative time spent at each 5-km interval are typically small. Finally, we place a Gamma
prior with shape 1 and scale 10 over the concentration parameters α and γ, and sample their values
following [50]. These hyperpriors are chosen in order to avoid the creation of too many spurious
clusters. Due to the huge amount of data, results are not very sensitive to hyperparameter values, as
long as they are not set to completely misleading and unrealistic values. In our application at hand,
we can actually set (and be able to explain) the values of the hyperparameters using all our prior
knowledge, as detailed above, which is important in order to incorporate the known information and
allow for the expected variances.
Posterior inference for all simulations is based on Gibbs sampling. Following Algorithm 8 in
[140], we do not integrate out the hidden variables, and we propose 10 new clusters at each iteration.
In our results in Section 3.4.1, we report the values of the hidden variables (means and shift delays)
averaged for the last 10, 000 iterations after running the sampler for 50, 000 iterations. For the per-
cluster variables, we carry out the averaging procedure to account for potential label switching.
3.4.1 Density Estimation
To model the finishing time of runners in the six considered NYC marathons, we compare our basic
ADDP mixture model described in Section 3.3 to a standard HDP mixture model with Gaussian
likelihood. For both models, we report 11 clusters, with σx = 5.8 minutes for the basic ADDP
model, and σx = 8.2 minutes for the HDP model. Figure 3.4 compares the overall density estimate
given by both models with the empirical histogram for a particular group of runners (we choose all
forty year-old male finishers for the plot). Both the ADDP and HDP models perform similarly in
terms of density estimation, and both provide comparable test log-likelihood values, in particular,
−0.0618/sample for the ADDP and −0.1053/sample for the HDP.
Note also that the empirical histogram in Figure 3.4 presents one narrow peak that is not fully
captured by the HDP nor the ADDP model. This peak, just under 4 hours, and the valley right
afterwards are due to some runners trying to finish (and succeeding) a sub-4-hour marathon, roughly
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Figure 3.4: Density estimation capacities for the basic ADDP and HDP model. The histogram corresponds
to the population of forty-year-old male runners, which is the largest age-gender group. The red curves are the
probability density functions inferred by the basic ADDP and HDP models. The blue dotted lines represent
the individual clusters inferred by the ADDP model.
9-minute-mile pace. This is a psychological effect that has limited interest for us, since it is not
indicative of runners’ inherent performance. Using cluster-specific values for the variance σ2x would
yield better density estimation, even capturing this peak, but it would fail to provide any comparison
between distributions. Here, we are interested in ordering runners into clusters for comparison, which
is achieved by having a shared value of σ2x for all clusters.
3.4.2 Impact of Age, Gender and Race
We now use the age-gender interaction ADDP model described in Subsection 3.3.2. In addition to
its density estimation capacity, the ADDP has an additional descriptive strength, since it can show
the impact of age and gender on runners performance straightforwardly through inference of the
age delays θj , gender factor δ and age-gender interaction factors ωj . Figure 3.5 shows the average
proportion of runners in each cluster, as well as the inferred cluster means µk, for both the HDP and
the ADDP. Runners aged above 69 are not reported because there are too few of them.
The HDP results are not easy to interpret, except for the first three clusters that show the time
degradation with age, because we do not know the cumulative percentage as the finishing time is
increased. In contrast, the ADDP model is easier to interpret. The first cluster contains the “Olympic”
quality runners for all ages, if Olympics were held for each age group (less than 1% of the runners).
The second cluster has the competitive runners (about 13% of the runners), the third cluster has the
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Figure 3.5: Age proportions per cluster. The HDP is at the top and the age-gender interaction ADDP is
at the bottom. Male and female runners are shown together. The colors design the age of the runners, from
18-year-old in blue to 69-year-old in dark red. For the ADDP model, the cluster labels correspond to µk + θj ,
with the value of θj corresponding to the 28-year-old male runners, the shifts for other age or gender can be
found in Table 3.1.
age 18 19
men 8.00 6.34
women 33.60 31.89
age 20 21 22 23 24 25 26 27 28 29
men 4.88 3.62 2.53 1.66 0.98 0.49 0.18 0.04 0.00 0.10
women 30.43 29.21 28.19 27.42 26.87 26.53 26.38 26.41 26.53 26.79
age 30 31 32 33 34 35 36 37 38 39
men 0.28 0.51 0.79 1.09 1.39 1.71 2.03 2.34 2.65 2.98
women 27.13 27.50 27.87 28.27 28.65 29.03 29.39 29.74 30.08 30.46
age 40 41 42 43 44 45 46 47 48 49
men 3.30 3.66 4.11 4.61 5.25 5.99 6.85 7.90 9.09 10.47
women 30.82 31.23 31.78 32.41 33.21 34.13 35.24 36.58 38.07 39.81
age 50 51 52 53 54 55 56 57 58 59
men 12.01 13.74 15.66 17.74 20.00 22.38 24.91 27.51 30.21 32.95
women 41.73 43.88 46.23 48.75 51.47 54.29 57.26 60.27 63.36 66.44
age 60 61 62 63 64 65 66 67 68 69
men 35.70 38.44 41.16 43.80 46.35 48.77 51.06 53.17 55.09 56.81
women 69.50 72.51 75.46 78.26 80.93 83.42 85.73 87.83 89.69 91.31
Table 3.1: Averaged values of θj for men (or θj + δ + ωj for women) for all age groups in minutes.
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standard marathoners (about 33% of all runners), and so on. The x-axis in Figure 3.5 provides the
value of µk + θj for 28 year-old male runners and the degradation for other ages and sex is shown
in Table 3.1. Using the plot and the table, we can know the proportion of runners in each group and
how much extra time they need compare to the fastest group.
Figure 3.6 shows the value of the inferred cluster means µk plus and minus one standard devi-
ation, shifted according to θj , δ, and ωj for both men and women. We only depict the two fastest
clusters, and compare the corresponding values of the finishing time with the entry requirements of
different marathons and the WMA records. Best performance for females and males is predicted, re-
spectively, at 26 and 28 years old, which is consistent with [186]. The plateau afterwards illustrates
a stable period of performance between the 30’s and 40’s for both genders.
All plots behave in a similar way. This is what we meant in the introduction by that the first
insights should not be foreign to us, so experts in marathon modeling can take other conclusions as
plausible. Now, we focus on what is different. The most striking difference is how the entry levels
penalize younger male runners, specially runners under 25. To be fairer to the youngest runners, their
entry time should be raised (in about 7 minutes compared to the 30 years-old). The Boston marathon
entry level is perfectly aligned with our second cluster for 40+ years old men and almost perfectly
match the female second cluster, except for the runners under 23. There is a penalty of about 4-7
minutes for runners aged 25-39 and between 7-14 minutes for 18-24 year-old runners. The entry
times slightly favor the 45-50 year-old runners.
The London marathon also penalizes excessively runners in their fifties compared to those in
their forties and sixties, which seems odd.6 It is also clear that over 50 (or even 45), the degradation
of the finishing times per year is significant enough to merit a finer scale to guarantee entry times
(this may also apply for 18-23 years-old). For example, a runner of 60 years old is doing almost 15
minutes less than a runner of 64 (which is a very long time in any marathon). Finally, the WMA
curve for men penalizes the older male runners, while for older female runners it seems to have a
similar trend than the first cluster of the ADDP model. For younger runners, the difference between
the typical women in the olympic cluster and the WMA is larger than the difference between the
typical men in the olympic cluster and the WMA.
Figure 3.7 shows the finishing time gap between women and men. The gap seems to be of about
30 minutes and slightly increasing with age. There are very few runners over 65 for the final decay to
be statistically significant. We can come up with two different plausible explanations, but we do not
have data to confirm whether this empirical effect is due to any of them or to some other unknown
6the entry time in London is only for UK residents and it is not a common way to get in the race, which might explain
the weird pattern.
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Figure 3.6: Inferred cluster means and entry requirements. Comparison of the inferred cluster means, i.e.,
μk+θj with k ∈ {1, 2}, with the entry requirements (runners below the curve can qualify) for New York City,
Boston and London marathons. (Top) Men. (Bottom) Women.
factor. The degradation with age between women and men might be due to physiological factors, i.e.,
women age differently than men for long distance running, or it might be due to socio-economical
factors, i.e., women above 30 cannot train as much as men do.
Comparison across Multiple Races
We compare the NYC marathons to the ones in Boston and London, using the H-ADDP model
described in Section 3.3.2. We consider both the 2010 and 2011 marathons, and we split the runners
into age groups instead of using their actual age because we do not have this data available for
London marathon. Figure 3.8 shows the inferred values of the per-race weights πrk. The values
for μk + θj in the x-axis are those of the 45-49 male runners and the value of σx = 19 minutes.
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Figure 3.7: Gender effect on the final performance. Averaged inferred value for the gender coefficients.
First, we notice that the values of pirk are quite different for each place, but they show little variation
between different years. We can argue that this pattern is mainly due to the race difficulty, assuming
a stationary selection of the runners.
Boston has the most striking pattern, which can easily be explained by the strict entry requirement
time. For 45-49 years old the entry time is 3h25m and the cluster with 70% of the runners has a mean
of 3h19m20s. There is a group of almost 15% of the runners that finish just under 4 hours and about
15% of the runners that do much worse than their qualifying time. This might be due to poor training
or having some issue during the race. For the Boston marathons, there are no runners in the 3h
cluster and around 1% runners in the fastest cluster. The void in the 3h group is due to the massive
proportion of runners in the 3h19m group, which makes any runner in that group to be represented
by the 3h19m cluster. The runners under 3h are the runners that do much better than the needed
qualifying time and cannot be represented by the massive 3h19m group.
The proportions in NYC and London are more similar to each other, as both marathons allow
runners to enter the race in more ways than just by entry requirement.7 The 3h group is more
populous in London than NYC, but the 3h19m and 3h53m clusters contain a larger proportion of
NYC runners. The 4h30m group is equally probable in both races. London seems to attract a higher
proportion of slower runners (over 5 hours). This difference might be due to the difficulty of the
marathons (profile and weather conditions) or the pull of runners. NYC race is more hilly than
London, which can explain the difference in the first cluster, but the runners in NYC are more diverse
(coming from different parts of the country and world), while London attracts more local runners.
7Being these two races more accessible or democratic, we can consider the proportions in the different clusters closer
to the general population of marathon runners.
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Figure 3.8: Mixture weights for the H-ADDP mixture model. The figure shows the mixture weights pirk
for each race r and cluster k. The legend shows the different races, and the x-axis corresponds to different
clusters.
This might also explain the pattern of the slowest athletes.
3.4.3 Accounting for the Speed of Runners
We now apply the model extension in Section 3.3.2 with cluster-dependent shift delays θjk. Fig-
ure 3.9 and Figure 3.10 show the inferred cluster means for men and women respectively. Although
the overall shape of the curves is quite similar across clusters, which validates our previous conclu-
sions, there are some noticeable differences for the fastest runners and we concentrate on those.
The most interesting difference is the behavior of the fastest cluster for under 50 years-old run-
ners, as to the naked eye it seems to suggest that women are faster than men. The fastest cluster
for women captures the Olympic runners that are doing under 2h45m, and its proportion is very low
(less than 1%). The second fastest cluster for women covers those runners doing under 3h45m and
it represents 13% of the female runners. There is a significant difference between Olympic female
runners and competitive female runners, so two clusters are needed. For men under 50, the first clus-
ter represents 13% of the runners and it captures those doing under 3h30. The model considers that
the Olympic runners can be modeled by the tail of the distribution of competitive runners, without
requiring a new cluster as the Olympic women need. Male runners over 50 behave as women do, and
two clusters are needed to separate the Olympic and the competitive groups.
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Figure 3.9: Inferred cluster means μk+θjk for men. We have used the extended model with speed-dependent
clusters. The legend shows the inferred value of the proportions πk for each cluster.
For men under 50, the small cluster that represents the fastest women sits in between the two
populous clusters, becoming irrelevant in terms of density estimation. The reason why it appears is
because the model forces the same proportion for all clusters across age and gender groups. In order
to support this conclusion we have depicted the histogram of the 28-year-old runners together with
the inferred density in logarithm scale in Figure 3.11a and Figure 3.11b. In this ﬁgure, the blue solid
line represents the inferred distribution, the green dash-doted line is the histogram with 6-minute
bins, and the red dashed lines represent each one of the clusters multiplied by their averaged weight.
In this plot, we can see that the Olympic male runners just doing over 2 hours can be modeled by
the same cluster as the competitive male runners, while the ﬁnishing time for the Olympic female
runners could not be explained by the competitive female ones, and hence a speciﬁc cluster is needed.
In the previous section, when θj was not allowed to vary with k, the cluster for the Olympic males
was visible, but this is an effect of forcing the same value of θj for all clusters, as women and older
male runners need it. This is the only signiﬁcant difference when we replace θj with θjk.
There may be several explanations for this effect. In the NYC marathon the Olympic women run
by themselves in an early wave, while the Olympic men start at the same time as everyone else, so
competitive men can try to follow them. However, this does not explain the need for a cluster for fast
male runners over 50. We can also hypothesize that female Olympic runners have a training that is
signiﬁcantly different from competitive female runners, while for male runners there is a continuum
in the training between Olympic and competitive runners. This could also apply for male over 50,
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Figure 3.10: Inferred cluster means μk + θjk for women. We have used the extended model with speed-
dependent clusters. The legend shows the inferred value of the proportions πk for each cluster.
in which there are not that many doing Olympic ﬁnishing times and competitive runners are not
as strong. Finally, we can also argue that younger male runners are more risky than female and
older male runners. Those that succeed do a better time and close the gap between the Olympic
and competitive runners. Older males and female competitive runners do not follow such a risky
approach and therefore they do not close the gap with the Olympic runners. There is some evidence
on this risky hypothesis in Section 3.5.2, in which we see that the reckless running pattern cluster is
mainly populated by younger males.
3.5 Analysis of Running Patterns
In our analysis of the marathon dataset, we also led a temporal analysis of the different running
patterns. Our objective here is twofold. First, we are interested in a tool that can capture latent
running proﬁles that reﬂect the marathon difﬁculties along the 26.2 miles (42.195 km). This can
be useful for athletes’ training purposes. Second, we aim at predicting the arrival time of runners
using intermediate records. This problem has already been addressed in [78], where ﬁnishing times
are imputed for the 2013 Boston marathon. One of the best approaches rely on the 100 nearest
neighbors, which has the limitation of clustering runners that are doing the same absolute times.
We propose to use an HDP [204], a tool that complements the analysis of the previously in-
troduced ADDP, in order to model the fraction of time each runner has spent at each intermediate
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Figure 3.11: Density estimation for 28-year-old runners. We have used the extended model with speed-
dependent clusters. The solid line shows the inferred distribution and the green dash-dotted line is the normal-
ized histogram with 6 minutes bins. Red dashed lines correspond to the individual Gaussian components that
define the inferred density, weighted by their proportions. The black dashed line corresponds to Cluster 1.
interval (typically, measures are taken every 5 km and at half-marathon). In this way, we cluster the
time ratio instead of the absolute times. Participants that run at different but constant speed will be
in the same cluster, no matter if they run each mile in five, eight or eleven minutes. Thus, this model
allows estimating finishing times for slower runners that have the same time-ratio profile than fast
ones. We use an HDP model in which the likelihood function is a Dirichlet distribution, and each DP
clusters the runners by age group and sex. When modeling the full race, it helps to understand the
different trade-offs and which parts of the race are harder.
We address the analysis of temporal evolution of runners during the race to understand how the
marathoners pace themselves to complete the marathon. We aim at discovering running patterns,
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i.e., distinguishing those overly optimistic runners, with decreasing speed along the race, from well-
trained runners who tend to keep a constant speed. It also helps to understand where the marathons
are harder, so that runners can know beforehand. The hidden running patterns can be used for training
purposes, as they can find out the typical shortcomings of athletes with respect to their age, which
may help runners train and run more intelligently. In addition, we also show that discovering running
patterns provides a new tool for prediction of finishing times, with results comparable to the best
reported method in [78].
3.5.1 Modeling
The idea is to cluster the data according to the relative time spent in each interval regardless of
each runner’s total time. In this sense, we are no longer interested in the absolute times, but in
the time proportions invested for each interval. Marathons tend to record the elapsed time every 5
kilometers, in addition to half and full-marathon times. Our input data in this case consists of an
N ×D dimensional matrix X with the time spent for each interval, together with the age and gender.
Here, N is the number of runners and D denotes the number of available time records.
We normalize our input data so that each runner is represented as a vector containing the fraction
of time spent for each intermediate interval. As in Section 3.3, we split the data X into J groups of
runners having the same age and gender. We use the HDP [204] to cluster the running patterns for
the different groups. In the HDP, clusters are allowed to show different probabilities for each group,
but the per-cluster parameters are shared across groups. As explained in Section 3.2, we first draw
a global base distribution from a DP as G0 ∼ DP(γ,H), where G0 =
∑∞
k=1 vkδφk , and for each
group j we draw a distribution from a DP using G0 as base distribution, i.e., Gj ∼ DP(α,G0). In
our model, the likelihood function is a Dirichlet distribution and can be written as
xji|cji = k,pk ∼ Dirichlet (τpk1, . . . , τpkD) , (3.15)
where xji is the normalized D-dimensional vector for runner i in group j, cji represents its cluster
assignment, pk = [pk1, . . . , pkD] is the vector of patterns representing cluster k, and τ is the con-
centration hyperparameter of the model. We place a Dirichlet prior over the per-cluster vectors pk,
pk ∼ Dirichlet (`1, . . . , `D) , (3.16)
where `d is the length of interval d, and  is its concentration hyperparameter.
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3.5.2 Experiments
Here, we consider temporal sequences of time measurements every 5 km, and at half and full
marathon, as explained in Section 3.5.1. We run 10, 000 iterations of the sampler and average the
results for the last 2, 000 iterations.
Running patterns. In this section, we use the data from 2007-2011 NYC marathons, with 194, 778
runners. We discarded data from the 2006 marathon because we observed that intermediate measure-
ments were not fully synchronized with the half and full marathon times. After applying our HDP
model, we found a modal value of 46 clusters. In Fig. 3.12 we show the twelve most populated
clusters, which account for around 90% of the population on average. The removed cluster do not
behave significantly different than the ones we show in this section. For clarity, we do not directly
plot the time proportion spent at each interval, but instead show the speed at each 5-km leg, assuming
a value of 11 km/h for the speed during the first 5 kilometers. We have removed the half-marathon
mark for clarity. The total net time, assuming this value for the initial speed, is shown in the legend
for each cluster. We also plot the approximate elevation profile of the marathon with a thin grey line.
Before the half marathon mark, we can roughly see three different types of clusters: those cor-
responding to athletes running at approximately constant speed (clusters 0, 1, 1− and 1−−), those
5 10 15 20 25 30 35 40 42.2
6
7
8
9
10
11
12
km
S
p
e
e
d
 (
k
m
/h
)
20
40
60
80
100
E
le
v
a
ti
o
n
 (
m
)
Cluster 0 (7.2%, T=3.80h)
Cluster 1 (24.4%, T=3.93h)
Cluster 1
−
(14.9%, T=4.03h)
Cluster 1
− −
(3.6%, T=4.16h)
Cluster 2A (13.4%, T=4.17h)
Cluster 2A
−
(11.3%, T=4.27h)
Cluster 2A
− −
(3.2%, T=4.43h)
Cluster 2B (1.1%, T=4.32h)
Cluster 2B
−
(1.6%, T=4.47h)
Cluster 3 (3.4%, T=4.56h)
Cluster 3
−
(4.4%, T=4.59h)
Cluster 3
−−
(1.4%, T=4.88h)
Figure 3.12: Inferred running patterns by the HDP. (Thick lines) Inferred running patterns or speed for
the twelve most populated clusters, assuming an initial speed of 11 km/h. The legend additionally shows the
average proportion of runners in each cluster, as well as the net time for that value of the initial speed. (Thin
grey line) Elevation profile of the race.
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that are already showing a decreased pace (clusters 2A, 2A−, 2A−−, 2B, and 2B−), and those for
which the decreased pace is significantly more relevant (clusters 3, 3−, and 3−−). Just before the
25-km mark, there is an overall drop in performance that can be explained by the Queensborough
bridge and, after that, the twelve clusters become clearly different one another, giving their labels an
obvious meaning.
People in Cluster 1 (the most populated cluster, one in every four runner) are well trained runners
that run at almost constant speed and the changes can be explained by the hills in each 5-Km interval
and they speed up to finish a strong race in the last kilometer, while Clusters 1− and 1−− suffered the
effect of the Manhattan hills and bridges in and out of the Bronx, besides the natural weariness after
running for 35 km. Cluster 1−− correspond to the runners that outpaced themselves and finished the
marathon at a very low speed, compared with what they could have done. Cluster 0 corresponds to
runners who could have done a better race if they had run faster from the beginning and not only
after half the race. The rest of the clusters correspond to those overly optimistic runners who could
not run as fast as they thought at the beginning. These are the runners who suffered the most. For
all the clusters, we can observe an increased speed in the last 2 km, which can be explained by the
proximity to the finishing line and the effect of trying to finish under some target time.
Fig. 3.13 shows the averaged inferred proportion of runners pijk in each of the twelve most pop-
ulated clusters for both men and women, broken down by age groups (blue represents the youngest
runners). Clusters 1−, 1−−, 2A−, 2A−− and 2B− are mostly populated by men (e.g., 19.4% of men
and only 6.7% of women are in Cluster 1−, and 5% of men and 0.9% of women are in cluster 1−−).
In other words, the clusters of overconfident runners are mostly populated by men. Clusters 2A−
and 2A−− present a constant proportion across ages for both genders. The proportion of women in
Clusters 0 and 2A is higher than for men (e.g., 7.5% of men and 24.1% of women are in Cluster
2A). These clusters represent the conservative runners that have some doubts about how fast they
can finish a 42.2-km race. In Cluster 0 there is a larger proportion of 18-19 year-old runners for
both genders. These are probably first timers, which is consistent with the inexperienced behavior of
runners in that cluster. In contrast, Cluster 1 (well-trained athletes) is mostly populated by runners in
their thirties, forties and fifties. Custer 2A becomes more popular for older runners. In this cluster,
the runner speed slightly decreases in the first part of the race, but it remains constant in the second
half-marathon, which might indicate that after the initial 10 km, the runners slow down to make sure
that they can continue at a somewhat constant pace.
In Fig. 3.14, we show the averaged proportion of runners in each of the twelve most populated
clusters, broken down by their net time, up to 7 hours. As expected, Clusters 0, 1 and 1− comprise
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Figure 3.13: Age proportions for each running pattern. (Top) Men. (Bottom) Women. The legend shows
the different age groups considered.
a high proportion of the fastest runners, i.e., those that can complete the marathon below 4 hours.
In contrast, Clusters 3, 3− and 3−− are mostly populated by the slowest runners, with a net time
above 5.5 hours. Clusters 2A, 2A−, 2A−−, 2B and 2B− have the highest proportion of runners with
net time between 4.5 and 5.5 hours. These results are consistent with the description of the clusters
provided above.
Prediction of final performance. We can also apply our model to predict the arrival time of ath-
letes. In this case, observations correspond to time proportions at each interval, up to the last available
record. We train our model with the subjects in both the test and the training set, assuming that ob-
servations up to interval D are known for all of them. Regarding the prediction task, we apply a
Bayesian approach in which we take into account the weights from the posterior probabilities of
being in each cluster. At each iteration of the sampler and for each runner in the test set, we first
compute the posterior probability of being in each of the clusters found using the training set. Sec-
ond, we project forward his last available time record to obtain the predicted finishing time for each
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Figure 3.14: Proportion of runners for each running pattern broken down by net time. The x-axis indexes
the clusters found by the HDP model. The legend shows time intervals for the marathon finishing time.
cluster. Third, our prediction is computed as the weighted average of the predictions for each cluster
(weighted by the posterior probabilities of belonging to each cluster). In order to project forward the
last available time record for each cluster, we multiply by a factor the time up to interval D of the
considered runner. This factor is computed as the median of the quotient of the finishing time and the
time up to interval D for those runners in the training set and in the corresponding cluster. Finally,
we average our predictions for the last iterations of the sampler.
In Fig. 3.15, we show the empirical density of the prediction error for all subjects in the test set of
the 2011 NYC marathon. As the number of available records D increases, the curves tend to shrink
around zero.
Table 3.2 reports the average prediction errors, as well as the root of the mean square error,
compared with the results obtained following the 100-NN method with forward projection described
in [78], for 2010 and 2011 NYC marathons. We do not outperform the discriminative method, but
our proposal has the advantage of dealing with time proportions instead of absolute times, which
allows predictions for slower runners based on the arrival time of faster ones. Although our model
only uses relative times (it has one less degree of freedom) it does equally well, the differences being
negligible. Both methods are basically unbiased, as the bias only explains less than 2% of the root
of the mean square error, but this bias seems to be always positive, which means that the estimations
are optimistic on average.
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Figure 3.15: Prediction error. Density of the prediction error for different values of D (number of available
intermediate records).
100-NN HDP
avg rmse avg rmse
D = 1 2.819 19.033 3.778 19.533
D = 2 2.554 16.586 3.226 17.224
D = 3 1.842 13.408 2.207 14.290
D = 4 1.717 12.620 2.000 13.436
D = 5 1.264 9.748 1.255 10.536
D = 6 0.733 6.913 0.705 7.448
D = 7 0.221 3.921 0.212 4.195
D = 8 0.031 1.355 0.037 1.434
(a) Predictions for year 2010.
100-NN HDP
avg rmse avg rmse
D = 1 3.384 20.419 4.247 20.104
D = 2 2.777 17.124 3.368 17.610
D = 3 2.121 13.833 2.428 14.746
D = 4 1.942 13.019 2.219 13.788
D = 5 1.624 10.202 1.625 10.962
D = 6 0.863 7.279 0.821 7.837
D = 7 0.283 4.117 0.269 4.440
D = 8 0.035 1.394 0.046 1.471
(b) Predictions for year 2011.
Table 3.2: Test prediction errors for year 2010. We show the average error for both 100-NN and HDP
methods (“avg”), as well as the square root of the mean square error (“rmse”). Results are all expressed in
minutes. Rows represent number of available time records.
3.6 Connexion to Infinite Mixture of Experts
The presented ADDP model described in Section 3.3 has been applied so far in this chapter to conduct
a data exploratory analysis of marathon races. However, this model can also been used as a general
non-linear regression approach, able to handle heteroscedastic noise and arbitrary output likelihoods.
Instead of using a single GP that tracks the mean underlying function, we have several GPs that model
the underlying distribution for each input vector as an infinite mixture of Gaussians. These GPs cover
the whole input space, i.e., globally, allowing the predicted posterior probability to be non-Gaussian,
multimodal, heteroscedastic and/or non-stationary, without the need of explicitly indicating or even
knowing that those effects might be into play. Our approach is also able to provide accurate percentile
information, and can easily be used for Bayesian integral computation. An infinite mixture of global
Gaussian processes (IMoGGP) can potentially capture any complex functional behavior, in a similar
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fashion that an infinite mixture of Gaussians can approximate any arbitrary density function.
For test input vector, our model provides an estimate of the output that is a linear combination of
GPs. The proposed method is a discriminative regression algorithm, in the same way standard GPs
are. Hence, we make no probabilistic assumptions over the input space. If we are strictly interested
in making a probabilistic statement over the output space given the input, adding a probabilistic
model over the input might be detrimental, both in terms of computational complexity and accuracy
of our predictions. The mixing proportions are held constant throughout the input space, so that
all GPs are active in the whole input domain. Hence, we avoid the need of relying on a gating
function, which is typically used to select a particular local functions. The mixing proportions, as
well as the hyper-parameters of the Gaussian processes, are inferred given the data. In this inference
phase, as we change the mixing proportions and the inputs are shuffled between the different global
GPs, we are able to capture any of the effects previously described (e.g. non-Gaussian likelihoods,
heteroscedasticity, colored noise or multimodality) without needing to know if they are present.
Our algorithm is universal for solving any regression problem, but it is more effective for moderate-
sized input spaces and a larger number of samples per input dimension, because if the input dimen-
sion is large the fitting with one Gaussian process will prevail (i.e., we get the standard GP fitting) and
if the input dimension were low (or nonexistent), the solution would be that of a DP for a Gaussian
mixture. In short, our algorithm transitions seamlessly between the two limiting processes.
In Figure 3.16 a), we show a one-dimensional cartoon solution that our discriminative regression
algorithm would be able to provide. Our algorithm is an infinite mixture of experts (IMoE), but not
a typical one in which the input space is chopped locally, using a gating function that decides who is
the expert for each input (see cartoon in Figure 3.16 b). The proposed approach divides the available
data in independent GPs, so it presents the same computational savings as the standard mixture of
expert algorithms based on GPs. The data division is not based on local proximity rules, but on
improving the prediction accuracy of the output.
Our algorithm is a direct application of the DDP [125]. But our interpretation as a nonparametric
universal regression discriminative procedure is novel, as the standard interpretation of DDPs is that
of an indexed collection of distributions.8 Moreover, the DDP should be understood as a general
framework instead of a specific algorithm, as many existing models can be explained as such. In
Section 3.6.1, we review the literature thoroughly, because our work is related to several well-known
algorithms. But we want to emphasize that although our algorithm is similar to others, those have
been presented in the past under narrow conditions or specific applications, which do not show the
8Actually, the author in [125] proposed a simple 1-D linear regression application in which the strength of the DDP for
nonparametric regression and its many desirable properties are not exploited nor hinted.
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Figure 3.16: Conceptual comparison of different approaches. Sketch comparing a) IMoGGP (proposed
approach), b) IMoE, c) Overlapping GPs for multi-tracking, d) Spatial DP, and e) time series clustering. Each
color represents a different GP.
potential of such algorithm for general regression with the properties described earlier.
For example, in [123], the authors infer trajectories, i.e., time series, in which each trajectory is
represented by a GP, as shown in Figure 3.16 c), but there is no regression interpretation nor future
predictions, and the number of time series has to be known beforehand. In [58], the authors want
to estimate the 10-day aggregated rainfall in 39 locations in southern France and 6 test locations.
They assume that the input space has a low cardinality of potential locations, and each sample had
an observation in all input locations. As sketched in Figure 3.16 d), the output is a collection of
vectors, each one with same dimension as the cardinality of the input space; this is far from a typical
regression scenario and can be seen as a particular case of our method. Our algorithm is also similar
to the clustering of time series using DPs [86], as illustrated in Figure 3.16 e), but in that case samples
are treated as whole sequences a priori, and the goal is to identify clusters. Our algorithm would be
able to solve these applications directly or with minor modifications, while the solution in those
papers cannot be applied to solve the general regression problem.
3.6.1 Related Works
In this subsection, we review the literature that is related to our approach and indicate the main
differences with our proposal. We have carried out a thorough literature search and, for brevity, we
only reference those that are directly related to our approach, so many papers that are not directly
comparable have been left out. We know this is a widely-research field and if any relevant body of
work has not been referenced, it has been unintentional.
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Modeling with Mixture of GP Experts
Mixture of expert models in which each expert is a GP has been proposed in the literature in several
occasions. One of the most popular methods in Bayesian regression is the IMoE to capture local
properties of the signal in different areas of the input space [63]. A gating function is used to de-
termine which GP is active in each area, making it useful locally. Extensions of the IMoE include
modeling the input and output jointly, i.e., modeling p(x, y) [128], or allowing the use of the same
experts in different input areas through hierarchical DPs [199]. Our work addresses GP components
at a global scale, which is a more natural way to capture heteroscedastic noise and other gradual
behaviors. Global GP priors were previously proposed in [113], but only considering a fixed number
of mixtures. Also the work in [195] proposes a mixture of global Gaussian Processes for traffic flow
prediction, but their approach is generative and models the input space too.
Multiresolution GPs [55] relies on a hierarchy of GPs to partition the whole space in order to
capture long-range, non-Markovian dependencies while allowing for abrupt changes. Our method
does not partition the input space and allows for multiple functions at a same input location instead.
Additive GPs in [48, 162] divide the output function into low-dimensional components of varying
degrees. Our method is different as we allow for multiple output functions instead of a partitioning
of the output dimensions, i.e.
g(yi) =
∞∑
k=1
fk(xi1, . . . , xiD) (IMoGGP)
g(yi) = f(xi1) + f(xi2) + f(xi3, xi4) + . . . (aGP)
The additive GPs approach seems more suitable for high-dimensional input spaces, it fails to capture
heteroscedasticity or multimodality, as our proposal does.
Density Regression with Dependent Dirichlet Processes
DDPs are useful to model collections of distributions that vary in time, space or experimental settings.
In the literature, it is often the case to use a semiparametric model, i.e., a parametric function for
the signal, and a nonparametric prior for the noise, in order to capture heteroscedasticity or non-
Gaussianity [47, 178, 58, 44, 71]. Our model considers a more general formulation by assuming a
completely nonparametric model for both signal and noise.
In [178], a DDP prior is used to model the joint distribution p(x, y), given different experimental
conditions. With such a generative approach, modeling x might dominate over y, resulting in an
under-fitting of y. Our approach directly focus on the conditional distribution p(y|x), and applies
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the DDPs in a different way, directly over the input space x. Such discriminative perspective typi-
cally gives better accuracy and has the advantage of estimating less parameters than in the generative
approach. The work in [37] uses sp-DDPs, i.e., DDPs with constant weights over x, to cluster the
behavior of multiple ANOVA models under different experimental conditions. Here again, their ap-
proach is generative, whereas we use the DDP to directly model the conditional distribution p(y|x).
In [47], DDPs are used for Bayesian density regression with kernel-varying weights, assuming a
linear relationship between y and x. Our approach generalizes this work by replacing the linear basis
functions by arbitrary non-linear functions with a GP prior each. The authors in [58, 44] introduce a
DDP-based model for spatial modeling applications called the spatial DP prior, which is a probability
weighted collection of random surfaces. They use a linear process for the signal and a mixture of
GPs to capture the noise. Because each atom in the DP corresponds to a realization of a random field
over the input space, their algorithm needs the assumption that multiple points are available at each
location x and in particular, that the number of points assigned to each GP is always uniform. Our
approach removes those restrictions and assumes no particular functional form of the signal.
Clustering of Time Series
Finally, hierarchical mixtures of GPs have often been used in the literature to cluster time series, as
in [190], [86] and [180]. All these works assume prior knowledge of which points belong together
to the same temporal sequence, and assign the points of a temporal sequence jointly to the same GP.
All these models are generative and seek interpretable results. In our case, cluster assignments are
purely auxiliary variables, we only care about predictive accuracy. Slightly different and also closely
related to our approach is the work in [123], which uses a parametric mixture of GPs for the data
association problem. The objective there is to find the appropriate cluster assignments for each point
and recover multiple trajectories, which is useful in multi-tracking scenarios. In our case, mixture
assignments are just auxiliary variables, and we assume a potentially infinite number of mixtures to
represent the data.
3.6.2 Infinite Mixture of Global Gaussian Processes
The aim in a regression problem is to estimate y ∈ R given an input x ∈ RD and a database
Dn = {xi, yi}ni=1. From the available data it induces a general relation between the input x and the
output y. In probabilistic modeling this relation is expressed by a conditional model:
p(y|x,Dn). (3.17)
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To introduce our IMoGGP we are going to start from the standard stick-breaking construction of
DPs for countably infinite mixture models [200]. Observations are then generated as follows:
pi|α ∼ GEM(α) (3.18)
zi|pi ∼ Multinomial(pi) (3.19)
θm|H ∼ H (3.20)
yi|zi, {θm} ∼ F (θzi), (3.21)
where GEM stands for the stick-breaking prior by Griffiths, Engen and McCloskey [152], α is the
concentration parameter of the DP, and the mixing proportions pi are sampled using a stick breaking
procedure [99]. zi indicates the cluster assignment of observation i, and θm designates the cluster
parameters for cluster m, which are sampled from the base measure H . Finally, observations are
sampled from F (·) given the cluster assignments and parameters. One standard selection for F (·) is
a Gaussian distribution in which θm represents its mean and variance.
In the regression setting, each yi is associated with an input xi, so (3.21) can be modified as
yi|zi, {θm},xi ∼ F
(
θzi(xi)
)
, (3.22)
θm|H,φm ∼ Hφm , (3.23)
where we assume that F
(
θzi(xi)
)
is Gaussian-distributed with mean µzi(xi) and variance σ
2
zi(xi),
and Hφm is a Gaussian process prior with hyperparameters φm. Now each cluster parameter θm
corresponds to a latent function over the input space. This construction with a general F (·) is exactly
a sp-DDP where the mixture weights are constant over the input space [125], and the parameters of
each component of the infinite mixture model is indexed by the input variable x.
The inference in this model is straightforward, because given {θm}, sampling zi andpi is identical
to the inference of cluster assignments in DPs. Given the number and proportions of clusters and
cluster assignments for all pairs (xi, yi), {θm} can be inferred by sampling from the posterior GP
distribution, and φm can be obtained by sampling (or maximizing) the evidence for each individual
GP in parallel [172]. Specifically, we perform inference by a simple Markov chain Monte Carlo
(MCMC) procedure. We first use the auxiliary variable approach from Algorithm 8 in [140], i.e., we
do not integrate out the hidden variables, and we propose T new clusters at each iteration, which then
allows to sample zi in parallel. Hyperparameters for potential new GPs are sampled from the prior
at each iteration. The procedure for each iteration is detailed in Algorithm 1, in which we have used
the standard vector notation, i.e. y = [y1, . . . , yn]>, X = [x1, . . . ,xn]> and z = [z1, . . . , zn]>. To
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evaluate the GP posterior, i.e., p(y|X, z, {θm}), we only need to consider the subset of points that
are related to each GP, providing huge computational gains.
Algorithm 1 Inference for the IMoGGP
I - Initialize all hidden structures.
II - For each iteration of the Gibbs sampling procedure:
1: Sample extended vector of mixture proportions:
pi|z, α ∼ Dirichlet(n1, . . . nK , α/T . . . α/T︸ ︷︷ ︸
T times
)
(3.24)
2: Sample latent functions, i.e., cluster parameters θm, m = 1, . . . ,M+:
p(θm|pi,y,X, z) ∝ p(θm|Hφm)p(y|X, z, θm) (3.25)
3: Sample cluster assignments:
p(zi|pi, yi,xi, z−i, {θm}) ∝ p(zi|pi) p(yi|xi, z, {θm}) (3.26)
4: Sample hyperparameters φm, m = 1, . . . ,M+:
p(φm|pi,y,X, z) ∝ p(φm|H)p(y|X, z, φm) (3.27)
5: Sample concentration parameter α for the mixture model
The prior probability of assigning a data point to a new GP is proportional to the concentration
parameter α. This hyperparameter directly influences the total number of GPs used to model the
data. We sample α using an auxiliary variable η as in [50]. Allowing α to vary makes the model
more flexible and ready to be used for different datasets.
Finally the predicted distribution for a new input x∗ is given by:
p(y∗|x∗,Dn) =
M+∑
m=1
pimp(y
∗|x∗,Dn, z, {θm}), (3.28)
where
p(y∗|x∗,Dn, z, {θm}) = N (µm(x∗), σ2m(x∗)), (3.29)
µm(x
∗) = k>mC
−1
m ym, (3.30)
σ2m(x
∗) = km(x,x)− k>mC−1m km, (3.31)
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and km = [km(xm1 ,x
∗), km(xm2 ,x∗), . . . , km(xmnm ,x
∗)], Cm = Km + σ2mI. The set {xmj }nmj=1
are the xi for which zi is equal to m and (Km)rs = km(xmr ,x
m
s ). Finally km(x,x
′) is the kernel or
covariance function for each GP. This covariance function inﬂuences the behavior of each individual
GP, and popular choices are a squared exponential or Mattern kernels, a positive linear mixture of
kernels or their products, see [172] for further details about valid covariance functions.
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Figure 3.17: Properties that can be captured by the IMoGGP model: (a) non-stationary, heteroscedastic
noise; (b) non-Gaussian likelihoods, speciﬁcally a Student’s t with Gamma distributed noise; and, (c) multi-
modal predictive distributions. Point assignments to different GPs are represented with different colors and
shapes. The legend lists number of points associated to each GP.
In Figure 3.17, we illustrate with synthetic data the complex behaviors and interesting properties
that our IMoGGP is able to capture. Figure 3.17a shows a quadratic function y = x2 − 0.5 +  with
added input-dependent Gaussian noise  ∼ N (0, (0.01+sin(2πx/10)2)2). In Figure 3.17b, we show
a cubic function y = 4x3−1+ 12+3γ with added Student’s t and gamma noise,  ∼ Students′ t(10)
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and γ ∼ Gamma(2, 0.5).9 In Figure 3.17c, we have generated 3 GPs with a Mattern covariance
functions plus Gaussian noise. In all these examples the underlying GP covariance function was a
squared exponential and the likelihood model was Gaussian. It can be seen that our IMoGGP model
is able to deal with heteroscedastic data, heavy tailed and asymmetric noise, and parallel Gaussian
processes with the same regression model, by adding global GPs over the whole input space to
capture these behaviors.
3.6.3 Simulations
This Section compares the performance of the proposed model IMoGGP against a single GP and
the IMoE from [171]. The three algorithms are compared in exactly the same conditions, with the
same hyperparameters and input splits into training and test data. Each simulation is run for 1000
iterations, and averaging is done for the last 500 iterations. Because data points are clustered in
multiple GPs, our algorithm benefits from the same computational gains than in the IMoE case, and
both algorithms are much faster to train than a single GP. All results are computed on an independent
test set corresponding to 20% of the total input data, and we perform 10 different splits at each time.
For all our experiments, we use the popular Noisy Squared Exponential (NSE) kernel, given by
K(x,x′) = v exp
(
− ‖x− x
′‖2
2w2d
)
+ v0δ(x,x
′) (3.32)
where v is the signal variance affecting the output range, v0 is the noise variance and wd is the length
scale per dimension d of x, which controls how quickly the function can vary, e.g. bigger values
for wd result in a smoother function for dimension d. This kernel has been proved to be universal,
i.e., a single GP with a noisy squared exponential kernel can approximate arbitrary smooth functions
if given enough data [130]. For both the IMoGGP and IMoE models, the overall computation is
decreased by separating data points in different GPs. For scalability reasons and fairness, we compare
our algorithm against an uncollapsed version of the IMoE algorithm presented in [171].
Database descriptions. The synthetic databases correspond to the examples in Section 3.6.2, and
include n = 2000 observations for each case. We also consider three different real databases, all
of them publicly available. The concrete database from [223] consists of 1030 observations and the
input dimension is 8. The objective is to predict the compressive strength (MPa) of concrete, which
is one of the most important materials in civil engineering. This is a highly nonlinear function of
age and ingredients that include cement, blast furnace slag, fly ash, water, superplasticizer, coarse
9We define the Gamma distribution in terms of shape and rate parameters.
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Heteroscedastic Non-Gaussian Multimodal Concrete Marathon RSSI
GP -0.0217 -3.4920 -3.3030 -0.5855 -1.6373 0.2033
IMoE 0.7017 -2.1248 -2.1604 1.9452 -1.6308 0.9943
L
L
H
IMoGGP 0.9008 -2.1237 -1.2575 2.3587 -1.5723 0.9846
GP 0.0288 4.8115 4.2815 93.4640 0.7877 86.6815
IMoE 0.0331 4.8394 5.2263 93.4640 0.7780 82.8929
M
SE
IMoGGP 0.0287 4.8500 4.2703 43.6710 0.7754 82.4264
Table 3.3: Comparison of Accuracy. Average test LLH and MSE for the single GP, the IMoE and the
proposed IMoGGP. The three first databases correspond to the toy examples plotted in Section 3.6.2. The last
three columns correspond to real databases described in this section and publicly available online.
aggregate, and fine aggregate. The actual concrete compressive strength (MPa) for a given mixture
under a specific age (days) was determined from laboratory.
For the New York City marathon data, the objective is to predict the arrival time of a runner given
his gender and age. The output y designates the arrival time, and x is a two dimensional vector with
the age and gender for each runner. We take a subset of 4, 800 runners in total, keeping the same
age/gender relative distribution.
Finally, the RSSI database consists of 4799 measurements of the Received Signal Strength Indi-
cator (RSSI), which captures the power of different wireless networks at different locations along a
large corridor.10 Modeling RSSI correctly is very important, as different signal strengths can have a
strong impact on functionality in wireless planning and localization [15].
Results. Table 3.6.3 shows quantitative results for both synthetic and real databases. We report
the mean predictive log likelihood (LLH) and mean square error (MSE) for each method and input
database. Bold values designate the best method in each case. In this experiments the PLLH is more
telling of the quality of the achieved results, because it captures the full output density estimate, while
the mean only measures the quality of the mean prediction. Nonetheless, we also report the mean for
completeness. For the same experimental conditions, our method gives the highest LLH in five out
of six databases.
The highest gains are achieved for the Multimodal and Concrete datasets. Indeed, the IMoGGP
is the only method able to use multiple functions at a single input location. On the other hand, the
Concrete database is the example with highest dimension (D = 8), and the curse of dimensionality
makes it harder for the IMoE to learn local functions. The IMoGGP is less affected as it uses global
GPs over the input space and is able to share more information across all dimensions.
The presented approach is simple, yet powerful to solve regression problems by using a IMoGGP
10This database is available in my personal webpage.
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that cover the whole input space. This method can deal with arbitrary output distributions, non-
stationary signals, heteroscedastic noise and multimodal predictive distributions straightforwardly. It
is suitable for very large databases of moderate dimension. The computational cost is not enormous
as the data points are partitioned in several GPs, and the sampling step of cluster assignments can be
run in parallel. As future work, we would like to extend this work to deal with high input dimensions.
In such scenario, it might be desirable to have varying mixture weights across the input space like
in [30] and a selection of relevant input dimensions and orders, such as in [48].
3.7 Summary
In this chapter, we have presented a novel application of BNP to model marathon runners. By
including constraints over a sp-DDP prior, we have provided insightful solutions to the problem
of age-grading in marathon races. The ADDP model informs us of the impact of age and gender
on runners’ performance. Statistical age-grading curves have been inferred, which allow us to rank
and reward athletes in a fair manner in official events. A model extension lets us capture the impact
of meteorological conditions or even topology on runners. We infer the latent difficulty for each
competition at different years, allowing robust comparison across different marathon events.
Regarding the applicability of our approach, we remark that the idea of comparing group den-
sity distributions fairly within a single model is an attractive research path, that could result in a
huge and broad number of applications. It can be applied to many problems involving stratified data
and a certain control variable (e.g., age, gender, nationality). In problems concerning group data
or any competitive human activity, sharing the mixture weights across groups is a sensible assump-
tion. Some application examples can be found in pediatrics (e.g., comparison of children population
according to weight and height), social sciences (e.g., analysis of gender impact on actual salary in-
come across countries), or pharmaceutics (e.g., monitoring certain drug responses according to some
patient covariates).
The novelty of the proposed approach relies not only on the application, but also on the necessary
steps to transform a prior that provides accurate estimates into a prior that also gives interpretable
results. Non-trivial structural assumptions and design solutions are made to find hidden properties of
the athletes while providing accurate predictions. We believe that BNP models will be more useful
for non-machine-learning experts in the future if we can tailor the priors to provide accurate and
understandable solutions.
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4
Case-control Indian Buffet Process for
Analysis of Clinical Trials
Biomarker discovery in clinical trials is of the utmost interest to understand both disease mecha-
nisms and drug effects on patients [136]. Traditional approaches for screening potentially interesting
biomarkers suffer from at least one of the following: population heterogeneity, i.e., the fact that each
individual has unique characteristics at all levels (demographics, environment or biological aspects)
resulting in different disease progressions and drug responses; strong correlations among biomark-
ers that might difficult their detection if screened individually; difficulty to isolate drug effects from
natural patient response, specially in small sample-size scenarios.
This chapter presents a novel Bayesian nonparametric (BNP) method for subpopulation charac-
terization and biomarker discovery in clinical trials which overcomes the aforementioned problems.
The case-control Indian buffet process (C-IBP) allows for the identification of prognostic and predic-
tive variables globally and specifically to each subgroup. It extends the general latent feature model
(GLFM) [210] by additionally sharing information across case-control patients in a structured way.
Empirical results on a phase II clinical trial for liver cancer demonstrate that the C-IBP can find
already well-known relevant biomarkers and discover statistically significant new ones.
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4.1 Introduction
Clinical trials constitute a key research tool for advancing medical knowledge and patient care [103,
179]. They are crucial not only in the assessment of drug efficiency and undesired side-effects, but
also in the understanding of complex biological mechanisms, and discovery of interesting biomarkers
for personalized diagnosis and precise treatment [85, 100]. In this chapter, we refer to biomarker as
any variable that can be used as an indicator of a particular disease state. Biomarker discovery
is central in the study of disease mechanisms, and is particularly useful for prediction of disease
progression, prescription of appropriated drugs based on patient characteristics, or even as potential
targets in the development of new drugs, tailored to specific subpopulations [32].
Ultimately, we seek to identify two types of biomarkers: prognostic and predictive variables.
A prognostic factor is a clinical or biological characteristic that provides information on the likely
outcome of a patient disease without considering any treatment. In contrast, a predictive factor
provides information on the likely benefit from treatment, e.g., in terms of tumor shrinkage or sur-
vival [136, 92]. Such predictive factors can be used to identify subpopulations of patients who are
most likely to benefit from a given therapy. Some good examples of predictive biomarkers being used
in the daily clinical oncology practice are estrogen and progesterone receptors to predict sensitivity
to endocrine therapy in breast cancer, HER2 to predict sensitivity to Herceptin treatment, and KRAS
mutation to predict resistance to EGFr antibody therapy [85]. Both types of biomarkers are typically
used in precision oncology for molecular diagnosis of chronic myeloid leukemia, colon, breast, and
lung cancer, as well as in melanoma [139].
Looking for interesting biomarkers has proved so far to be a very challenging task given the high
number of potential candidates, inherent complexity of biological mechanisms, and patient hetero-
geneity [108]. Indeed, clinicians might have a certain amount of information about their patients,
including genetic data, clinical observations, lab measurements, or environmental factors. Data are
typically quite heterogeneous, noisy (might contain missing data), high-dimensional, and highly
correlated, which makes it difficult to handle. Moreover, underlying biological mechanisms are ex-
tremely complex and patient populations are largely diverse. As a consequence, disease progression
or drug response end up being practically unique for each patient, which makes it challenging to
optimize treatment or develop effective drugs. For instance, most major drugs are known to be ef-
fective in only 25 to 60 percent of patients, and more than 2 million cases of adverse drug reactions
occur annually in the United States, including 100,000 deaths [218]. Such problem is aggravated in
small sample-size settings, i.e., when the number of patients is smaller than the number of available
observations per patient, which is often the case in clinical trials. Thus, improved statistical methods
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are imperatively needed to analyze data from clinical trials, which can account for heterogeneous,
noisy, and missing data. Such methods should also be able to:
(i) model population heterogeneity by sharing information across patients.
(ii) deal with correlations in high-dimensional data.
(iii) differentiate between natural response of patients and effects due to the treatment.
This chapter proposes a BNP method to discover both prognostic and predictive biomarkers,
while identifying relevant subpopulations in clinical trials. Our methodology allows us to isolate drug
effects, i.e., we are able to automatically differentiate between effects due to the natural response
of patients and those caused by the treatment itself. At the same time, we are able to discover
different subpopulations that might be characterized by different sets of biomarkers. We identify
global biomarkers that are relevant for the whole patient population, as well as local biomarkers that
only affect specific subpopulations. By performing differential analysis between subpopulations, we
can give information on the direction of change and effect size1 of each variable. Our method is
nonparametric, which means that the number of subpopulations and sets of relevant biomarkers are
automatically learned from data.
We follow a Bayesian approach to better account for missing data and uncertainty [75, 191].
Our method extends the GLFM, an approach based on the Indian buffet process (IBP) that is able
to deal with mixed continuous and discrete data [72, 210]; we extend and adapt such model to deal
with the case-control clinical trial scenario. The IBP has already been used in biological applications
such as analysis of gene expression data [107], biological interaction networks [77], multi-platform
genomics [173], genetic tumor variation [28, 112], or comorbidity analysis of psyquiatric disor-
ders [211]. To the extent of our knowledge, this is the first time that the IBP has been applied to ana-
lyze data from clinical trials. We demonstrate the usefulness of our novel approach on a real dataset,
i.e., a randomized phase II case-control study for the assessment of a cutting-edge immunotherapy
treatment for liver cancer [2]. Not only our method finds already well-known relevant biomarkers, it
also discovers new biomarkers that could not be found with previous methods, both at a global and
subpopulation specific level [158].
4.2 General Latent Feature Model
Latent feature models are unsupervised approaches to analyze complex datasets. They model the
joint probability of the data p(X) using a set of latent features [135]. Each latent feature captures
1In statistics, an effect size is a quantitative measure of the strength of a phenomenon. See Section 4.3.3 for further
details.
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common correlation patterns among the dimensions, and the objective is to learn the most probable
set of such latent features.2 Figure 4.1 illustrates the idea underlying a latent feature model. X can be
decomposed into the product of two matrices that should be learned from data: a feature-activation
matrix (also called weight matrix) Z and a dictionary matrix B. Each element xnd of matrix X
results from a linear combination of K feature elements Bkd, i.e., xnd corresponds to the realization
of a random variable following the probability distribution f(Zn•B•d), where Zn• is the n-th row of
Z and B•d is the d-th column of B. The simplest latent factor model assumes Gaussian priors over
both the weight and dictionary matrices.
The GLFM, which was ﬁrst introduced in [209], improves upon classical latent factor models
in three aspects. First, it is a Bayesian nonparametric model where the number of latent features is
also learned from data [61, 72]. In other words, the model assumes an a priori unbounded number
K of latent features, usually denoted by K → ∞. This is a useful property, given that the number
of correlation patterns (corresponding to each latent feature) to be discovered is generally not known
beforehand.
Second, the GLFM can handle heterogeneous datasets and missing observations straightfor-
wardly. This comes handy to deal with clinical trial data, where observations for each patient are
typically diverse in nature, and missing values occur frequently (e.g., not all patients might get the
same tests run, others might drop out from the study at some point, etc.).
Figure 4.1: Illustration of the matrix factorization scheme. Z is the feature-activation matrix, B is the dic-
tionary matrix, and f is the model likelihood which depends on the type of data of each dimension. Although
we depict a single function f in the diagram, this is a slight abuse of notation, since the transformation might
be different for each dimension d. We will see later that f actually corresponds to multiple link functions
Td(· ;φd) that will vary column-wise depending on the type of data and be applied element-wise.
The third advantage of the GLFM is that it allows for a partition of the patients in different sub-
populations. The model assumes a binary feature-activation matrix Z ∈ {0, 1}N×K , which admits
an easy interpretation in which each latent feature can be either active or inactive for each patient.
Patient subpopulations can then be identiﬁed by gathering all patients that have the same set of active
features. Within the Bayesian framework, the GLFM resorts to the IBP as a prior for the feature-
2More precisely, the objective is to learn a posterior distribution for each latent feature.
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activation matrix Z [209].
To deal with mixed continuous and discrete observations together [210], the GLFM assumes that
each observation xnd comes from the transformation of an auxiliary Gaussian-distributed random
variable ynd, resulting in the following generative model:
xnd = Td(ynd;φd) (4.1)
ynd|Z,B ∼ N (Zn•B•d, σ2y), Z ∼ IBP(α). (4.2)
Gaussian priors are assumed over each elementBkd ∼ N (0, σ2B). The function Td(· ;φd) is the like-
lihood transformation for dimension d, a link function which will depend on the type of data at hand,
and φd are eventual parameters for the chosen transformation Td(· ;φd). The inference proposed for
such model follows a Markov chain Monte Carlo (MCMC) approach, namely, an accelerated Gibbs
sampling (AGS). The idea of AGS is that, instead of completely collapsing B, we instantiate it at
each iteration using a subset of the data, randomly chosen and different at each iteration. Algorithm 2
shows the inference procedure for a single iteration of the GLFM.
Algorithm 2 Single iteration in the MCMC procedure for the GLFM (see [210] for further details).
Input: feature activation matrix Z, pseudo-observations Y, observations X
1: update Z given Y using AGS
2: for d = 1, . . . , D do
3: sample Bd given Z, Yd
4: sample Yd given X, Z, and Bd
5: end for
Output: activation matrix Z, pseudo-observations Y, and dictionary B
4.3 Our Approach
Let us consider a clinical trial for the assessment of a certain treatment. N is the total number of
patients involved in the clinical trial, and D is the number of available observations for each patient
– those might include demographics, genetic data, clinical or environmental information. Let X
be the N × D input matrix of the observations for all patients. Such matrix might be incomplete,
noisy and heterogeneous (it might contain very diverse data such as continuous, positive real-valued,
categorical, ordinal, or count data). Among the N patients, N0 patients have taken a placebo (we
refer to this group as the placebo arm), and N1 others have received the actual drug, thus belonging
to the treatment arm. Let R ∈ {0, 1}N×1 be the drug indicator vector, which takes non-zero values
for patients belonging to the treatment arm.
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Among the D available dimensions for each patient, we have a variable d∗ (or several) that
captures how well patients are doing, e.g., the elapsed time until tumor size increases.3 In such
scenario, our objective is to discover prognostic and predictive biomarkers with respect to d∗, i.e.,
prognostic variables that help us predict the natural evolution of patients regardless of treatment, and
predictive variables to anticipate patient drug responses.
Here, we resort to an unsupervised approach4 based on the GLFM where we model the joint
probability distribution p (X). The gist of our method for biomarker screening is to first, find an
useful projection of the patients population into a latent space, and second, conduct a set of hypothesis
tests based on such partition of the patients, i.e., a multiple hypothesis testing procedure to quantify
the statistical significance of each biomarker. Finding an adequate basis for the latent space is crucial
to reveal an useful set of subpopulations (patients with similar biomarker profiles) where drug effects
are isolated from natural disease responses, thus revealing potential targets for improvement of the
efficiency of the drug.
4.3.1 Modeling
In order to deal with the small sample-size scenario typical from clinical trials, we adapt the GLFM to
share information between patients in the placebo and treatment arm. In particular, we allow for two
types of latent features: global features and treatment-specific features. Global features are learned
from patients in the placebo arm, and can be active for any patient, capturing general patterns in the
patient population regardless of any treatment. In contrast, drug-specific features are learned from
treated patients solely, and can only be active for patients in the treatment arm, capturing correlations
linked to the effect of the drug. We call this extension the case-control Indian buffet process (C-IBP)
feature model.
Let Z and W be the feature activation matrices for global and drug-specific features respectively.
Note that the model will learn the necessary number of global features K and treatment-specific
features K ′. The complete generative model is given by
3The definition of variable d∗ is important for the post-processing statistical analysis of the model output.
4Note that dimension d∗ is included in matrix X, we treat such variable in the same way as any other observation, in
contrast to any supervised approach such as linear mixed models or hazard modeling. A standard supervised approach was
already conducted for our application at hand at [2].
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Y•d XR
φd
Z B•d
σ2B
α
W C•d σ2Cα
d = 1 . . . D
Figure 4.2: Graphical model for the C-IBP. Nodes represent random variables: grey ones are observed,
whereas white ones are hidden. X is the observation matrix for all patients, and R is the drug indicator vector
to distinguish patients in the placebo and treatment arms. Z and W are the feature activation binary matrices
for global and treatment-specific features, whereas B and C are the respective dictionary matrices.
xnd = Td(ynd;φd) (4.3)
ynd|Z,W,B,C,R ∼ N (Zn•B•d + 1[Rn = 1]Wn•C•d, σ2y) (4.4)
Bkd ∼ N (0, σ2B), Ckd ∼ N (0, σ2C) (4.5)
Z ∼ IBP(α), W ∼ IBP(α), (4.6)
where B and C are the dictionary matrices for global and treatment-specific features, respectively.
Figure 4.2 shows a graphical representation of the C-IBP. Concerning the link functions Td(· ;φd),
we use the default transformations described in [210].
4.3.2 Inference
Following [210], we use an MCMC method, which has been broadly applied in other IBP-based
models [72, 131, 219]. An important remark is that conditioned on Y, the feature activation matrices
Z, W, and the dictionary matrices B, C, are all independent from the observation matrix X. In order
to infer matrices Z and W, we resort to a collapsed Gibbs sampler, which presents better mixing
properties than the uncollapsed one. Gibbs sampling is often chosen in the context of the standard
linear-Gaussian IBP because of its simplicity, but its computational cost is relatively high [72]. To
make the algorithm more efficient, we resort to the AGS which is fully described in [39]. Some of
the sampling steps for the feature activation matrices can then be done independently and in parallel,
as in the uncollapsed case.
A simple sub-optimal inference procedure for the C-IBP can be directly derived based on the
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inference for the GLFM. We first learn the global features by training the GLFM with patients be-
longing to the placebo arm exclusively. We thus learn a set of global features to describe general
placebo patients. Next, we learn the drug-specific features for patients in the treatment arm. This is
performed by training the GLFM model with the whole patient population and imposing the follow-
ing constraints:
(i) global features (corresponding to matrix B) are kept fixed to the values learned previously.
(ii) feature activations for patients in the placebo arm are initialized to their previous value.
(iii) drug-specific features are forced to be inactive for all patients in the placebo arm, i.e., these
features are learned solely based on patients belonging to the treatment arm. These allow us to
completely isolate the effect of the drug.
More precisely, let Z0 ∈ {0, 1}N0×K and Z1 ∈ {0, 1}N1×K be the global feature activation
matrices for patients in the placebo and treatment arm respectively, whereK is the number of inferred
global features, N0 is the number of patients in the placebo arm, and N1 is the number of patients
belonging to the treatment arm. Also, let us define Y0 and Y1 as the auxiliary variables for placebo
and drug patients respectively. Patients in the placebo arm are only affected by matrices Z0, Y0, and
B. For these latent variables, we can directly apply the inference procedure described in Algorithm 2.
Once Z0, Y0, and B have been sampled, global feature activations for drug patients Z1 can be
sampled as
p(Z1nk = 1|Z−nk,B) ∝
mk
N
D∏
d=1
N (ynd|
∑
j
Z1njBjd, σ
2
y), (4.7)
where mk is the number of patients for which feature k is active. Note that at this stage, we do not
allow for the creation of new global features: we only want to know the assignment of global features
for the drug population. Given all feature activation matrices Z and W, C and Y1 can be sampled
in the same way as B and Y0 before. The whole inference procedure is summarized in Algorithm 3.
4.3.3 Statistical Methodology
Once the model has been trained (samples from an approximate posterior distribution can be drawn),
we proceed with a classical frequentist approach5 to identify statistically significant prognostic and
predictive biomarkers. The whole procedure is summarized in Algorithm 4. First, we take M pos-
terior samples from the posterior distribution of Z. For each sample, patients that have the same
5Although Bayesian approaches to quantify statistical significance exist, such as posterior predictive checks or Bayesian
factors, classical statistics predominate in the bio-medical field.
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Algorithm 3 Sub-optimal inference procedure for the C-IBP model.
Input: observation matrix X
1: Initialize: feature activation matrices Z and W, and pseudo-observations matrix Y
2: for each iteration do
3: sample Z0, Y0, and B given X, according to Algorithm 2
4: for d = 1, . . . , D do
5: sample Z1 given Y1 and B according to (4.7)
6: end for
7: sample W given Z1 and Y1 using AGS
8: for d = 1, . . . , D do
9: sample Cd given Z, W, and Y•d
10: sample Y1d given X, Z, W, B•d and C•d
11: sample φd if needed
12: end for
13: end for
Output: feature activation matrices Z and W
activation pattern of features can be grouped together in the same subpopulation. For instance, sub-
population (1001) refers to all patients having the first and forth feature active. Let P refer to the
total number of inferred subpopulations across the M posterior samples. By considering multiple
posterior samples, we obtain slightly different partitions of patients in subpopulations. This can be
seen as performing soft-clustering of patients, i.e., patients that are in-between subgroups might be
assigned to different subpopulations in different posterior samples. Thus, the method is more robust
against model inaccuracies at clustering patients. This is an important benefit of Bayesian modeling
in general.
Next, in order to also make our method robust against outliers (patients with extreme biomarker
values), we perform bootstrapping L times, for each subpopulation and posterior sample. Boot-
strapping relies on random sampling with replacement. It is a technique used for computing robust
estimators against outliers by sampling from an approximating distribution, which is particularly use-
ful for hypothesis testing when the model assumptions are in doubt or unknown [216]. The standard
bootstrapping approach relies on the construction of an estimator for hypothesis testing based on a
number L of resamples with replacement of the observed dataset (and of equal size to the observed
dataset), i.e., sampling with replacement from the empirical distribution of the observed data.
Given M posterior samples and L bootstrapping instances for each sample, we end up with ML
different subpopulation instances. Measures of effect size (quantitative measure of the difference
between two subpopulations) and statistical significance can be computed for each instance and then
averaged across them, so that partition inaccuracies and outlier effects are mitigated. In the described
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algorithm, we suggest to compare each possible pair of subpopulations,6 but we might want to focus
only on the biggest communities or specific subpopulations of interest to reduce computational cost.
LetQ be the total number of considered comparisons between subpopulations. In our particular case,
Q = P · (P − 1)/2 as we consider each pairwise comparison among the P subpopulations. Let i(q)
and j(q) refer to the set of subpopulation indexes corresponding to comparison q, e.g., i(q) = 4 and
j(q) = {1, 2, 3} corresponds to the comparison of subpopulation 4 against subpopulations 1, 2, and
3 aggregated. In the following, we will describe how to compute the Q×D effect size and statistical
significance matrices.
Algorithm 4 Statistical approach for biomarker discovery (post-processing procedure).
Input: M posterior samples from Z and W, list of P subpopulations, and Q comparisons
1: for m = 1, . . . ,M do
2: bootstrap for each subpopulation L times
3: end for
4: for q = 1, . . . , Q do
5: choose subpopulations Gi(q) and Gj(q)
6: compute effect size according to Eq. 4.8, 4.9, and 4.10.
7: compute statistical significance (p-value) according to the Mann-Whitney test for continuous
variables and Fisher test for discrete variables, adjusting for multiple hypothesis testing [17]
8: end for
Output: effect size matrix ∆ and significance matrix Υ, both of dimensions Q×D
Effect size. For each comparison q and dimension d, we compute the effect size ∆qd as:
∆qd = Em,l [δqd(m, l)] , (4.8)
where δqd is an M × L matrix of relative effect sizes for each posterior sample m and bootstrap
iteration l. The expectation is done across all posterior samples and bootstrapping iterations, which
are equally probable. In the case of continuous variables, we define
δqd(m, l) = log2
µd
(
Gi(q)ml
)
µd
(
Gj(q)ml
)
 , (4.9)
where Gi(q)ml and Gj(q)ml refer to subpopulations i(q) and j(q) in the posterior sample m and bootstrap
iteration l, and µd(G) is the mean value of variable d within a given subpopulation G. Taking the
logarithm facilitates interpretation, such that an increase or decrease ratio has the same scale: for
6Other comparison schemes are possible, such as a leave-one-out strategy consisting in the comparison of each individ-
ual subpopulation against the rest. Note that as the number of comparisons increase, the correction for multiple hypothesis
testing shall be stronger.
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instance, δqd(m, l) = 0 means that variable d has exactly the same averaged value in both subpopu-
lations, δqd(m, l) = +1 means that variable d is twice higher in subpopulation i, and δqd(m, l) = −2
means that variable d is four times smaller in subpopulation Gi(q)ml with respect to subpopulation Gj(q)ml .
In the case of a discrete variable d, we check for mean differences, i.e.,
δqd(m, l) = µd(Gi(q)ml )− µd(Gj(q)ml ). (4.10)
Note that we define different measures for continuous and discrete variables as the dynamic range of
continuous variables is generally much higher, making the logarithmic scale more appropriate.
Statistical significance. To measure how significant an effect size δqd(m, l) is, for each poste-
rior sample m and bootstrap instance l, we compute a statistical significance value υqd(m, l) as the
p-value resulting from a certain two-sample test. In general, selecting the most appropriate statis-
tical test in hypothesis testing is a challenging task [94, 127]. Here, we opt for one statistical test
for all continuous variables and another one for discrete variables for simplicity, although more so-
phisticated strategies could certainly be investigated. We use the Mann-Whitney test for continuous
variables and the Fisher test for discrete variables. The Mann-Whitney test is a general nonparametric
statistical test to check whether the distribution of both populations are equal without requiring any
normality assumption. The Fisher test is a standard test for categorical variables [216]. We define
the Q×D matrix of statistical significance Υ, for each comparison q and biomarker d as the median
p-value across the M samples and L bootstrapping instances:
Υqd = medianm,l [υqd(m, l)] , (4.11)
where υqd denote the M × L matrix of statistical significance values υqd(m, l) for each posterior
sample m and bootstrapping instance l. Finally, we follow the Benjamini Hochberg procedure for
multiple hypothesis testing to adjust the statistical significance threshold αs such that a certain false
discovery rate (FDR) is guaranteed [17]. A biomarker d is said to be statistically significant for com-
parison q if its significance value Υqd (the median p-value across posterior samples and bootstrapping
instances) is smaller than the adjusted threshold, i.e., Υqd < αs.
4.4 Results
To evaluate the performance of our method, we consider a randomized phase II trial regarding an im-
munotherapy treatment against liver cancer [2]. This clinical trial studies the effect of Codrituzumab,
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a manufactured antibody treatment against a liver cancer protein called Glypican-3 (GPC3) that is
expressed in hepatocellular carcinoma (HCC). GPC3 is a member of the glypican family, a group
of heparan sulfate proteoglycans linked to the cell surface and which plays an important role in cell
growth, differentiation, and migration [116, 52]. GPC3 is highly expressed in HCC and has become
a useful diagnostic marker for HCC by immunohistochemical (IHC) studies, since the adjacent non-
tumoral tissue does not express GPC3 [221]. GPC3 may promote HCC growth by stimulating the
canonical Wnt pathway, and/or interacting with the IGFII-IGF1R pathway, or it may play a role in
FGF signaling [26]. Therefore, GPC3 may represent a specific tumor marker and a potential target
for therapy in HCC [138].
4.4.1 Antibody Treatment for Hepatocellular Carcinoma
Codrituzumab is a recombinant, humanized monoclonal antibody that binds to human GPC3 with
high affinity [98, 197]. Codrituzumab interacts with CD16/FcγRIIIa and triggers antibody-dependent
cytotoxicity (ADCC), as shown by [137]. Non-clinical characterization of Codrituzumab demon-
strates that it elicits ADCC against GPC3-positive human hepatoma cell lines, using human periph-
eral blood mononuclear cells as effector cells [198]. Phase I studies in US and Japan showed that
Codrituzumab was well tolerated up to 20 mg/kg/wk without dose limiting toxicity [227, 93].
Here, the considered phase II clinical trial aims at comparing Codrituzumab versus placebo in
advanced HCC patients who had failed prior systemic therapy (whole body treatment). The database
consists of 180 patients, 60 patients in the placebo arm and 120 patients in the treatment arm. For
each patient n, we consider 71 observations which include demographic information, characteristics
of the tumor and diverse clinical measurements. We used progression free survival (PFS) as a clinical
endpoint in our analysis. This variable measures the elapsed time in months until the tumor grows in
size, which is correlated to the survival of HCC patients.
According to a first analysis of this database published in [2], Codrituzumab was not found
to be effective against liver cancer, although it was suggested that a higher dose of Codrituzumab
or selecting patients with high level of GPC3 could improve the outcome. This directly relates to
the patient heterogeneity problem explained in Section 4.1. By directly addressing this issue, our
approach gives us additional information that could not be extracted in that first study.
4.4.2 Identified Subpopulations
As shown in Table 4.1, the C-IBP model identified twelve subpopulations from the set of 180 patients,
and three latent features (F1, F2, and F3) which capture correlation patterns of biomarker values.
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Sub-
population
Drug
Identifier
F1 F2 F3 Average num.
of patients
Mean PFS
(months)
Median PFS
(months)
1. 0 0 0 0 33.37 3.06 1.65
2. 0 0 1 0 4.07 2.29 2.24
3. 0 1 0 0 17.84 2.72 1.81
4. 0 1 1 0 4.72 7.05 7.18
5. 1 0 0 0 51.52 3.22 2.55
6. 1 0 0 1 16.77 4.17 3.65
7. 1 0 1 0 8.38 1.74 1.33
8. 1 0 1 1 2.07 2.69 2.65
9. 1 1 0 0 29.88 3.36 2.03
10. 1 1 0 1 4.90 4.44 4.34
11. 1 1 1 0 4.53 6.31 5.31
12. 1 1 1 1 1.94 10.04 10.01
Total 120.0 63.82 25.72 25.69 180 3.44 2.04
Table 4.1: List of subpopulations identified by the C-IBP. Each subpopulation (row) is represented by a
feature activation pattern, e.g., (1100). Last row respectively corresponds to the average number of patients
having each feature active, as well as the total size of the database, global mean and median PFS values.
These features can be either active (= 1) or inactive (= 0) for each patient individually. A feature
is active when the corresponding pattern contributes to the total biomarker values of that patient.
A subpopulation is defined as a group of patients having similar biomarker values, encoded by the
same set of active features. Among the three inferred features, F1 and F2 are global, and F3 is a drug-
specific feature. The later captures variations exclusively due to the drug, as it can only be active for
patients in the placebo arm, corresponding to subpopulations 1 to 4. The last three columns in the
table tell us how many patients are present on average in each subpopulation,7 as well as the mean
and median values of the PFS.
In the placebo arm, the C-IBP model inferred four subpopulations from data (groups 1 to 4
in Table 4.1). Subpopulation 4 has a significantly higher PFS, indicating better prognosis. In the
treatment arm (groups 5 to 12 in Table 4.1), subpopulations with feature F3 active (6, 8, 10 and 12)
have higher PFS values. The effect of F3 on prolonged survival was found across all subpopulations,
as seen by pairwise comparisons between subpopulations in the treatment arm with F3 active vs. the
ones with F3 inactive (e.g., 5 vs 6, 7 vs 8, etc).
Table 4.3 shows a boxplot illustration for PFS values within each of the twelve inferred subpop-
ulations. Within the placebo arm, subpopulation 4 is the only sub-group that has much longer PFS
values or survival, whenever both F1 and F2 are active. Concerning the treatment arm, the last three
7Note that the size of each subpopulation is not an integer number of patients because we are averaging over different
posterior samples and bootstrapping iterations at each time, as discussed in Section 4.3.3
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communities (subpopulations 10, 11, and 12) have PFS values that are more than twice higher with
respect to the global average. Yet, it is not clear a priori whether such communities have longer PFS
because of the drug, or because they had a good natural predisposition from the beginning. Latent
features can help us answer this question. In particular, by looking at the global features F1 and F2,
we can see that communities 11 and 12 share the same activation pattern than subpopulation 4; this
means that they share the same biomarker values/good conditions for a positive natural response, in-
dependently of the drug. In contrast, community 10 has the same activation pattern than community
3 for the global features, which indicates that there is no a priori reason to expect a positive natural
response from these patients: the survival increase in that case would be exclusively due to the drug,
and captured by feature F3. In general, note that whenever feature F3 is active, there is a systematic
increase in PFS values for each community with respect to their equivalent subpopulation with F3
equal to zero. Thus, we can say that F3 captures a positive effect of the drug on patients, which is
stronger whenever feature F2 is also active. Figure 4.3 shows the survival or PFS values as box plots
for each inferred subpopulation.
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Figure 4.3: Survival boxplots for each subpopulation. We represent the distribution of PFS (in months) for
each subpopulation. The patterns in the x-axis correspond to those listed in Table 4.1.
4.4.3 Discovered Biomarkers
Next, we analyze the effect of each latent feature activation on the biomarker values. Figure 4.4 depict
the relative mean effect size of each biomarkers in relation to each of the three latent features (F1-F3).
The black vertical lines correspond to two standard deviations of the relative effect size matrix δqd.
Biomarkers which are statistically significant at significance level αs = 0.001 are marked with a red
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circle. Table 4.2 corresponds to the same information in numerical values, as well as p-values for
each biomarker. More precisely, these figures and tables result from the comparison of aggregated
subpopulations in which one particular feature is active against all the other subpopulations (where
that particular feature is inactive). For instance, Figure 4.4a results from the statistical procedure
described in 4.3.3 applied to subpopulations (3,4,9,10,11,12) against (1,2,5,6,7,8). The sign (+ or -)
is important for the biological interpretation of the data, and indicates the direction of the biomarker
effect on the case group versus the control group, such that positive effect means that the biomarker
has a higher value in the case group versus the control group.
Variable
description
Effect
size Mw-test
AFP 3.65 1.31e-07
H score Mem 1.30 1.53e-21
H score Cyt 0.69 2.08e-16
sGPC3 11/96 0.47 1.34e-04
sGPC3 30/57 0.40 1.53e-05
sGPC3 30/607 0.34 6.21e-10
sGPC3 114/165 0.32 2.48e-10
CD56-CD16+ 0.34 1.42e-03
CD56dimCD16- 0.22 7.69e-04
NK 0.42 4.40e-03
CD56dimCD16
bright 0.42 6.23e-03
CD16 0.10 3.88e-03
NKP46 0.09 3.08e-03
CD8 0.07 1.41e-02
CD3 0.05 5.38e-03
CD45 0.05 6.88e-03
Variable
description
Effect
size F-test
IHC 3+ 0.84 1.96e-31
IHC 1+ -0.42 9.97e-11
IHC 2+ -0.23 3.67e-06
IHC 0 -0.19 4.42e-05
FCGRIIIA-158-
C/A -0.25 7.16e-04
FCGRIIIA-158-
A/A 0.20 9.21e-03
(a) Feature F1
Variable
description
Effect
size Mw-test
CD3/CD16
necrotic / stroma 3.94 1.29e-17
P Necrotic /
stroma 3.91 9.39e-18
CD3/CD16
tumor viable -1.27 1.29e-17
P Tumor Viable -1.24 9.39e-18
sGPC3 30/607 -0.25 4.02e-04
AAT -0.58 1.54e-03
sGPC3 114/165 -0.21 2.43e-03
Variable
description
Effect
size F-test
- - -
(b) Feature F2
Variable
description
Effect
size Mw-test
CD56dimCD16
bright 1.27 2.18e-09
NK 1.24 2.13e-10
CD56-CD16+ 0.61 2.19e-06
CD56dimCD16- 0.42 1.04e-05
CD8 NK 0.37 7.13e-08
DN 0.27 3.73e-05
CD16 0.24 6.06e-10
NKP46 0.22 1.14e-09
CD8 0.20 3.44e-09
CD45 0.14 5.09e-11
CD3 0.13 1.49e-08
CD4 0.12 5.06e-06
H score Mem -0.89 1.73e-03
DP 0.54 3.55e-04
B 0.19 8.55e-04
CD56 0.18 3.05e-03
AFP -3.34 1.86e-02
P Stroma -1.26 6.70e-03
CD4/CD8 -0.75 9.05e-03
Ctrough 0.59 4.24e-03
P Tumor 0.35 1.10e-02
sGPC3 30/607 -0.19 1.59e-02
Variable
description
Effect
size F-test
- - -
(c) Feature F3
Table 4.2: Significant biomarkers associated to the activation of each inferred latent feature. F1 and
F2 are global features, whereas F3 is a treatment-specific feature. Colors code for the different statistical
significance levels: αs = 0.001 (black), αs = 0.005 (blue), and αs = 0.01 (green). Continuous variables on
the top, discrete variables on the bottom.
Feature F1 in Figure 4.4a is associated with high levels of alpha-fetoprotein and GPC3 expression
both in tumor (GPC3 cytoplasmic and membrane IHC staining), and as soluble protein sGPC3 (as
detected by four serum assays). Feature F2 is associated with higher levels of inflammatory T and NK
cells (positively stained for CD3/CD16) in tumor necrotic tissue and adjacent peri-tumoral stroma,
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Figure 4.4: Relative effect size of biomarkers associated to each latent feature inferred by the C-IBP
model. Significant biomarkers according to the Mann-Whitney test are marked with red circles (αs = 0.001).
F1 identifies two types of patients with similar prognosis but different characteristics, F2 and F3 are asso-
ciated with higher Progression Free Survival: F2 capture prognostic biomarkers while F3 capture predictive
biomarkers.
82
CHAPTER 4. CASE-CONTROL IBP FOR ANALYSIS OF CLINICAL TRIALS
and low levels of CD3/CD16 in viable tumor cells, as shown in Figure 4.4b. Feature F3 is associated
with higher levels of T (CD3, CD45) and NK (CD16, NKp46) cell markers, and low levels of alpha-
fetoprotein (see Figure 4.4c).
4.4.4 Discussion
The identification of biomarkers in complex datasets affected by multiple confounding factors can
be challenging. In drug development, clinical trials are powered to deal with situations of con-
stant drug exposure, and traditional statistical methods have difficulties extracting signals from data
confounded by factors like differential drug exposure. Therefore, sensitive analytical methods are
needed to deconvolute real signals from biological and technical noise. We applied the C-IBP to a
phase II clinical study of Codrituzumab in HCC which had failed to meet the primary endpoint due
to insufficient drug exposure in the treatment arm. Traditional statistical approaches did not render
useful insights into potential biomarkers of response; in contrast, the IBP-based analysis identified
several biomarkers that stratified patient subgroups with statistical significance.
The C-IBP model identified two kinds of features: global features, which were active for pa-
tients regardless of treatment and indicated prognostic markers, and drug-specific features, which
were active for patients only in the treatment arm. Global prognostic features included known
prognostic markers in HCC, like alpha-fetoprotein and GPC3 expression in the tumor. In addi-
tion, global features included levels of inflammatory T and NK cells in tumor necrotic tissue and
adjacent peri-tumoral stroma. Patients with higher levels of CD3/CD16 staining in peri-tumoral tis-
sue and lower levels in viable tumor cells had better prognosis, which is consistent with the role of
inflammatory cells in anti-tumor response [57]. Drug-specific features included different NK cell
subtypes. This is consistent with the mode of action of Codrituzumab, which requires engagement
of the CD16/FcγRIIIa receptor in NK cells to recruit NK cells to the tumor and subsequent tumor
lysis [137]. The C-IBP method allows for flexible interrogation of the data, for example, the effect
of F3 on prolonged survival was found across all subpopulations, as seen by pairwise comparisons
between subpopulations in the treatment arm with F3 active vs. the ones with F3 inactive (e.g., 5 vs
6, 7 vs 8, etc. . . in Table4.1).
4.5 Summary
In this chapter, we have presented a BNP method for subpopulation characterisation and biomarker
discovery in clinical trials. The BNP is very flexible, as it automatically infers the required number
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of latent features that better explain the observations. We were able to identify both prognostic and
predictive variables, and quantify the direction of action, effect size and statistical significance for
each biomarker. Our model handles noise and missing information naturally, as well as heterogeneity
in the types of data (continuous versus discrete).
Through the use of global and drug-specific features, the C-IBP model clearly separates between
drug effects and natural prognostic factors. Also, our methodology of combining a Bayesian model
with classical statistical tools is robust in several aspects: first, instead of doing hard-clustering, we
compute a soft-partition by using the average of all feature activations in the posterior. Second, we
combine bootstrapping techniques with posterior samples of the model, and statistical significance
is assessed using classical well-known statistical tests. In summary, the C-IBP applied to a complex
phase II clinical study in HCC confounded by several factors was able to identify prognostic and
predictive biomarkers of response to Codrituzumab. Given the large heterogeneity in response to
cancer therapeutics, novel methods of identifying mechanisms and biology of variable drug response
and ultimately treatment individualization will be indispensable [148].
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4.A Appendix: General Latent Feature Modeling Toolbox
GLFM is a software library to perform latent feature modeling in heterogeneous datasets, where
the attributes describing each object can be either discrete, continuous or mixed variables. Up to
our knowledge, this library provides the first available software for latent feature modeling in het-
erogeneous data, and includes functions for the two main applications of the GLFM, i.e., missing
data estimation (a.k.a. table completion) and data exploratory analysis [210]. The core algorithm is
developed in C++ and includes user interfaces in both Python and Matlab.8
4.A.1 Implementation
The main function of the package, hidden = GLFM.infer(data),9 runs the inference algo-
rithm given the input structure data and returns the learned latent variables in the output structure
hidden. This function receives as input an observation matrix Xd and a vector indicating the type
of data for each dimension (optionally, model hyperparameters and simulation settings can be cus-
tomized by the user). The latent variables are learned by making use of the mapping transformations
listed in Table 4.3 to account for both continuous and discrete data types. Here, the parameters µ and
w are used to shift and scale the raw input data, and are respectively set to the empirical mean and the
standard deviation for real-valued attributes, and to the minimum value and the standard deviation
for positive real-valued and count attributes. This guarantees that the prior distributions on the latent
variables are equally good for all the attributes in the dataset, regardless their support. The output
structure hidden contains the latent feature vectors Zn• for n = 1, . . . , N , the weighting vectors
B•d, as well as auxiliary variables for both the likelihood and link function. Our implementation of
the GLFM makes use of the GNU Scientific Library (GSL),10 to efficiently perform a large variety
of mathematical routines such as random number generation, and matrix or vector operations.
4.A.2 Usage
Data preprocessing and initialization. A convenient property of the GLFM package is that it can
be used blindly on raw data without requiring any preprocessing step on the dataset, nor special
tunning of hyperparameters. The only requirement for the user to use the package is to format the
data as a numerical matrix of size N × D and indicate in an additional vector the type of data for
each of the D attributes. As mentioned above, the parameters of the transformations in Table 4.3 are
8GLFM code is publicly available in https://github.com/ivaleraM/GLFM
9This call corresponds to a python call. The equivalent call in Matlab is hidden = GLFM infer(data).
10https://www.gnu.org/software/gsl/
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Type of Variable Domain Transformation x = fd(y)
Real-valued x ∈ < x = w(y + u) + µ
Positive real-valued x ∈ <+ x = log(exp(w(y + u) + µ) + 1)
Categorical x ∈ {1, 2, . . . , R} (unordered set) x = arg maxr∈{1,...,R} yr
Ordinal x ∈ {1, 2, . . . , R} (ordered set) x =

1 if y ≤ θ1
2 if θ1 < y ≤ θ2
...
R if θR−1 < y
Count x ∈ {1, 2, 3, . . .} x = blog(exp(w(y + u) + µ) + 1)c
Table 4.3: Mapping functions implemented in the toolbox.
internally fixed to ensure that the pseudo-observation for all attributes fall in a similar interval of the
real line, so that the prior distribution on the latent variables is equally good for all attributes.
However, we incorporate an additional functionality that allows the user to specify external pre-
processing functions to further improve the performance of the algorithm. For instance, in cases in
which the distribution of an attribute presents a clearly non-Gaussian behavior, e.g., it is concentrated
around a single value or heavy-tailed, it might be suitable to pre-process this variable by applying a
logarithmic transformation, as shown Figure 4.5.
Missing data estimation. GLFM can be used for estimation and imputation of missing data in
heterogeneous datasets, where the missing values can be encoded with any (numerical) value that
the user specifies. The Bayesian nature of the GLFM allows to efficiently infer the latent fea-
ture representation of the data using the available information (i.e., the non-missing values), and
using it to compute the posterior distribution of each missing value in the data. Note that given
the posterior distribution of each missing value, one might opt for different approaches to impute
missing values, e.g., one might opt for imputing a sample of the posterior distribution or sim-
ply the maximum a posteriori (MAP) value. The GLFM package provides the function [Xmap,
hidden]=GLFM.complete(data) which infers the latent feature representation, given the (in-
complete) observation matrix, and returns a complete matrix where the missing values have been
imputed to their MAP value. This function therefore runs the inference function GLFM.infer(),
as well as the function GLFM.computeMAP(), which computes the MAP of a single missing ele-
ment xdn given z
n and Bd.
86
CHAPTER 4. CASE-CONTROL IBP FOR ANALYSIS OF CLINICAL TRIALS
−2 0 2 4 60
0.5
1
(a) Pseudo-observations yd
60 70 80 90 100
0
0.05
0.1
0.15 Empirical
1 0 0 0
0 1 0 0
(b) Xd without pre-processing
60 70 80 90 100
0
0.05
0.1
0.15 Empirical
1 0 0 0
0 1 0 0
(c) Xd with log pre-processing
Figure 4.5: Illustration of optional data pre-processing. Panel (a) shows the histogram a heavy-tailed
attribute and panel (b) the attribute after a logarithmic transformation, as well the distribution of the inferred
latent feature patterns. Here we observe that the distribution of the attribute is better captured by the latent
model when a pre-processing step is performed to correct/minimize the non-Gaussian behavior of the attribute.
Data exploration analysis. GLFM can also be used as a tool for data exploratory analysis, since
it is able to ﬁnd the latent structure in the data and capture the statistical dependencies among the
objects and their attributes in the data. GLFM provides (weighted) binary latent features, easing their
interpretation and making it possible to cluster the objects according to their activation patterns of
latent features. Moreover, it also allows to activate a latent feature that is active for all the objects
(a.k.a. bias term), which might be useful to capture the mode of the distribution of each attribute in the
dataset. In order to ease data exploration, GLFM provides the function GLFM.plotPatterns(),
which plots the posterior distribution for of each attribute under the given latent feature patterns,
and therefore, allows us to ﬁnd patterns and dependencies across both objects and attributes. This
function, in turn, makes use of the function GLFM.computePDF(), which evaluates the posterior
distribution of an attribute under a given latent feature vector.
4.A.3 Showcase Example: Voters Proﬁle in Presidential Election
In this subsection, we illustrate the usefulness of the GLFM for data exploration in the context of
politics, to identify meaningful demographic proﬁles, together with their geographic location, and
voting tendencies in the United States. This showcase example shows how to include the speciﬁc
domain knowledge into the proposed GLFM to ease the data exploration process. We apply the
GLFM library to understand the correlations between demographic proﬁles and political vote ten-
dencies. In particular, we focus on the United States presidential election of 1992, in which three
major candidates ran for the race: the incumbent republican president George H. W. Bush, the demo-
cratic Arkansas governor Bill Clinton, and the independent Texas businessman Ross Perot. In 1992,
the public’s concern about the federal budget deﬁcit and fears of professional politicians allowed the
independent candidacy of billionaire Texan Ross Perot to appear on the scene dramatically [9], to the
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point of even leading against the major party candidates in the polls during the electoral race.11 The
race ended up with the victory of Bill Clinton by a wide margin in the Electoral College, receiving
43% of the popular vote against Bush’s 37.5% and Perot’s 18.9% [109]. These results are noted for
being the highest vote share of a third-party candidate since 1912, even if Perot did not obtain any
electoral votes [109].
Our primary objective in this section is to find and analyze the different types of voters’ profiles,
as well as which candidate each profile tends to favor. To this aim, we used the publicly available
counties dataset gathering diverse information about voting results, demographics and sociological
factors per counties.12 This dataset contains information for 3141 counties. Table 4.4 lists the per-
county attributes that we used as input for our model.
Attribute description Type of data
State in which the county is located Categorical with 51 categories
Population density in 1992 per squared miles Positive real data
% of white population in 1990 Positive real data
% of people with age above 65 in 1990 Positive real data
% of people above 25 years old with bachelor’s degree or higher Positive real data
Median family income in 1989 (in dollars) Count data
% of farm population in 1990 Positive real data
% of votes cast for democratic president Positive real data
% of votes cast for republican president Positive real data
% of votes cast for Ross Perot Positive real data
Table 4.4: List of considered attributes regarding the United States presidential election of 1992. At-
tributes 1 to 7 include demographic information and sociological factors, while the last three attributes sum-
marize the percentage voting outcome in each county.
Active Feature F1 F2 F3 F4 F5
Empirical Prob. 0.4874 0.2703 0.2700 0.0411 0.0372
Table 4.5: Empirical feature activation probabilities for the counties dataset. We show the empirical
probability of having at least one latent feature. These are directly computed from the inferred IBP matrix Z.
Patterns (000) (100) (101) (010) (110)
Empirical Prob. 0.2636 0.2407 0.1063 0.1060 0.0748
Table 4.6: Empirical probability of pattern activation for the top-five most popular patterns. These are
computed directly from the inferred IBP matrix Z. Features F4 and F5 are always switched off, and are thus
omitted from the labels.
11New York Times: http://www.nytimes.com/1992/06/11/us/
the-1992-campaign-on-the-trail-poll-gives-perot-a-clear-lead.html
12Database available at: http://biostat.mc.vanderbilt.edu/wiki/pub/Main/DataSets/
counties.html
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Experimental setup. We run our inference algorithm with α = 5, σ2B = 1, σ
2
θ = 1 and the
mapping transformation from the real numbers to the real positive numbers: f(x) = log(w · (x −
µ) + 1), with µ = E[xd] and w = 2/max(xd). In this experiment, we activate the bias term
and sample the variance of the pseudo-observations for each dimension/attribute. A challenging
aspect of this database is that the distributions of some of its attributes are heavy-tailed, leading to a
large number of latent features as output of the GLFM, whose purpose is to capture the tails of the
distributions. This is not an issue for estimation and imputation of missing data, but it renders data
exploration more tedious. To solve this limitation, we here perform an additional data preprocessing
step by applying a logarithmic transformation to heavy-tailed attributes. In more detail, we apply the
function g1(x) = log(x + 1) for population density, median family income, and percentage of farm
population. For the percentage of white population, we used the function g2(x) = log((100−x)+1)
since the distribution has most of its density close to 100%.
Results. Running the GLFM on this data results in 5 latent features, whose empirical activation
probabilities are shown in Table 4.5. Here, we observe that while the first three features are active
for at least 27% of the counties, the last two features are active only for around 4% of the counties.
Moreover, we find that the different combinations of the three first latent features represent more
than 92% of the counties in USA. In the following, we will thus focus on the analysis of the three
first features and, in particular, of the top-five most popular feature patterns. We show in shown in
Table 4.6 the empirical probabilities of these five patterns, which represent around 80% of the U.S.
counties. Figure 4.6 shows the distribution of vote percentage per candidate associated to each of
these top-five patterns, while Figure 4.8 shows the corresponding geographic distribution (i.e., the
empirical activation probability) across states for each of these patterns. In these figures, we observe
that:
(i) pattern (000), corresponding to the bias term, tends to model middle values for the percent-
age of votes for the three candidates (with an average percentage of votes of ∼ 50% for the
democrat candidate, ∼ 48% for the republican candidate and ∼ 27% for Perot), and activates
mainly in the east and west coasts of the country, as well as Florida;
(ii) pattern (100) provides similar percentage of votes for the democrat and republican candidates
as in pattern (000), but it favors the independent candidate Perot (with an average percentage
of votes above 30%), and activates mostly in the north central-east region of the country and
Maine (state where Perot’s party managed to beat the Republican party);
(iii) pattern (101) activates in the north central-west region of the USA (not including the coast)
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and represents a profile inclined towards the republican party (with an average percentage of
votes of ∼ 55%) while also favoring in a lower extent the independent candidate; and
(iv) patterns (010) and (001) clearly capture democrat-oriented profiles, and activate mainly in
the south east region of the USA, including the state from which Bill Clinton comes from,
Arkansas.
Note that the demographic results above are in agreement with the outcome of the election per
counties,13 as shown in Figure 4.9. Next, we analyze the demographic information associated to
each of the feature patterns above. To this end, we show in Figure 4.7 the distribution of each at-
tribute/dimension of the data for each of the considered patterns.
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Figure 4.6: Inferred probability distribution for the five most popular patterns. The patterns are sorted in
the legend according to their degree of popularity, as described in Table 4.6.
13https://en.wikipedia.org/wiki/United_States_presidential_election,_1992
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Figure 4.7: Inferred probability distribution for the most occuring patterns.
First, we observe that pattern (000), which activates mostly in the coasts and Florida, corresponds
to the highest population density, average income, and percentage of college degrees, as well as an
important race diversity and low farming activity. These observations align with the typical profile
characterizing “big-cities”. As stated before, this pattern is the most balanced in terms of voting
tendency, with an equilibrated support for both democrat and republican, as well as intermediate
91
CHAPTER 4. CASE-CONTROL IBP FOR ANALYSIS OF CLINICAL TRIALS
(a) Pattern (000) (b) Pattern (100) (c) Pattern (101)
(d) Pattern (010) (e) Pattern (110)
Figure 4.8: Empirical probability of pattern activation per state. We focus on the top-five most popular
combinations of features. The label for each pattern indicates whether F1, F2, and F3 are active (value ‘1’) or
not (value ‘0’). Features F4 are F5 are always inactive in the five most common patterns, and thus are omitted
in the labels.
values for the percentage of votes cast for Perot.
Second, patterns (100) and (101) represent the largest share of Perot’s votes, both with an average
percentage of votes above 30% for Perot. Figure 4.7 shows that Perot’s main supporters, character-
ized mainly by pattern (101), also correspond to republican main supporters, who tend to live in low
populated areas in the north central part of the country where farming activity is considerable, and
the percentages of white population and over-65 years old population are also high. The second vot-
ing force backing Perot, captured by pattern (100) and located in the north east-central part of USA,
corresponds mostly to white population with an intermediate-high average income and an average
percentage of college degrees around 18% (the red curve in Figure 4.7e overlaps the green line).
These results back the analysis in [115], which showed that the majority of Perot’s voters (57%)
were middle class, earning between $15,000 and $49,000 annually, with the bulk of the remainder
drawing from the upper middle class (29% earning more than $50,000 annually). Perot’s campaign
ended up taking 18.9% of the votes, finishing second in Maine and Utah, as captured by pattern (100)
and (101) respectively.
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Figure 4.9: Outcome of the 1992 presidential election per counties. Blue color corresponds to a majority
of votes for the democrat party, red corresponds to a victory for the republican party, green corresponds to a
victory of the independent party of Ross Perot.
Finally, Democrat’s patterns (010) and (110) are mainly active in the Southeastern United States,
and capture a diverse range of voters in terms of their demographic properties. On the one hand,
pattern (010) captures highly populated counties, with low values of family income, percentage of
college degrees, percentage of white population and percentage of farming population. On the other
hand, pattern (110) captures low populated counties with a large percentage of population above
65 year old, as well as a larger presence of farming activity and lower average income. These re-
sult might be explained by the broad appeal across all socio-ethno-economic demographics that the
Democratic party has historically targeted.
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4.B Appendix: Details on the phase II Clinical Trial for Codrituzumab
4.B.1 List of Biomarkers
Biomarker Description Type of Biomarker
Age Age Clinical data and demographics
F Sex Female Clinical data and demographics
AS Race Asian Clinical data and demographics
AA Race African American Clinical data and demographics
OT Race Other Clinical data and demographics
WH Race White Clinical data and demographics
Weight Baseline Weight Clinical data and demographics
Height Baseline Height Clinical data and demographics
BMI Baseline Body Mass Index (kg/m2) Clinical data and demographics
D Duration of Exposure (days) Clinical data and demographics
ECOG ECOG Performance Status at Baseline Clinical data and demographics
Sorafenib Prior Sorafenib Treatment Clinical data and demographics
CP score Child Pugh Score Clinical data and demographics
SDTL Sum diameter (measurable) target lesions Clinical data and demographics
IHC 0 GPC3 IHC Tumor Histology
IHC 1+ GPC3 IHC 1+ Tumor Histology
IHC 2+ GPC3 IHC 2+ Tumor Histology
IHC 3+ GPC3 IHC 3+ Tumor Histology
Vascular Invasion Macrovascual Invasion or Extrahepatic Tumor Histology
CD16 CD16 cell density Tumor Histology
CD3 CD3 cell density Tumor Histology
%CD16 % OF CD16 in stroma Tumor Histology
%CD3 % OF CD3 in stroma Tumor Histology
%Stroma % of stroma Tumor Histology
CD3/CD16 necrotic CD3/CD16 count in necrotic tissue Tumor Histology
CD3/CD16 tumor CD3/CD16 count in tumor Tumor Histology
CD3/CD16 viable CD3/CD16 count in viable cells Tumor Histology
%Necrotic % necrotic cells in tissue Tumor Histology
%Tumor % tumor in tissue Tumor Histology
%Viable % viable cells in tissue Tumor Histology
H score Cyt GPC3 H score cytoplasmic Tumor Histology
H score Mem GPC3 H score membrane Tumor Histology
Ctrough Ctrough at Cycle3 Day1 Exposure
AFP Alpha Fetoprotein Circulating protein
AAT Alanine Aminotransferase Circulating protein
CRP C Reactive Protein Circulating protein
sGPC3 114/165 Soluble GPC3 GT114-GT165 Circulating protein
sGPC3 30/57 Soluble GPC3 GT30-GT57 Circulating protein
sGPC3 30/607 Soluble GPC3 GT30-GT607 Circulating protein
sGPC3 11/96 Soluble GPC3 M3C11-GT96 Circulating protein
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ADCC CD107
Antibody-dependent cell cytotoxicity
CD107A activity
Blood cell activity
ADCC CD16
Antibody-dependent cell cytotoxicity CD16
activity
Blood cell activity
CD45 CD45+ cell count Blood cell subset
B B cell count Blood cell subset
CD3 CD3+ cell count Blood cell subset
CD4 CD4+ cell count Blood cell subset
CD8 CD8+ cell count Blood cell subset
CD4/CD8 CD4/CD8 ratio Blood cell subset
CD8 NK CD8+ NK cells Blood cell subset
CD16 CD16+ cell count Blood cell subset
CD56-CD16+ CD56-CD16+ NK cells Blood cell subset
CD56bright CD56bright NK cells Blood cell subset
CD56dimCD16- CD56dimCD16- NK cells Blood cell subset
CD56dimCD16bright CD56dimCD16bright NK cells Blood cell subset
NK NK cell count Blood cell subset
CD56 CD56+ cell count Blood cell subset
NKP46 NKP46+ NK cell count Blood cell subset
DN Double negative cells Blood cell subset
DP Double positive cells Blood cell subset
CD16MESF CD16 MESF Blood cell subset
NKP46MESF NKP46 MESF Blood cell subset
FCGRIIIA-158 A/A FCGRIIIA-158 A/A DNA polymorphism
FCGRIIIA-158 C/A FCGRIIIA-158 C/A DNA polymorphism
FCGRIIIA-158 C/C FCGRIIIA-158 C/C DNA polymorphism
FCGRIIIA-158 NA FCGRIIIA-158 NA DNA polymorphism
FCGRIIA-131 A/A FCGRIIA-131 A/A DNA polymorphism
FCGRIIA-131 A/G FCGRIIA-131 A/G DNA polymorphism
FCGRIIA-131 G/G FCGRIIA-131 G/G DNA polymorphism
FCGRIIA-131 NA FCGRIIA-131 NA DNA polymorphism
PFS Progression Free Survival (Months) Clinical endpoint
4.B.2 Study Design and Patients
Adult patients with unresectable advanced or metastatic HCC who were previously treated with
at least one line of systemic agent and with progressive disease were enrolled in a randomized,
placebo-controlled, double-blind, multicenter phase II trial (NCT01507168). Patients received either
intravenous Codrituzumab at 1600 mg every two weeks or placebo (with a patient ratio of treat-
ment:placebo of 2:1) until disease progression, and were followed for overall survival. Details of
study design have been previously described [2].
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4.B.3 GPC3 Expression in Tumor
All patients enrolled in the study provided a tumor tissue sample to determine the level of GPC3
expression by immunohistochemistry (IHC) under central review prior to study entry[2]. Specifically,
IHC was performed based on a formalin-fixed, paraffin-embedded (FFPE) block of the primary tumor
or the metastatic site collected within approximately 12 months prior to informed consent or four
4µm thick unstained slides (freshly cut from a FFPE block of the primary tumor or the metastatic
site obtained within approximately 12 months prior to informed consent). If no archival material
was available, a pre-treatment core needle biopsy with minimally 18-gauge needle was obtained.
The IHC staining was done on BenchMark XT (Ventana Medical Systems, Inc. or VMSI, catalog
number 750-700) or ULTRA (VSMI, catalog number 750-600) platforms. Each patient was assigned
a GPC3 IHC score with ordered categorical values 0, 1+, 2+, and 3+, corresponding to increasing
levels of GPC3 expression, with scores 0 and 3+ indicating the lowest and highest levels of GPC3
expression, respectively.
4.B.4 Flow Cytometry
Surface cell markers from circulating blood cells were measured by flow cytometry. Lymphocyte
subsets were assayed using Trucount tubes (Becton, Dickinson and Company or BD, catalog num-
ber 340334). The expression level of CD16 on NK cells was measured by flow cytometry analysis
of the pre-treatment peripheral blood mononuclear cells using CD16-specific antibody. Measure-
ment was done on FACSCantoTM II (BD, catalog number 657338). The quantification of CD16
expression level, or fluorescence intensity in units of Molecules of Equivalent Soluble Fluorochrome
(MESF), denoted by CD16 MESF, was calculated by converting fluorescence measurements of the
NK cell population to an MESF value based on an MESF calibration curve prepared according to flu-
orescence intensity of calibration beads (QuantumTM MESF bead standard, manufactured by Bang
Laboratories, IN, USA) [116].
4.B.5 Soluble Protein Measurements
Monoclonal antibodies against soluble GPC3 protein were generated as previously described12. Five
anti-N-terminal fragment mAbs (designated GT30, GT95, GT114, GT165 and GT607), and two
anti-C-terminal fragment mAbs (designated GT57 and M3C11), were used in combination in four
different assays (sGPC3 114/165, sGPC3 30/57, sGPC3 30/607, sGPC3 11/96) to detect full length
GPC3 protein, or any possible cleavage fragments containing N- or C-terminus. The protocol for
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sandwich ELISA assay has been described [81].
4.B.6 DNA Polymorphisms
Genomic deoxyribonucleic acid (DNA) was extracted from blood samples by using a QiAmp Blood
Mini Kit (Qiagen, Germany). DNA concentrations were measured by using NanoDrop ND-1000
(Thermo Fisher Scientific, Wilmington, DE, USA), and DNA samples were diluted in nuclease free
water to get a final concentration of 1 ng/µl. Patients were genotyped for two different Fc gamma
receptor polymorphisms, FcgRIIa-H131R and FcgRIIIa-V158F using TaqMan technology on Ap-
plied Biosystems (AB) 7500 Fast Real-Time PCR system (Applied Biosystems Inc., CA, USA).
Probes and primers (TaqMan SNP Assays for rs1801274 and rs396991) were ordered from Applied
Biosystems. Genotyping was performed following the manufacturer’s instructions.
4.B.7 Further Results
The mentioned subpopulations in the following table correspond to those listed in Table 4.1.
Continuous variables Effect size Mw-test
AFP 3.90 4.71e-06
H score Mem 1.34 9.64e-15
H score Cyt 0.75 4.66e-11
sGPC3 30/607 0.31 1.62e-06
sGPC3 114/165 0.29 1.26e-06
CD4 0.10 7.74e-05
CD3 0.09 9.16e-06
CD45 0.07 4.04e-05
sGPC3 11/96 0.48 9.40e-04
CD56-CD16+ 0.40 1.09e-03
sGPC3 30/57 0.39 5.42e-04
CD56dimCD16- 0.22 1.81e-03
CD8 0.11 8.52e-04
CD56dimCD16bright 0.47 6.50e-03
NK 0.46 4.13e-03
CD56 0.17 6.95e-03
DN 0.17 1.78e-02
NKP46 0.11 3.13e-03
CD16 0.11 4.19e-03
Discrete variables Effect size F-test
IHC 3+ 0.82 1.13e-20
IHC 1+ -0.37 2.29e-06
IHC 2+ -0.24 1.03e-04
IHC 0 -0.21 3.49e-04
(a) both F1 and F2 inactive
Continuous variables Effect size Mw-test
P Necrotic / stroma 1.92 4.38e-03
NK 1.10 3.85e-03
CD56dimCD16bright 1.02 7.74e-03
CD56-CD16+ 0.60 7.88e-03
CD56dimCD16- 0.56 6.37e-03
CD16 0.19 5.18e-03
P Tumor Viable -0.06 4.38e-03
Discrete variables Effect size F-test
- - -
(b) F1 active and F2 inactive
Table 4.8: Significant biomarkers associated with better prognosis in the treatment arm for different
subpopulations. (a) Comparison of subpopulation 6 vs 5, (b) comparison of subpopulation 10 vs 9. Continu-
ous variables on the top, discrete variables on the bottom. Colors code for the different statistical significance
levels: αs = 0.001 (black), αs = 0.005 (blue), and αs = 0.01 (green).
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5
Hierarchical Indian Buffet Process for
Discovery of Genetic Associations
Personalized medicine aims at combining genetic, clinical, and environmental data to improve med-
ical diagnosis and disease treatment, tailored to each individual [32]. Within this framework, this
chapter presents a Bayesian nonparametric (BNP) approach to identify genetic associations with clin-
ical features in cancer, in order to enhance clinical diagnosis and further understanding of the disease.
We propose a hierarchical approach, the hierarchical Poisson factor analysis (H-PFA) model, to share
information across patients having different types of cancer. To discover statistically significant asso-
ciations, we follow a similar statistical procedure to the one presented in Chapter 4, which combines
Bayesian modeling with bootstrapping techniques, and corrects for multiple hypothesis testing. We
compare the results of H-PFA with two other classical methods in the field: case-control (CC) setups,
and linear mixed models (LMMs).
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5.1 Introduction
Cancer encompasses not one, but a vast group of genetic diseases involving abnormal cell growth
with the potential to invade or spread to other parts of the body. Although a small set of common
underlying principles have been identified (the so-called “hallmarks” of cancer [79, 80]), each type of
cancer presents very unique properties, making this disease very hard to handle [151, 85, 194]. In the
last decade, high-throughput genotyping technologies have led to the discovery of cancer-correlated
gene mutations, most of which were not previously suspected to be related to carcinogenesis [49].
However, only the gene mutations with very strong effects have been discovered and many other
genes with weaker effects still remain to be found [10]. Genetic-association studies have been widely
used in the search for such genes, but success has been limited so far [151].
A first difficulty in cancer association studies is the immense phenotypic heterogeneity, which
reduces statistical power in the discovery method and causes some associations to remain hid-
den [164, 110, 176]. Second, cohort sizes tend to be small, especially in rare cancers, which makes
the discovery of small effect size associations difficult [10]. Third and last, cancers are driven by
the accumulation of mutations that may act epistatically or pleiotropically during the course of the
disease [213, 36, 183]. Epistasis refers to complex interactions between genetic variants that have
an effect on the same phenotype, while pleiotropy means that multiple phenotypes are influenced by
the same single mutation. Indeed, cancer is known to be polygenic and present complex pleiotropic
phenotypes [49]. New approaches need to be found in order to overcome these difficulties.
In recent years, efforts to mine electronic health records (EHRs) show promise to impact nearly
every aspect of healthcare [101]. The adoption of EHRs in hospitals has increased dramatically, and
has become an interesting resource for phenotyping [4, 129], with the potential for establishing new
patient-stratification principles and for revealing unknown disease correlations. Integrating EHRs
data with genetic data will also give a finer understanding of genotype-phenotype relationships [214].
EHRs consist of both structured and unstructured information. Structured data is a valuable source
of information that includes billing codes, laboratory reports, physiological measurements, and de-
mographic information, among others. Yet, most of the clinical data comes as unstructured notes,
e.g., around 98% of the EHRs [101]. These include a broad spectrum of clinically-relevant infor-
mation which might be useful to identify novel phenotypic relationships so far unknown by the
clinicians [129, 101].
This chapter presents a joint generative model to discover associations between genetic mutations
and clinical features in cancer that deals with phenotype heterogeneity, small cohort size, epistasis
and pleiotropy in a straightforward way. Our method is a generative model that infers latent topics
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from the clinical text, associated to hidden genetic factors that directly capture complex interactions
between the genes. It is directly inspired on the Poisson factorization model for recommendation sys-
tems in [69], with three important differences. First, we introduce confounding effects as conditional
variables, i.e., variables that might cause spurious associations to appear. In particular, our model
considers multiple types of cancer together (the type of cancer is treated as a confounder), and shares
information among all patients in a hierarchical fashion. Indeed, most cancers are known to share
a common pathogenesis despite specificities of the cell type and tissue origin [194]. By doing so,
specific effects for each type of cancer can be isolated, and novel (less well-known) associations with
gene mutations of smaller effect size can be obtained. Second, we force sparsity on the textual and
genetic topics by using shape parameters in the Gamma distribution priors smaller than one. Third,
we present a nonparametric alternative model to the work in [69] by replacing the continuous patient
weights with a binary matrix whose probability distribution is induced by a hierarchical extension of
the Indian buffet process (IBP). Also in the literature, the authors in [70] propose a nonparametric
Poisson factorization model, but they rely on a stick-breaking construction different from the IBP,
and the weights are continuous, which renders interpretability of the latent variables more tedious.
The discrete nature of the IBP helps in terms of interpretability, and allows combining the proposed
Bayesian model with classical frequentist approaches for statistical testing between the inferred pa-
tient partitions. An efficient Markov chain Monte Carlo (MCMC) procedure based on a slice sampler
for the hierarchical IBP is presented.
Bayesian modeling has already been proven useful for epistasis [225], pleiotropy [225, 224] or
sub-phenotyping aplications [147, 107]. Up to our knowledge, the proposed model is the first one
to deal with clinical text data and genetic information jointly, capturing phenotypic heterogeneity,
epistasis and pleiotropy in a straightforward way while correcting for the cancer type as confounder.
We consider multiple cancers jointly in order to increase statistical power, allow for the analysis of
rare cancers, and identify fundamental mechanisms shared across different types of cancer.
5.2 Genetic Association Studies
Any two human genomes differ in millions of different ways. Variations include individual nu-
cleotides of the genomes as well as larger variations, such as deletions, insertions and copy number
variations. Any of these variations may cause alterations in an individual’s traits, or phenotype, which
can be anything from disease risk to physical properties such as eye color or height [193]. We distin-
guish between two types of variations: somatic mutations and germline mutations. A somatic (also
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called “acquired”) mutation is a change in the genetic structure that is not inherited from a parent,
nor passed to offsprings: these are not inherited because they do not affect the reproductive cells
(sperm and egg) but any other type of cell. In contrast, germline mutations affect the reproductive
cells, and can thus be inherited. In this thesis, we solely focus on somatic mutations, which usually
appear by environmental causes, such as ultraviolet radiation or any exposure to certain chemicals.
Genetic association studies arise as a way to examinate a genome-wide set of genetic variants in
different individuals to see whether any variant is associated with a phenotypic trait. Such studies
have become popular in the last decades in order to study the relationship between the genotype and
phenotype of individuals [89, 114] and, in particular, in cancer research [49, 148].
Earlier genetic studies were focused on the effect of individual single-nucleotide polymorphisms
(SNPs), and are referred to as genome-wide association study (GWAS). We call SNP to a variation in
a single nucleotide that occurs at a specific position in the genome: these are the most common type
of variation among individuals [122]. For example, at a specific base position in the human genome,
the base C may appear in most individuals, but in a minority of subjects, the position is occupied by
base A. We then say that there is a SNP at this specific base position, and the two possible nucleotide
variations – C or A – are said to be alleles for this base position. A GWAS is a statistical analysis
which aims at finding individual correlations between any SNP and a particular phenotype [114].
Since the beginning of genetic association studies, there have been two general trends in the
literature. On the one hand, a wide range of different phenotypes have been considered, including
protein-protein network, gene expression, biomarkers, or intermediate clinical phenotypes at the or-
ganism level [151]. On the other hand, bigger sample size scenarios have been analyzed, with studies
of up to 200,000 individuals. Despite the efforts to gather information for many individuals, privacy
and ethical issues remain an important drawback for this task, such that most genetic association
studies still work in the order of thousands of individuals.
In addition to the screening of genetic associations, it is also common to take into account any
variables that could potentially confound the results. A confounder or confounding factor is a vari-
able that, if not observed, causes two other variables to appear correlated, while in fact these two are
independent given the confounder. A typical confounder example would be smoking to “drinking
coffee” and “having lung cancer”. Gender and age are other common examples of confounding vari-
ables. Moreover, it is also known that many genetic variations are associated with the geographical
and historical populations in which the mutations first arose.
Lack of well defined case and control groups, insufficient sample size, control for multiple
testing, and control for population stratification are common problems in genetic association stud-
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ies [114, 10]. Particularly the statistical issue of multiple testing is problematic as “the massive num-
ber of statistical tests performed presents an unprecedented potential for false-positive results” [150].
In our analysis, we resort to either the Bonferroni correction or the Benjamini-Hochberg proce-
dure [17] to control for multiple hypothesis testing, the former controls for the family-wise error
rate (FWER) (probability to reject at least one true hypothesis) while the latter estimates the false
discovery rate (FDR) and thus controls for the number of false positives.
5.2.1 Standard Approach: Case-Control Setup
The most common approach of GWAS is the case-control (CC) setup, which compares two large
groups of individuals, one healthy control group and one case group affected by a disease [31, 122].
All individuals in each group are genotyped for the majority of common known SNPs. For each of
these SNPs, it is then investigated if the allele1 frequency is significantly altered between the case and
the control group. In such setups, the fundamental unit for reporting effect sizes is the odds ratio. In
the context of GWAS, the odds ratio refer to the odds of disease for individuals having a specific allele
and the odds of disease for individuals who do not have that same allele. When the allele frequency
in the case group is much higher than in the control group, the odds ratio is higher than one, and vice
versa for lower allele frequency. A p-value for the significance of the odds ratio is typically computed
using a simple χ-squared test or Fisher test. Finding odds ratios that are significantly different from
one is the objective of the GWAS because this shows that a SNP is associated with the disease.
5.2.2 Confounder Correcting Approach: Linear Mixed Model
linear mixed models (LMMs) have proved particularly useful for GWAS due to its capacity to ac-
count for confounding effects and limit the number of false associations [121, 120]. Let xng
be the indicator variable for a somatic mutation in gene g ∈ {1, . . . , G} for a particular patient
n ∈ {1, . . . , N}. The variable xnd is binary and indicates whether any somatic mutation occurred in
the corresponding gene. Let ynq be the binary indicator variable of the presence of a certain clinical
feature q ∈ {1, . . . , Q} for a given patient n. Finally, let us define cnl as the binary assignment
variable of patient n to the cancer type ` ∈ {1, . . . , L}, where∑` cn` = 1 (we only consider patients
having one single type of cancer). For each pair of gene g and clinical feature q, a LMM can be
defined as follows:
y•q = x•gβqg + u•qg + ε•qg, (5.1)
1An allele refers to each of two or more alternative forms of a gene that arise by mutation and are found at the same
place on a chromosome.
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where βqg ∈ R refer to the fixed effect, and u•qg, ε•qg ∈ RN×1 are the random effects (structured
noise and observational noise, respectively). The prior assumptions for the structured and uniform
noises are u•qg ∼ N (0, σ2uK) and ε•qg ∼ N (0, σ2eI), where K refers to a similarity matrix between
the patients, for instance, the cosine similarity of the cancer type assignment vectors ci• and cj•,
K = CCT . The LMM assumes that the output y•q is Gaussian-distributed:
y•q ∼ N (x•gβqg, σ2uK + σ2eI). (5.2)
When the data is binary or count data, a common practice is to apply a standard rank-based inverse
normal transformation beforehand as a preprocessing step [96].
5.3 Our Approach
Let X ∈ NN×D be the observation matrix of count data for N patients and D dimensions, where D
includes both clinical and genetic information, i.e., D = G + Q, where G is the number of genes
and Q is the number of clinical terms. In the following, we propose two Poisson factor analysis
(PFA) approaches to model the joint observation matrix X of genetic information and clinical data.
In these models, patients will be represented by binary feature activation vectors, and each of these
features will capture common correlation patterns among the somatic mutations and clinical term
occurrences.
5.3.1 Bernoulli Process Poisson Factor Analysis
We first consider a simple nonparametric non-negative matrix factorization model with Poisson like-
lihood and Gamma-distributed factors:
xnd ∼ Poisson
(
Zn•B•d
)
, (5.3)
Bkd ∼ Gamma
(
αB,
µB
αB
)
, (5.4)
Z ∼ IBP(α), (5.5)
where α is the concentration parameter of the IBP controlling the a priori number of ones in matrix
Z (i.e., the a priori expected number of latent features), and µB, αB are the prior mean and shape
parameter for each element of matrix B. Sparsity can be induced easily in the factors by choosing
αB  1. From now on, we will refer to this basic model as the Bernoulli process Poisson factor
analysis (BeP-PFA). The “Bernoulli process (BeP)” designation in the naming emphasizes that each
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feature activation vector Zn• is a draw from a BeP.2 Inference is performed using a MCMC approach
based on a semi-ordered stick-breaking representation of the IBP prior [202]. A complete description
of the inference algorithm can be found in Section 8.2.2 of the final appendix.
5.3.2 Hierarchical Bernoulli Process Poisson Factor Analysis
Although different types of cancer are known to share similar phenotypes and underlying mecha-
nisms (shared activation of certain pathways), the mutation rate and phenotype occurrence might
vary in different proportions, according to each type of cancer. Given this premise, we propose a
hierarchical Bernoulli process Poisson factor analysis model to allow for different feature activation
levels depending on each type of cancer. In the following, we will shorten the name of this model to
hierarchical Poisson factor analysis (H-PFA).
Let rn ∈ [1, . . . , L] be a categorical variable indicating the type of cancer of patient n among
the total number of cancer types L (in the previous notation from Section 5.2, rn corresponds to the
index of the non-zero value in vector cn•). A hierarchical construction can be formulated based on
the finite representation of the IBP and lettingK →∞, such that different levels of feature activation
are allowed for each type of cancer. Let ρk be the global activation probability of feature k, and pi`k
be the specific activation probability of feature k for the cancer type ` ∈ [1, . . . , L]. We can then
assume that each specific activation probability is Beta-distributed such that E`[pi`k] = ρk:
ρk ∼ Beta
( α
K
, 1
)
pi`k|ρk ∼ Beta
( ρk
1− ρk , 1
) znk ∼ Bernoulli(pirnk )
Bkd ∼ Gamma
(
αB,
µB
αB
) (5.6)
xnd ∼ Poisson
(
Zn•B•d
)
, (5.7)
where the feature activation variables in vector Zn• are drawn from different activation probability
vectors {pi1, . . . ,piL} depending on the type of cancer cn of patient n. When K → ∞, this prior
over Z is equivalent to a hierarchical Beta process (BP) construction [206] on top of BePs in the
De Finetti representation introduced in Section 2.3.2. In the same way that a hierarchical Dirichlet
process (HDP) allows for atom sharing with varying weights across different groups of data (see
Section 2.3.1), the H-PFA allows for feature sharing with different activation weights across different
types of cancer.
2Traditionally, PFA refers to both continuous weights and dictionary components [226].
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5.4 Results
5.4.1 Database Description
So far, genomic testing of tumors has been done routinely only for certain solid cancer tumors, such
as melanoma, lung, or colon cancer. For most cancers, the available tests have been limited to analyz-
ing one or a handful of genes at a time, and within each gene, only the most common mutations could
be detected.3 A new targeted tumor sequencing test called MSK-IMPACTTM (Integrated Mutation
Profiling of Actionable Cancer Targets) is able to detect gene mutations and other critical genetic
aberrations in both rare and common cancers [29].
Using the MSK-IMPACT technique, somatic mutations regarding specific screened genes can
be obtained as follows. For each patient, tumor cells are compared with healthy cells of that same
patient, extracted from the blood stream. In this chapter, a gene is said to be mutated when there exists
at least one difference in the sequence between the tumor cells and healthy cells for that particular
gene.4 We finally obtain a binary matrix for N = 1946 patients and G = 410 genes where “1”
encodes a mutated gene and “0” otherwise. The screened genes have been shown to play a role in
the development or behavior of tumors,5 although their individual relation to specific phenotypes
remains obscure [29].
Concerning the clinical information, based on all EHRs, we build a bag-of-word representation of
unified medical language system (UMLS) terms, extracted using the Metamap6 processing tool [14].
The UMLS refers to a standardized, comprehensive thesaurus and ontology for biomedical concepts,
whose objective is to provide facilities for natural signal processing tasks [22]. Since each patient can
have a varying number of EHRs, we group all clinical history into a single EHR, and only consider
the appearance or absence of each UMLS term. We compute the tf-idf score for each UMLS term,
and only keep the 300 clinical terms with highest score.
The final database includes clinical and genetic information forN = 1946 patients and 5 different
cancer types: bladder cancer, breast carcinoma, colorectal cancer, non-small cell lung cancer, and
prostate cancer. We consider genes and UMLS terms that are present in at least 1% of the patient
population, resulting in D = 249 dimensions, including 72 genes and 177 clinical terms. Even if the
dataset is binary, we can use a Poisson likelihood because of the high sparsity degree of such matrix
(7.28% of non-zero values). In such scenario, the Poisson distribution is a good approximation of a
3https://www.mskcc.org/msk-impact
4The considered sequencing technology is able to remove most of the technical noise, in contrast to other technologies.
5https://www.mskcc.org/blog/new-tumor-sequencing-test-will-bring-personalized
-treatment-options-more-patients
6Source code available at: https://metamap.nlm.nih.gov/
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Bernoulli, and we adopt it by mathematical convenience in the inference process.
5.4.2 Experimental Setup
We compare the proposed H-PFA approach with a LMM and a standard case-control set-up for
each potential clinico-genetic association. The model parameters for each LMM are found by max-
imizing the log likelihood using standard optimization techniques within a python platform called
LIMIX [120]. In the final step, we obtain p-values for each pair (y•q, x•g) using likelihood ratio
tests. Regarding the case-control analysis, for each clinical term we consider a case and control
group corresponding to the patients having that clinical term active or inactive respectively. Given
such partition, we perform an individual Fisher test for each gene. For all methods, we correct for
multiple hypothesis testing based on the Benjamini-Hochberg approach [17]. Finally, concerning the
H-PFA model, we follow the statistical procedure described in Section 4.3.3. As already described in
the last chapter, we want to make our results more robust against outliers and reduce the number of
false associations, so that we take multiple posterior samples and perform bootstrapping one hundred
times of the whole process. For each statistical test, we obtain one hundred p-values, one for each
bootstrapping instance, which are summarized via the median p-value.7 An association is said to be
significant when this median p-value is higher than the adjusted significance level αs after correction
for multiple hypothesis testing. For all simulations, we adopt a significance threshold value 0.001
and only consider associations with a positive effect size, for simplicity. In order to increase model
interpretability, we also introduce one bias term to capture mean effects corresponding to cancer in
general. This bias term is forced to be active for all patients. Finally, we have set the hyperparameters
of the proposed H-PFA as αB = 0.01 and µB = 1, while we infer the values for the concentration
parameter α as described in Appendix 8.
5.4.3 Identification of Clinico-Genetic Associations
Figure 5.1 represents the number of associations found by each method, and how many overlap
across techniques. LMM found 14 clinico-genetic associations, CC found 178, and H-PFA found
95.8 As expected, LMM is the method that finds the least number of associations, since it corrects
for the cancer type as a confounder effect, in order to get rid of cancer-specific associations and only
get less well-known associations that are present across all types of cancer. CC is the method that
7Note that statistical significance could also be accounted for using Bayesian factors or posterior predictive checks [60].
We here adopt the most established approach for statistical significance assessment within this field.
8The H-PFA model is very flexible, as it can also find correlations between the genes, or between the clinical terms. 95
is the number of clinico-genetic associations only.
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Figure 5.1: Venn Diagram of number of associations.
Phenotype Gene
Stage IV Lung Adenocarcinoma EGFR
Adenocarcinoma of lung (disorder) EGFR
A
L
L
Malignant neoplasm of urinary bladder TERT
KRAS gene KRAS
Potassium Ion KRAS
Pulmonary function tests STK11
C
C
∩
L
M
M
Rash and Dermatitis Adverse Event
Associated with Chemoradiation TCF7L2
Colorectal Carcinoma APC
capecitabine APC
Colorectal KRAS
Lumpectomy of breast PIK3CA
Adriamycin PIK3CA
Renal function ARID1A
C
C
∩
H
-P
FA
Simple mastectomy GATA3
Hydronephrosis KDM6A
. . . . . .
Figure 5.2: Shared associations across methods.
discovered the highest number of associations, from which only 30% are shared with H-PFA. Out of
the 95 associations discovered by the H-PFA approach, 63% were also present in any of the other
methods. Figure 5.2 lists the associations that are shared across methods. Tables 5.1 and 5.2 present
the list of clinico-genetic associations found by LMM and CC methods (for CC, we only report a
random selection of associations, but the complete list can be found in Appendix 5.A).
Phenotype Gene βqg p-value
pump (device) APC 0.61 2.78e-53
S3 (sacral segmental innervation) TP53 0.29 1.02e-09
Stage IV Lung Adenocarcinoma EGFR 0.32 2.07e-29
Folinic Acid-Fluorouracil-Irinotecan Regimen APC 0.59 1.08e-60
Folinic Acid-Fluorouracil-Irinotecan Regimen KRAS 0.30 1.16e-18
Hepatectomy APC 0.65 1.21e-52
Hepatectomy KRAS 0.27 7.27e-12
FOLFOX Regimen APC 0.66 5.12e-113
Tract ARID1A 0.21 5.61e-12
Malignant neoplasm of urinary bladder TERT 0.55 1.07e-61
Renal function TERT 0.28 8.40e-12
Flushing APC 0.30 1.54e-11
Non-Small Cell Lung Carcinoma EGFR 0.18 4.11e-11
Colorectal Carcinoma APC 0.61 2.34e-63
Adenocarcinoma of lung (disorder) EGFR 0.26 1.49e-22
Simple mastectomy PIK3CA 0.16 3.40e-08
Immunotherapy TERT 0.23 2.76e-12
Imodium APC 0.30 6.51e-15
capecitabine APC 0.30 1.94e-15
Pulmonary function tests STK11 0.16 2.19e-09
Table 5.1: Subset of clinico-genetic associations found using the CC setup. A complete list can be found in
Appendix 5.A.
Next, Table 5.3 shows the list of inferred latent features by the H-PFA model. The bias term
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Phenotype Gene βqg p-value
Stage IV Lung Adenocarcinoma EGFR 0.14 9.90e-14
Pulmonary function tests STK11 0.11 5.67e-06
Esophagogastroduodenoscopy ERBB3 0.10 4.62e-06
Adenocarcinoma of lung (disorder) EGFR 0.09 3.20e-06
Rash and Dermatitis Adverse Event Associated with Chemoradiation TCF7L2 0.09 1.57e-04
Atrophic PTEN 0.09 2.06e-05
Esophagogastroduodenoscopy ALK 0.09 1.43e-05
Stage level 2 ERBB4 0.08 3.34e-05
Positive Surgical Margin EP300 0.08 1.43e-04
Esophagogastroduodenoscopy CDH1 0.08 1.33e-04
Esophagogastroduodenoscopy FLT4 0.08 4.15e-05
Malignant neoplasm of urinary bladder TERT 0.08 7.91e-05
Potassium Ion KRAS 0.08 6.72e-06
KRAS gene KRAS 0.07 9.76e-05
Table 5.2: Clinico-genetic associations found using the LMM approach. The associations have been sorted
according to the effect size βqg which refers to the linear weight of the regression, as described in Section 5.2.2.
F0 reflects the high rate mutation of the TP53 gene which occur across all types of cancer. The
TP53 gene is essential for the production of a protein called tumor protein p53. This protein acts
as a tumor suppressor, which means that it regulates cell division by keeping cells from growing
and dividing too fast or in an uncontrolled way. Because p53 is essential for regulating cell division
and preventing tumor formation, it has been nicknamed the “guardian of the genome” [142]. On
top of the bias term F0, H-PFA inferred 19 other latent features. Features F3, F5, and F17 capture
complex phenotypes (no somatic mutations involved), whereas F4 and F18 mostly capture somatic
mutations. Interestingly, F18 relates Esophagogastroduodenoscopy (a test to examine the lining of
the esophagus, stomach, and the beginning of the small intestine) to multiple somatic mutations,
which was already revealed by LMM in Table 5.2. The remaining 14 features capture co-ocurrence
of somatic mutations and clinical UMLS terms. Some latent features reflect well known relationships
in oncology research. To name a few, mutations of gene PIK3CA (captured by F1 and F16) are
present in over one-third of breast cancers; such mutations are nowadays known to be oncogenic
and also implicated in cervical cancers [74]. Somatic mutations in the triad APC-KRAS-TP53 genes
(captured by F0 and F6 together) are prominent in colon cancer [1]. Finally, previous studies have
found direct physiological and molecular evidence for a role of gene FOXA1 in controlling cell
proliferation in prostate cancer [95], which is accounted for in factor F12.
Figure 5.3 depicts the cancer-specific activation weights pi`l for each type of cancer `, as de-
scribed in previous section.The activation of features present strong variations across cancer types.
Some features are clearly cancer-specific (F1 and F3 typically activate for breast carcinoma patients;
F6, F11 and F15 are typically active for colorectal cancer; F7, F8 and F10 are almost exclusively
active for non-small cell lung cancer, etc.), whereas other factors occur in similar proportions across
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Feat. mk Phenotypes Genes
F0. 1946 - TP53 (0.40)
F1. 460
Simple mastectomy (0.17), Xeloda (0.15), Lumpectomy of breast (0.12),
capecitabine (0.09) PIK3CA (0.31)
F2. 402
Renal function (0.29), Coronary Artery Disease (0.28), Stent, device (0.22),
cardiologist (0.21), Urology (0.20), Hydronephrosis (0.16) MTOR (0.04)
F3. 400
Invasive Ductal Breast Carcinoma (0.57), axillary lymph node dissection (0.38),
Simple mastectomy (0.37), Noninfiltrating Intraductal Carcinoma (0.36),
Lumpectomy of breast (0.33), Adriamycin (0.29)
-
F4. 392 -
ETV6 (0.22), PTPRD
(0.19), ATR (0.19),
PTPRT (0.17), BRAF
(0.17), ATM (0.17), . . .
F5. 361
Entire intercostal space (0.22), Midclavicular line (0.21), Per Minute (0.20),
Prednisone (0.19), Upper Extremity (0.19), Entire head (0.18), Dizziness (0.17),
Redness (0.17), Serum (0.17), Bedtime (qualifier value) (0.16), . . .
-
F6. 352 Colorectal (0.39), FOLFOX Regimen (0.29)
APC (0.71), KRAS
(0.47)
F7. 350
Lobectomy (0.48), Pulmonary function tests (0.29), Thoracotomy (0.27),
Non-Small Cell Lung Carcinoma (0.27) EGFR (0.09)
F8. 326
Non-Small Cell Lung Carcinoma (0.13), Stage IV Lung Adenocarcinoma
(0.10), natural daughter - RoleCode (0.09), pemetrexed (0.08)
KRAS (0.36), STK11
(0.26), KEAP1 (0.20)
F9. 326
Lytic lesion (0.29), Zometa (0.27), Fracture (0.25), Sclerosis (0.25), Bone
Lesion (0.23), Bone structure of sacrum (0.23), Hip arthralgia (0.23), Bone
structure of ilium (0.19), Palliative Care (0.17)
ATRX (0.04)
F10. 266
Stage IV Lung Adenocarcinoma (0.62), pemetrexed (0.61), Adenocarcinoma of
lung (disorder) (0.60), mediastinal lymphadenopathy (0.35)
EGFR (0.30), TP53
(0.18)
F11. 265
FOLFOX Regimen (0.54), KRAS gene (0.45), Folinic
Acid-Fluorouracil-Irinotecan Regimen (0.43), Leucovorin (0.43), irinotecan
(0.39), Colorectal Carcinoma (0.39), Cold intolerance (0.37), Midclavicular line
(0.27), Sigmoid colon (0.27), Colorectal (0.27)
PTPRT (0.05),
CARD11 (0.04)
F12. 262
Prostate carcinoma (0.74), adenocarcinoma of the prostate (0.69), Biopsy of
prostate (0.62), Extracapsular (0.55), Lupron (0.46), Personal Attribute (0.40)
FOXA1 (0.11), APC
(0.06)
F13. 261
Tract (0.52), Malignant neoplasm of urinary bladder (0.51), Gross hematuria
(0.44), Incontinence (0.29), Immunotherapy (0.28)
TERT (0.66), KDM6A
(0.36)
F14. 169
Lovenox (0.28), Pulmonary Embolism (0.27), Deep Vein Thrombosis (0.23),
swollen feet/legs (0.19) -
F15. 159
Rectum (0.45), Rash and Dermatitis Adverse Event Associated with
Chemoradiation (0.28), capecitabine (0.26), Node stage N0 (0.23)
APC (0.14), TCF7L2
(0.14), TSC2 (0.09)
F16. 149
Consistency (0.55), Vagina (0.50), Clinic / Center - Mobile (0.43), Bilateral
Salpingectomy with Oophorectomy (0.39), Atrophic (0.39), New medications
(0.35), Personal Attribute (0.32), Uterus (0.31), Ovarian (0.30), Bone Mineral
Density Test (0.30), Ovary (0.29)
PIK3CA (0.12), PTEN
(0.07)
F17. 107
Depression motion (0.95), Structure of long bone (0.82), S3 (sacral segmental
innervation) (0.82), pump (device) (0.79), intrahepatic (0.78), Pulse taking
(0.74), Midclavicular line (0.73), Entire intercostal space (0.70), Hepatectomy
(0.62), Flowcharts (Computer) (0.57)
-
F18. 95 Esophagogastroduodenoscopy (0.12)
POLE (0.65), ROS1
(0.61), DNMT1 (0.59),
ATR (0.58), ATM
(0.57), FAT1 (0.54), . . .
F19. 41 Optic Nerve (0.90), Gross hematuria (0.90), Dyspepsia (0.57), Lupron (0.45) AR (0.22)
Table 5.3: Latent features inferred by H-PFA. We depict the UMLS terms and genes with highest weights,
up until the weight decays more than 50% separately. mk is the number of patients with each feature active.
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cancers, e.g., feature F5 which capture typical adverse effects that manifest for all types of cancer
(Prednisone is a synthetic corticosteroid drug which is regularly used to treat certain types of cancer,
but has significant adverse effects).
F0 F1 F2 F3 F4 F5 F6 F7 F8 F9
Inferred latent features
0
0.2
0.4
0.6
0.8
1
l k
F10 F11 F12 F13 F14 F15 F16 F17 F18 F19
Inferred latent features
0
0.2
0.4
0.6
0.8
1
l k
Bladder Cancer
Breast Carcinoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Figure 5.3: Activation weights pi`k for each cancer type ` inferred by H-PFA.
Table 5.4 presents a list of the biggest subpopulations found by H-PFA in decreasing size. A
subpopulation in this context refers to patients that have the exactly same set of latent features active.
Given these subpopulations, we follow the statistical methodology presented in Chapter 4 of running
two-sample test comparisons between different sets of subpopulations. In this case, we adopt a one-
leave-out comparison strategy, which consists in running two-sample individual tests between each
subpopulation against all the rest. We thus obtain different sets of statistically significant components
(one set for each comparison), which are listed in Tables 5.5, 5.6, 5.8,5.9, and 5.10.
For each clinical and genetic term, we give both the effect size and significance. Our method
is able to provide concise grouping of both clinical terms and somatic mutations. Among the clin-
ical terms, we find both phenotypical terms, as well as names of chemotherapy medications (Adri-
amycin, Irinotecan, or Leucovorin). Table 5.5 shows cancer-specific clinico-genetic associations. We
recover well-known associations (such as APC gene mutation being prominant in colorectal cancer,
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Id Activation pattern Nr. patients
1. 11010 00000 00000 00000 106
2. 10000 00000 00100 00000 91
3. 11000 00000 00000 00000 69
4. 10000 00000 00000 00000 68
5. 10000 00110 00000 00000 46
6. 10000 01000 01000 00000 40
7. 11010 00001 00000 00000 40
8. 10000 01000 00000 00000 30
9. 10100 00000 00100 00000 30
10. 10000 00000 00010 00000 29
11. 10100 00000 00010 00000 28
12. 10000 00000 10000 00000 27
13. 10000 01000 01000 10000 27
14. 10001 00110 00000 00000 27
15. 10001 00000 00010 00000 26
Table 5.4: Subpopulations found by H-PFA.
or STK11 to lung carcinoma), but other associations are more surprising, such as GATA3 gene with
bone mineral density.
Finally, H-PFA found several statistically significant sets of associations involving somatic mu-
tations in gene TERT, as shown in Table 5.6. Somatic mutations in the gene promoter of telomerase
reverse transcriptase (TERT) have been found in 70–79% of bladder tumors in a multi-institutional
study published in European Urology [149]. Table 5.6 shows that TERT mutations are associated to
not only malignant neoplasm of urinary bladder (which is not surprising), but also hematuria and hy-
dronephrosis. Hematuria refers to the presence of red blood cells in the urine. Also, hydronephrosis
is a condition that typically occurs when the kidney swells due to the failure of normal drainage of
urine from the kidney to the bladder. Hydronephrosis is not a primary disease, but results from some
other underlying disease (cancer in this case) as the result of a blockage or obstruction in the urinary
tract. H-PFA points out to interesting gene relationships (KDM6A, CREBBP, and ARID1A genes)
with TERT, which have been partially studied in the literature [141, 167, 97].
5.5 Summary
This chapter proposes a novel BNP procedure for genetic association studies that identifies poten-
tially interesting associations between gene-level mutations and clinical features encoded via UMLS
terms from EHRs. We propose a hierarchical Bernoulli process Poisson factor analysis model based
on a hierarchical construction of BPs and BePs. The delivered associations are statistically signifi-
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cant after correction for multiple hypothesis testing combined with a bootstrapping procedure, which
makes the approach particularly robust against false positives. These associations give potentially
interesting insights for future research in oncology. Studies like this one can provide us with accu-
rate diagnosis, and ultimately inform us about actionable pathways when considering cancer therapy,
where interventions through drug administration can be designed.
Clinical record Genetic information
Invasive Ductal Breast Carcinoma 0.64 3.54e-49 PIK3CA 0.22 4.38e-07
Simple mastectomy 0.39 4.26e-22 GATA3 0.12 3.08e-05
Noninfiltrating Intraductal Carcinoma 0.34 2.02e-20
Lumpectomy of breast 0.32 3.94e-17
axillary lymph node dissection 0.28 3.43e-16
Fishes 0.22 1.01e-10
Adriamycin 0.21 4.09e-11
Bone Mineral Density Test 0.15 2.19e-06
(a) 100% breast carcinoma
Clinical record Genetic information
FOLFOX Regimen 0.80 1.52e-29 APC 0.63 3.50e-17
Colorectal 0.37 4.04e-09 TP53 0.42 3.50e-08
Sigmoid colon 0.35 1.88e-09
Colorectal Carcinoma 0.33 8.49e-08
Cold intolerance 0.32 2.03e-08
irinotecan 0.29 8.72e-08
Leucovorin 0.29 4.90e-07
Folinic Acid-Fluorouracil-Irinotecan Regimen 0.25 1.19e-05
Hepatectomy 0.23 3.35e-06
(b) 100% non-small cell lung cancer
Clinical record Genetic information
Lobectomy 0.37 4.98e-11 KRAS 0.36 2.73e-08
Non-Small Cell Lung Carcinoma 0.31 5.69e-08 STK11 0.26 1.74e-07
(c) 97% breast carcinoma, 3% non-small cell lung cancer
Clinical record Genetic information
Lobectomy 0.37 3.60e-07 STK11 0.38 8.62e-08
KEAP1 0.35 1.17e-07
(d) 100% bladder cancer
Table 5.5: Clinico-genetic associations found by the H-PFA (1/2).
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Clinical record Genetic information
Tract 0.37 3.39e-08 TERT 0.57 4.56e-12
Malignant neoplasm of urinary bladder 0.36 3.92e-07 FGFR3 0.50 4.15e-13
Gross hematuria 0.33 2.67e-06
(a) 100% colorectal cancer
Clinical record Genetic information
Gross hematuria 0.74 1.81e-20 TERT 0.58 5.59e-12
Malignant neoplasm of urinary bladder 0.41 2.80e-08 KDM6A 0.31 6.48e-06
Tract 0.39 2.08e-08
chain of objects 0.32 1.92e-06
Hydronephrosis 0.26 2.52e-05
(b) 100% prostate cancer
Clinical record Genetic information
Gross hematuria 0.39 1.72e-07 TERT 0.64 4.86e-13
Malignant neoplasm of urinary bladder 0.37 9.85e-07 FGFR3 0.50 1.97e-11
Tract 0.30 2.19e-05 KDM6A 0.36 1.20e-06
CREBBP 0.32 3.19e-06
(c) 100% non-small cell lung cancer
Clinical record Genetic information
Malignant neoplasm of urinary bladder 0.56 4.24e-12 TERT 0.67 1.79e-14
Tract 0.46 2.00e-10 ARID1A 0.45 2.32e-08
Renal function 0.45 5.51e-11
Gross hematuria 0.36 8.69e-07
(d) 100% bladder cancer
Table 5.6: Clinico-genetic associations found by the H-PFA (2/2). All these associations involve gene TERT.
One same set (depicted in bold) appears in all associations.
114
CHAPTER 5. HIERARCHICAL IBP FOR DISCOVERY OF GENETIC ASSOCIATIONS
5.A Appendix: Complete List of Associations
5.A.1 Case-control setup (CC)
Clinical term Gene βqg p-value
FOLFOX Regimen APC 0.66 5.12e-113
Leucovorin APC 0.65 6.61e-65
Hepatectomy APC 0.65 1.21e-52
irinotecan APC 0.62 4.39e-47
pump (device) APC 0.61 2.78e-53
Colorectal Carcinoma APC 0.61 2.34e-63
Colorectal APC 0.60 2.31e-73
Folinic Acid-Fluorouracil-Irinotecan Regimen APC 0.59 1.08e-60
Malignant neoplasm of urinary bladder TERT 0.55 1.07e-61
S3 (sacral segmental innervation) APC 0.54 3.58e-35
intrahepatic APC 0.53 1.03e-30
Tract TERT 0.50 1.62e-42
Sigmoid colon APC 0.48 6.82e-38
Gross hematuria TERT 0.47 1.23e-47
Flowcharts (Computer) APC 0.47 4.29e-32
Entire intercostal space APC 0.42 1.33e-41
Unresectable APC 0.42 1.78e-20
Structure of long bone APC 0.42 5.86e-29
Midclavicular line APC 0.41 1.46e-41
KRAS gene APC 0.39 6.40e-29
Cold intolerance APC 0.39 1.70e-22
Rectum APC 0.38 3.88e-26
Data Port APC 0.37 1.35e-19
pump (device) TP53 0.35 8.51e-17
Depression motion APC 0.35 5.62e-22
Avastin APC 0.35 1.58e-22
KRAS gene KRAS 0.33 2.44e-23
FOLFOX Regimen KRAS 0.32 1.96e-32
Stage IV Lung Adenocarcinoma EGFR 0.32 2.07e-29
Tract KDM6A 0.31 1.66e-24
Unresectable TP53 0.31 3.62e-10
capecitabine APC 0.30 1.94e-15
Imodium APC 0.30 6.51e-15
Ulcer APC 0.30 3.96e-12
Flushing APC 0.30 1.54e-11
Folinic Acid-Fluorouracil-Irinotecan Regimen KRAS 0.30 1.16e-18
irinotecan KRAS 0.30 5.60e-14
FOLFOX Regimen TP53 0.29 4.61e-19
Hepatectomy TP53 0.29 1.19e-10
S3 (sacral segmental innervation) TP53 0.29 1.02e-09
Colorectal KRAS 0.29 2.18e-21
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Leucovorin KRAS 0.29 8.95e-16
Ablation APC 0.29 5.61e-15
Rash and Dermatitis Adverse Event Associated with Chemoradiation APC 0.29 5.40e-13
Pulse taking APC 0.29 2.28e-15
Malignant neoplasm of urinary bladder KDM6A 0.29 5.14e-27
Potassium Ion KRAS 0.28 4.17e-14
Renal function TERT 0.28 8.40e-12
Structure of long bone TP53 0.27 5.79e-11
Hydronephrosis TERT 0.27 3.21e-12
Hepatectomy KRAS 0.27 7.27e-12
Xeloda APC 0.26 1.53e-11
Midclavicular line TP53 0.26 6.98e-15
Adenocarcinoma of lung (disorder) EGFR 0.26 1.49e-22
Leucovorin TP53 0.26 1.57e-09
Entire intercostal space TP53 0.26 1.47e-13
Data Port KRAS 0.26 4.25e-11
Gross hematuria KDM6A 0.26 4.71e-22
Folinic Acid-Fluorouracil-Irinotecan Regimen TP53 0.26 8.08e-11
Colorectal Carcinoma TP53 0.24 1.39e-09
pump (device) KRAS 0.24 2.59e-11
Sigmoid colon TP53 0.24 3.38e-09
Potassium Ion APC 0.24 4.02e-10
Colorectal Carcinoma KRAS 0.23 3.18e-12
Immunotherapy TERT 0.23 2.76e-12
intrahepatic TP53 0.23 1.37e-05
Rectum TP53 0.22 5.43e-08
Neutrophil count decreased APC 0.22 8.18e-07
Response process APC 0.22 9.43e-07
Tract FGFR3 0.22 1.16e-15
Colorectal TP53 0.21 5.78e-09
Flowcharts (Computer) TP53 0.21 1.46e-06
Tract ARID1A 0.21 5.61e-12
Sigmoid colon KRAS 0.21 6.84e-10
Flowcharts (Computer) KRAS 0.21 1.20e-08
Rectal hemorrhage APC 0.21 1.88e-09
Avastin TP53 0.21 4.41e-07
Bilateral Salpingectomy with Oophorectomy PIK3CA 0.20 1.65e-06
Unresectable KRAS 0.20 6.65e-07
Urology TERT 0.20 8.42e-09
Depression motion TP53 0.20 1.43e-06
irinotecan TP53 0.20 3.11e-05
Combined Modality Therapy APC 0.20 4.41e-06
hearing impairment TERT 0.19 1.41e-06
Malignant neoplasm of urinary bladder FGFR3 0.19 4.27e-15
Gross hematuria FGFR3 0.18 3.11e-14
Adriamycin PIK3CA 0.18 4.47e-06
pemetrexed EGFR 0.18 2.06e-12
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Entire intercostal space KRAS 0.18 2.80e-10
S3 (sacral segmental innervation) KRAS 0.18 1.25e-05
Non-Small Cell Lung Carcinoma EGFR 0.18 4.11e-11
Rash and Dermatitis Adverse Event Associated with Chemoradiation KRAS 0.18 6.24e-06
Creatinine TERT 0.17 1.24e-05
Bone Mineral Density Test PIK3CA 0.17 1.65e-06
Hydronephrosis KDM6A 0.17 1.01e-07
Cold intolerance KRAS 0.17 2.64e-06
intrahepatic KRAS 0.17 3.49e-05
Avastin KRAS 0.17 3.87e-07
KRAS gene TP53 0.17 1.28e-05
Lobectomy EGFR 0.16 1.72e-08
Malignant neoplasm of urinary bladder ARID1A 0.16 3.25e-09
lung lesion APC 0.16 8.22e-06
Attribution EGFR 0.16 8.10e-06
Simple mastectomy PIK3CA 0.16 3.40e-08
Renal function ARID1A 0.16 8.41e-06
Pleura EGFR 0.16 4.16e-07
Gross hematuria ARID1A 0.16 1.34e-08
Pulmonary function tests STK11 0.16 2.19e-09
Tract CREBBP 0.16 8.83e-10
Invasive Ductal Breast Carcinoma PIK3CA 0.15 8.87e-09
Midclavicular line KRAS 0.15 5.38e-08
capecitabine KRAS 0.15 1.89e-05
Lumpectomy of breast PIK3CA 0.15 7.20e-07
Malignant neoplasm of urinary bladder ERBB2 0.15 1.40e-10
Incontinence TERT 0.15 1.07e-06
chain of objects TERT 0.15 1.08e-05
Renal function KDM6A 0.15 6.54e-06
Stent, device TERT 0.14 4.23e-06
Superficial TERT 0.14 1.68e-05
Tibialis anterior muscle structure EGFR 0.14 1.34e-06
Thoracotomy STK11 0.14 9.65e-07
Tract ERBB2 0.14 1.87e-07
Urology KDM6A 0.13 2.55e-06
Lobectomy STK11 0.13 1.25e-07
Malignant neoplasm of urinary bladder RB1 0.13 5.74e-08
Lobectomy KEAP1 0.13 1.22e-08
Tract STAG2 0.13 4.54e-07
Malignant neoplasm of urinary bladder CREBBP 0.12 8.84e-08
Leucovorin SMAD4 0.12 5.31e-08
Tract PBRM1 0.12 2.11e-07
Tract ROS1 0.12 1.89e-05
Bilateral Salpingectomy with Oophorectomy GATA3 0.12 1.93e-05
Non-Small Cell Lung Carcinoma STK11 0.12 1.09e-07
Non-Small Cell Lung Carcinoma KRAS 0.12 8.61e-05
Folinic Acid-Fluorouracil-Irinotecan Regimen SMAD4 0.11 8.21e-08
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Malignant neoplasm of urinary bladder EP300 0.11 2.57e-07
Pulmonary function tests KEAP1 0.11 8.29e-07
Colorectal Carcinoma SMAD4 0.11 4.47e-07
FOLFOX Regimen SMAD4 0.11 2.03e-10
Tract FAT1 0.11 3.77e-05
Urology ERBB2 0.11 1.95e-05
KRAS gene SMAD4 0.11 4.34e-07
irinotecan SMAD4 0.11 1.45e-05
Immunotherapy RBM10 0.11 9.55e-06
Rash and Dermatitis Adverse Event Associated with Chemoradiation TCF7L2 0.11 2.14e-05
Tract EP300 0.10 1.24e-05
Superficial FGFR3 0.10 2.29e-05
Immunotherapy FGFR3 0.10 4.13e-05
Colorectal PTPRS 0.10 9.11e-07
Malignant neoplasm of urinary bladder ATM 0.10 8.03e-05
Non-Small Cell Lung Carcinoma PTPRD 0.10 9.64e-06
Adenocarcinoma of lung (disorder) KEAP1 0.10 1.46e-07
Tract SPEN 0.10 3.32e-05
Gross hematuria CREBBP 0.10 1.43e-05
Gross hematuria NSD1 0.10 7.95e-07
Tract FANCA 0.10 3.20e-05
Gross hematuria ERBB2 0.10 1.81e-05
Sigmoid colon TCF7L2 0.10 6.46e-06
Tract ERBB3 0.10 2.09e-05
Non-Small Cell Lung Carcinoma KEAP1 0.10 1.02e-06
Invasive Ductal Breast Carcinoma GATA3 0.10 3.71e-08
Malignant neoplasm of urinary bladder ERBB3 0.09 6.40e-06
Sigmoid colon SMAD4 0.09 3.46e-05
Colorectal ERBB4 0.09 3.22e-05
Adenocarcinoma of lung (disorder) STK11 0.09 1.91e-05
Simple mastectomy GATA3 0.09 2.59e-06
pemetrexed STK11 0.09 1.23e-05
Extracapsular FOXA1 0.08 3.92e-05
Malignant neoplasm of urinary bladder PBRM1 0.08 7.37e-05
Malignant neoplasm of urinary bladder NSD1 0.08 4.75e-05
pemetrexed KEAP1 0.08 1.31e-05
Colorectal SMAD4 0.08 1.87e-05
Malignant neoplasm of urinary bladder BRCA1 0.08 1.80e-04
Colorectal TCF7L2 0.08 2.29e-05
Stage IV Lung Adenocarcinoma RBM10 0.08 5.16e-05
FOLFOX Regimen PTPRS 0.08 1.31e-05
Non-Small Cell Lung Carcinoma EPHA3 0.08 7.61e-05
Prostate carcinoma FOXA1 0.07 3.61e-05
Table 5.7: Complete list of clinico-genetic associations found using the Case-Control Set-up. βqg refers to
the linear weight as described in Section 5.2.2. Associations in bold have also been discovered by the H-PFA.
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5.A.2 Hierarchical Poisson Factor Analysis
Clinical record Genetic information
Prostate carcinoma 0.63 4.06e-43
Biopsy of prostate 0.52 1.63e-34
Extracapsular 0.48 3.54e-32
adenocarcinoma of the prostate 0.43 3.98e-26
Personal Attribute 0.33 2.23e-16
Robotics 0.25 5.86e-13
Pelvic lymph node group 0.20 2.34e-09
Lupron 0.20 2.37e-07
Incontinence 0.17 7.87e-07
External Beam Radiation Therapy 0.17 1.04e-06
Positive Surgical Margin 0.14 7.71e-06
(a) 100% prostate cancer
Clinical record Genetic information
Invasive Ductal Breast Carcinoma 0.47 1.86e-11
Adriamycin 0.37 6.54e-11
Lytic lesion 0.33 2.45e-09
Lumpectomy of breast 0.33 4.86e-08
Zometa 0.32 2.47e-08
Palliative Care 0.22 8.32e-06
(b) 32.3% breast carcinoma, 41.2% non-small cell lung cancer, 26.5% prostate cancer
Table 5.8: Additional clinical associations (complex phenotypes) found by the H-PFA.
Clinical record Genetic information
FOLFOX Regimen 0.77 3.47e-19 APC 0.59 5.34e-11
Rectum 0.59 1.56e-14
Sigmoid colon 0.43 8.36e-09
Rash and Dermatitis Adverse Event Associated with
Chemoradiation
0.42 1.24e-09
capecitabine 0.42 5.37e-09
Colorectal 0.42 1.19e-07
Folinic Acid-Fluorouracil-Irinotecan Regimen 0.40 1.11e-07
KRAS gene 0.38 2.12e-07
Ulcer 0.36 3.64e-08
irinotecan 0.35 3.10e-07
Rectal hemorrhage 0.34 3.31e-06
Avastin 0.32 1.13e-05
Leucovorin 0.29 2.95e-05
Combined Modality Therapy 0.26 5.02e-05
Response to treatment 0.25 4.10e-05
Table 5.9: Additional clinico-genetic association found by the H-PFA involving APC gene. This group of
associations was found in a subgroup of 100% bladder cancer patients.
Clinical record Genetic information
Stage IV Lung Adenocarcinoma 0.64 3.47e-15 EGFR 0.35 8.65e-06
Adenocarcinoma of lung (disorder) 0.56 3.92e-11
pemetrexed 0.51 7.89e-10
Tibialis anterior muscle structure 0.32 3.40e-06
Table 5.10: Additional clinico-genetic associations found by the H-PFA involving EGFR gene. This group
of associations was found in a subgroup of 100% non-small cell lung cancer patients.
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6
Flexible Indian Buffet Process Priors for
Understanding International Trade
This chapter presents Bayesian nonparametric (BNP) latent factor models specially suitable for ex-
ploratory analysis of high-dimensional count data. First, we perform a non-negative doubly sparse
matrix factorization that has two main advantages: on the one hand, we are able to better approximate
the row marginal input distribution of the observation matrix; on the other hand, the inferred topics
are also sparse, and thus, easier to interpret. By combining the stable-Beta process [201] with the
restricted Indian buffet process [43], we increase the model flexibility, allowing for a full spectrum
of sparse solutions in the latent space. Second, we propose a dynamic Poisson factorization model
based on the Markov Indian buffet process [56] with varying activation of the latent features over
time. We demonstrate the usefulness of our approaches in the analysis of countries’ economic struc-
ture based on two different databases of export portfolios, ranging from 1964 to 2010. Compared
to other approaches, empirical results show our model’s ability to give easy-to-interpret information
and better capture the sparsity structure underlying data.
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6.1 Introduction
In this chapter, we focus on finding an interpretable representation for international trade, a topic of
central interest to the theory of economic growth and, in particular, to the recently introduced concept
of economic complexity [88, 83, 192]. Our objective is to help explain the productive structure
and competitiveness of world economies based on the thresholded revealed comparative advantage
(RCA) matrix [16]. This is a well-established normalized metric correcting for size of economies,
defined as:
RCAnd =
End/
∑
pEnd∑
nEnd/
∑
n,dEnd
, (6.1)
xnd =
1, if RCAnd ≥ 10, otherwise . (6.2)
where End is the raw export of product d by country n in dollars. RCAcp > 1 indicates that country
c’s share of product p is larger than the product’s share of the entire world market, thus “revealing”
a comparative advantage of the country in the corresponding product. Let X be the resulting N ×D
sparse high-dimensional matrix reflecting the relative export advantages of N countries at exporting
each of the D products.
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Figure 6.1: Country-product matrix constructed from real trade data in 2010. A non-zero entry reflects
a relative advantage of a country at exporting a given product. Columns and rows have been arranged in
decreasing order according to the number of ones per row and column.
An interesting property of such data is its approximately triangular sparse structure after re-
ordering of rows and columns, as shown in Figure 6.1. Rather than a niche economic paradigm where
countries focus in the production of a few specialized products (this would result in a block-diagonal
matrix), data suggests that countries have different diversity degrees in their export portfolios, and
thus different trade strategies and skills. Our objective herein is twofolds: first, we want to find an
underlying representation that is easy to understand and able to capture this triangular structure in
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the input data for a single year; second, we want to study the evolution of such matrix over time.
This chapter proposes Poisson sparse non-negative matrix factorization models which place In-
dian buffet process (IBP)-based priors over the country-feature matrix to learn the appropriate num-
ber of hidden features from the data to deal with a static and dynamic scenario. To enforce sparsity
in the feature-product matrix, we use a component-wise gamma prior with a shape parameter smaller
than one. This prior has a similar effect to the spike and slab prior, but is more amenable for inference.
In the static scenario (single year), we additionally modify the IBP prior according to two recent
advances [201, 43]. First, we use the tree-parameter Indian buffet process (3P-IBP) formulation
from [201] that allows for a different degree of sharing between features, and an eventual power-
law distribution over the feature weights. Such flexible prior allows to capture different kinds of
realities, from a world in which countries with few skills focus on different types of products, to
a world in which poor countries have a strong overlap in export portfolios. Second, we also rely
on the restricted Indian buffet process (R-IBP) formulation from [43], which allows for a general
marginal distribution over the number of active features per row. Indeed, a priori we expect countries
to exhibit different degrees of diversification in the exports, which translates in different amounts of
active latent features per row. Poor countries might have very little features active, whereas other
diversified countries might have almost all features active.
In the dynamic scenario (multiple years), we extend the basic Bernoulli process Poisson factor
analysis (BeP-PFA) model in order to analyze the evolution of countries’ capabilities (latent features)
over time. Based on the Markov Indian buffet process (mIBP), we design a BNP model in which
countries are allowed to acquire or loose capabilities along the years according to a Markovian struc-
ture. This temporal perspective is particularly useful in terms of policy recommendation or future
export predictions, and allows us to build a finite state machine of latent binary patterns.
The inference for both the static and dynamic models, which we denote as Three-parameter
restricted Bernoulli process Poisson factor analysis (3RBeP-PFA) model and Dynamic Bernoulli
process Poisson factor analysis (dBeP-PFA) model respectively, is based on Markov chain Monte
Carlo (MCMC) approaches. We use auxiliary variables to make our models conditionally conjugate,
together with Metropolis-Hasting within Gibbs and Adaptive Rejection Metropolis sampling [126]
in the static case, and forward-filtering backward-sampling (FFBS) [56] in the time-varying case.
In the experimental section we use the proposed models to analyze multiple international trade
databases. Our models exhibit similar predictive accuracy than other approaches, while it outper-
forms them in terms of interpretability strength. In the static scenario, the proposed model is the best
one at capturing the input triangular structure of the data. Both a quantitative and qualitative analysis
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are provided for export data from 2010. We further demonstrate the usefulness of our models to
analyze the temporal dynamics of countries’ exports between 1964 and 2010.
6.2 Flexible IBP Extensions
6.2.1 Three-Parameter Indian Buffet Process
In the 3P-IBP, the feature weights follow a more flexible distribution that covers power-law behav-
iors [201]. This can be achieved by replacing the beta process directing measure in the IBP by a
stable-beta process:
µ ∼ stable-BP(1, α,H), Zn• ∼ BeP(µ, f) (6.3)
As its name indicates, this process can be fully specified by three parameters: α is the same mass
parameter from the IBP that controls the a priori expected total number of non-zero entries in matrix
Z. Additionally, the stability exponent σ ∈ [0, 1) controls the power-law behavior of the model
(weight decay), and c > −σ is the concentration parameter that affects the a priori number of ones
per column (sharing degree per column). When c = 1 and σ = 0, we recover the standard IBP.
Using the usual culinary metaphor of customers entering an Indian buffet restaurant and sequen-
tially choosing dishes from an infinite buffet, the 3P-IBP generalizes as follows:
• Customer 1 tries Poisson(α) number of dishes.
• Customer n+ 1 tries:
– each dish with probability mk−σn+c for each one that has been previously tried; mk is the
number of customers who previously sampled from dish k.
– Poisson
(
αΓ(1+c)Γ(n+c+σ)Γ(n+1+c)Γ(c+σ)
)
new dishes.
In such process, the number of hidden features is expected to grow as O(Nσ) where N is the
number of samples. By introducing parameters c and σ, Z can have a more flexible structure, re-
gardless of the sparsity density which is controlled by α. Compared to the IBP, the 3P-IBP gives
more flexibility on the feature weights, but has the disadvantage that the number of ones per-row is
still a priori Poisson distributed, which might not always be desirable, particularly in our analysis of
international trade.
6.2.2 Restricted Indian Buffet Process
The R-IBP is a recently developed model that allows an arbitrary prior distribution to be placed over
the number of active features underlying each observation [43]. A natural way to build such process
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is to replace the underlying Bernoulli processes in the IBP by restricted Bernoulli processes defined
as:
R-BeP(Zn•;µ, f) = f (Jn) ·
∏∞
k=1 pi
znk
k (1− pi1−znkk )1(
∑
K znk = Jn)∑
z′∈Z
∏
k pi
z
′
k
k (1− pik)(1−z
′
k)1(
∑
K z
′
k = Jn)
(6.4)
where the directing measure µ =
∑
k pikδθk , pik and θk are the feature weight and location cor-
responding to each latent feature k, α is the same mass parameter of the IBP, Jn is the number of
ones per row n, Z is the set of all possible binary vectors, and f is the a priori distribution over the
number of active features per row. The R-IBP can thus be formulated as:
µ ∼ BP(1, α,H), Zn• ∼ R-BeP(µ, f) (6.5)
We then have two degrees of freedom α and f to control for sparsity degree and sparsity structure of
Z. Note that columns are not exchangeable anymore, i.e., the parameter f creates correlation among
the features, which has to be handled during inference.
The intuition behind the R-IBP can be explained using the previously stated culinary metaphor.
Customers in the R-IBP have varying degrees of hunger: some of them sample from many dishes in
the buffet, while others only taste a reduced set of dishes. This interpretation makes specially sense
in our international trade application, where developed countries are known to have more assets,
and thus are expected to exhibit a higher number of latent features (capabilities) compared to poor
countries.
6.3 Static Scenario
6.3.1 Three-Parameter Restricted Bernoulli Process Poisson Factor Analysis
To decouple sparsity density and sparsity structure in the latent matrix, we combine the advantages
of both the R-IBP and 3P-IBP into a single prior,
Z ∼ 3R-IBP(α, c, σ, f) (6.6)
where the mass parameter α controls the sparsity degree of matrix Z, c is the concentration parameter
that accounts for the degree of sharing between features, σ is the stability exponent responsible for
the power-law behavior of the feature weights, and f is the a priori distribution over the number
of ones per row. By doing so, we expect our model to be able to find highly-specific and easy-to-
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interpret hidden features. In our application, we should be able to find ”high-tech” features which
involve only a few products and are active for a small number of countries, which would be consistent
with the economic literature [82].
Let X ∈ NN×D be our input matrix of N samples and D dimensions. Using the three-parameter
restricted IBP prior, we build an infinite latent feature model for count data with Poisson likelihood
and Gamma-distributed factors as follows
xnd ∼ Poisson
(
Zn•B•d
)
, (6.7)
Bkd ∼ Gamma
(
αB,
µB
αB
)
, (6.8)
where αB and µB are the shape and mean parameters of the prior Gamma distribution for each
element of matrix B. In this model, both matrices Z and B are non-negative and sparse, which
makes the inferred latent variables very easy to interpret. In particular, sparsity in matrix B can be
induced simply by choosing αB  1.
In our particular application of international trade, we have N countries, D products and K+
non-empty latent features to be inferred. A given row Zn• captures which latent features are active
for country n. B represents the effect of each latent feature on every product. For instance, if a latent
feature k is active for a certain country, all products having high values in vector Bk• will be more
likely to be exported by that country1.
We further restrict the model in two ways. First, we use a bias term, labeled as feature F0 that is
active for all the countries. This bias term is not sparse, and will capture the general ad-hoc trading
that might exist in a country punctually but not as a trend, and thus does not constitute a feature.
A bias term allows for the active features to be sparser and more interpretable, as well as reducing
the number of features that are necessary to explain the whole database. Such approach has already
been followed in [182, 159] to alleviate identifiability problems in the inferred solution. Second,
we rely on a negative binomial distribution for f in (6.6). The negative binomial distribution is best
understood as an overdispersed Poisson [226]. Hence it will naturally allow for countries to exhibit
a much variable range of active features, from not having any additional feature on top of the bias, to
having all the latent features active. These two extremes are less likely to happen in the standard IBP
model.
We call the whole model three-parameter restricted Bernoulli process Poisson factor analysis
(3RBeP-PFA). This model can be seen as a probabilistic extension of non-negative matrix factor-
1The vector Bk• corresponds to the k-th row of matrix B.
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ization where the number of latent features is not fixed a priori, both matrices are sparse, and soft-
constraints on the latent sparsity structure are imposed through the prior.
6.3.2 Inference
Since exact computation of the posterior distribution for the latent variables is intractable, we resort
to a Markov Chain Monte Carlo (MCMC) approach. In particular, our algorithm uses Gibbs sampling
together with Metropolis-Hasting (MH) and Adaptive Rejection Metropolis Sampling (ARMS) [126].
We use a finite-dimensional approximation for the latent measure pi by allowing at most K features.
For each observation xnd, we introduce the auxiliary variables x
′
nd,1, . . . , x
′
nd,K such that xnd =∑K
k=1 x
′
nd,k, and x
′
nd,k ∼ Poisson(ZnkBkd) for k = 1, . . . ,K. Given such auxiliary variables,
the model is conditionally conjugate, and a Gibbs sampler can be derived straightforwardly. The
complete sampling algorithm is described in Algorithm 5. Further details regarding the slice sampler
for the BeP-PFA based on the one-parameter IBP can be found in Section 8.
Algorithm 5 A single iteration of the MCMC inference procedure for the 3RBeP-PFA model.
1: Sample each element of matrix Z using inclusion probabilities [5, 43].
2: Sample latent measure pi using MH steps [43]. The ARMS is needed to sample the feature
weights of completely new features.
3: Sample each element of B and X
′
from their conditional distributions.
4: Sample hyperparameter α according to [50].
In the case of the 3RBeP-PFA model, the inference algorithm proceeds as follows:
1. Sample Z element-wise from each conditional probability distribution, according to [43]. In-
clusion probabilities are combined with f and the data likelihood p(X|Z,B).
2. Sample the latent measure pi. Since the beta process is not conjugate to the restricted Bernoulli
process, we cannot directly Gibbs sample pi. Instead, we use a Metropolis-Hastings within
Gibbs sampling step. We use the posterior distribution from the standard IBP as a proposal
distributionQ. The posterior distribution of weights in the case of non-empty features is given
by
Q(pik|Z•k) ∝ Beta(αc
K
+
N∑
n=1
znk − σ, N −
N∑
n=1
znk + c+ σ) (6.9)
In the case of new (empty) features, the posterior distribution is not conjugate anymore, so
we need to use additional sampling techniques such as Adaptive Rejection Metropolis Sam-
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pling [126]. Note that the posterior of the latent measure is not a stable-beta process anymore.
The posterior distribution from which we should sample is given by
Q(piknew |Z•k) ∝ α
Γ(1 + c)
Γ(1− σ)Γ(c+ σ)pi
−σ−1
knew
(1− piknew)c+N+σ−1 (6.10)
The acceptance probability is given by
a =
p(pi
′
,Z)
p(pi,Z)
Q(pi|Z)
Q(pi′ |Z) (6.11)
=
∏N R-BeP(Zn·;pi′ , f)∏N R-BeP(Zn•;pi, f) p(pi
′
)
p(pi)
Q(pi|Z)
Q(pi′ |Z) (6.12)
where
R-BeP(Zn•;pi, f) = f (Jn)
∏∞
k=1 pi
znk
k (1− pi1−znkk )1(
∑
K znk = Jn)∑
z′∈Z
∏
k pi
z
′
k
k (1− pik)(1−z
′
k)1(
∑
K z
′
k = Jn)
(6.13)
Let us call DKJn the denominator in (6.13). This value can be computed easily using a dynamic
programming approach. Indeed, we can exploit the recursive form DKJn = (1− piK)DK−1Jn +
piKD
K−1
Jn−1.
3. Gibbs sample B, the auxiliary variables X′, and hyperparameter α in the same way as in the
standard IBP model.
6.4 Time-varying Scenario
6.4.1 Dynamic Bernoulli Process Poisson Factor Analysis
In the following, we focus on the temporal dynamics of the hidden features. Our objective is to
monitor which capabilities each country acquires or loses over time, in order to further understand
the development paths of an economy. We extend the basic BeP-PFA based on the infinite factorial
hidden Markov model [56]. Note that we take the BeP-PFA as a starting point instead of the improved
3RBeP-PFA model for simplicity reasons in the modeling and for inference speed; an extension
based on the 3RBeP-PFA is in the agenda for future work. Let X(t) be our country-product matrix at
timestamp t = 1, . . . , T . The new likelihood function for each element in this matrix can be written
as:
x
(t)
nd ∼ Poisson
(
Z
(t)
n•B•d
)
(6.14)
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where Z ∈ {0, 1}N×K×T is a three-dimensional matrix for N countries, K → ∞ inferred latent
features, and T timestamps. Our model assumes that each latent feature k has independent and
constant Markov dynamics over time, shared for all countries. Let Qk be the transition matrix for
feature k, defined as:
Qk =
 1− ak ak
1− bk bk
 (6.15)
where ak is the activation probability of feature k, and bk is the probability of staying active, some-
times called the persistence parameter.
The feature activation matrix Z is generated via a collection of mIBPs with shared transition
matrices and hyperparameters across countries. In particular, for each country n, we have Z(•)n• ∼
mIBP(α), which is equivalent to the following generative process when K →∞:
ak ∼ Beta
( α
K
, 1
)
, (6.16)
bk ∼ Beta(γ, δ), (6.17)
z
(t)
nk |ak, bk ∼ Bernoulli
(
a
1−z(t−1)nk
k b
z
(t−1)
nk
k
)
(6.18)
z
(0)
nk = 1 (6.19)
The prior for each element Bkd is the same as in the BeP-PFA model, i.e., a Gamma distribution
with shape parameter smaller than one in order to enforce sparsity in the latent features. We call the
complete model dynamic Bernoulli process Poisson factor analysis (dBeP-PFA).
Since it is not possible to directly extent the 3RBeP-PFA to the dynamic scenario, we resort to a
one-parameter IBP prior,
6.4.2 Inference
To make inference tractable, we make the same assumption as in the static scenario, namely, that
each observation x(t)nd is equal to the sum of K Poisson-distributed auxiliary random variables, i.e.,
x
(t)
nd =
∑K
k=1 r
(t)
nd,k where r
(t)
nd,k ∼ Poisson(z(t)nkBkd) for k = 1, . . . ,K. We adopt the convention that
a zero-rate Poisson is equivalent to a delta at zero2. Notice that vector Z(t)n• works as a mask on the
multinomial auxiliary variables, and therefore there exists a very strong correlation between Z(t)n• and
r
(t)
n•,• for each country n and timestep t. For interpretability purposes, we force the first feature to be
active for all samples. Such feature works as a bias term, it captures the a priori count rates (average
2This corresponds to the assumption that 0 · log(0) = 0.
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values) for each dimension d, and avoids numerical problems.
As explained in [187], a naı¨ve Gibbs sampling in a time series model is typically very slow due
to potentially strong coupling between successive time steps. Thus, we resort to a blocked Gibbs
sampler which fixes all but one column of Z, and runs a forward-filtering backward-sampling sweep
on the remaining column [56]. Matrix B can be sampled exactly conditioned on all other variables.
We start with an initial Z matrix and sample ak, bk ∀k. Next, conditional on our initial Z
and our observations X, we sample the feature effect matrix B. We then start an iterative sampling
scheme described in Algorithm 6. Further details concerning the complete conditionals and the FFBS
procedure can be found in the Appendix 8.
Algorithm 6 Slice sampler for the dBeP-PFA
1: Sample the auxiliary slice variable µ. This might involve extending the representation of the
other latent variables, e.g., r and B.
2: For all the represented features, sample Z, r and B,
3: Sample the model hyperparameters α, γ, δ,
4: Remove all unused features.
6.5 Results
Data description. To illustrate the usefulness of our model, we consider two publicly available
trade datasets, both involving N countries and D products. The first considered database is the UN
COMTRADE Standard international trade classification (SITC) rev.2 dataset, which disaggregates
products to the four digit level, provided by the team of the Observatory of Economic Complexity. In
order to clean unreliable or inadequately classified data, we restrict the dataset to the same countries
that were used in the Atlas of Economic Complexity [83]. This leaves us with data on 126 countries
and 744 products.
The second database that we use is the Harmonized system (HS) rev. 1992 classification disag-
gregated to six digit level (4890 products). The original data was collected by UN COMTRADE,
and was further cleaned by the team of the Observatory of Economic Complexity (the HS data were
also cleaned by the BACI team). Both databases are available at http://atlas.media.mit.
edu/en/resources/data/.
The biggest difference between both datasets is the number of considered products and sparsity
density, as stated in Table 6.1. Note that D  N , which is not the common scenario for latent
feature models. The data matrix is binary and represents the RCA of countries, which is a normalized
common measure in economics [16]. Basically, an entry xnd in the country-product matrix X equals
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N D Nr. entries (2010) Nr. entries (all years) Sparsity
SITC 126 744 16k 1.1M 0.17%
HS 123 4890 77k 1.5M 0.13%
Table 6.1: Databases on International Trade considered in this chapter. The available time windows for
both databases are (1964-2014) for the SITC data and (1995-2014) for the HS database.
one when country n has a relative advantage at exporting product d, and zero otherwise. Even if
the matrix is binary, we may use a Poisson likelihood because of the high degree of sparseness in
data. Such approximation has already been adopted successfully in the case of recommendation
systems [67].
Experimental setup. Regarding the models’ hyperparameters, we choose a Gamma prior over the
concentration parameter α with shape and scale parameters equal to one. The concentration param-
eter α is sampled as described in Section 6.3.2. We set αB to 0.01 to induce sparsity, and µB equal
to one. In the static setting, we choose a flexible marginal prior f as Negative-Binomial(r, p), with
r = [1, 2], and p = [0.1, 0.3, 0.5]. The results are equivalent using any of these priors. Specifically,
we report the results for r = 1 and p = 0.1. Additionally, we run experiments for each combination
of c = [1, 10, 20, 50] and σ = [0, 0.25, 0.5, 0.75, 1]. Even if the results did not vary considerably
when changing those hyperparameters, setting c > 1 and σ > 0 allows for a higher a priori sparse-
ness in the latent features and potential power-law behaviors in the feature weights respectively. All
figures and tables in the static case correspond to c = 50, and σ = 1. Finally, for the dynamic
scenario, we assume a Beta prior for bk, with both γ and δ equal to one (which is equivalent to the
uniform distribution).
6.5.1 Static Scenario
Quantitative Evaluation
We first perform a quantitative evaluation of our model in terms of predictive accuracy, interpretabil-
ity strength and ability to capture the row marginal distribution of the input, using data from 2010.
Simulations are run for 10 different train-test splits with a proportion of 90-10% entries. The burn-in
period for the MCMC inference algorithm is 30,000 iterations, and results are averaged using the
last 1,000 posterior samples. Table 6.2 compares our model against probabilistic matrix factoriza-
tion (PMF) [134], non-negative matrix factorization (NNMF) [185], the standard BeP-PFA, and the
sparse sparse Bernoulli process Poisson factor analysis (sBeP-PFA) which uses αB  1.
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Metric PMF NNMF BeP-PFA SBeP-PFA 3RBeP-PFA
Log Perplexity 1.68± 0.01 1.61± 0.01 1.59± 0.04 3.26± 0.17 1.62± 0.01
Coherence −264.60± 4.74 −263.27± 7.45 −149.36± 7.56 −178.44± 4.50 −140.51± 2.73
(a) 2010 SITC database (N = 126, D = 744)
Metric PMF NNMF BeP-PFA SBeP-PFA 3RBeP-PFA
Log Perplexity 1.48± 0.01 1.47± 0.01 1.58± 0.01 2.56± 0.12 1.57± 0.02
Coherence −264.73± 3.11 −264.67± 6.22 −148.91± 10.57 −168.39± 13.16 −134.51± 4.43
(b) 2010 HS database (N = 123, D = 4890)
Table 6.2: Quantitative Evaluation of Accuracy and Interpretability for 3RBeP-PFA. We compare PMF,
NNMF, BeP-PFA, sBeP-PFA and 3RBeP-PFA in terms of mean and standard error of the test log-perplexities,
and topic coherence.
Accuracy. We use perplexity to measure predictive accuracy, i.e. the harmonic mean of the inverse
test log likelihood (the lower, the better), defined as:
Perplexity(Xtest) = exp
(
− ln p(Xtest|Xtrain)
Ntest
)
(6.20)
ln p(Xtest|Xtrain) ≈ Poisson
(
E [p(Z|Xtrain] E [p(B|Xtrain)]
)
(6.21)
All models present similar perplexity, except the sBeP-PFA model, in which the sparseness restriction
degrades its performance significantly. Our 3RBeP-PFA has the same sparse restriction, but it has
a more flexible prior that it is able to compensate the penalty in perplexity and perform close to
the non-sparse models, i.e. PMF, NNMF and BeP-PFA. The combination of the negative binomial
and the stable-Beta process allows to match the perplexity performance of non sparse methods, but
keeping the results interpretable, as we illustrate in the next paragraphs.
Interpretability. In order to assess semantic quality, we rely on the coherence [51], which is an
often-used metric in topic modeling literature. The coherence Ck of a feature is defined as:
Ck =
M∑
m=2
m−1∑
l=1
log
R(vkm, v
k
l ) + 1
R(vkl )
(6.22)
where vki is the i-th product with highest weight in factor k, andM represents how many top products
should be evaluated, here we take M = 20 products. Also R(x) refers to the number of countries
exporting product x, and R(x, y) is the number of countries exporting both products x and y. The
closer coherence is to zero, the better. The 3RBeP-PFA outperforms the BeP-PFA and sBeP-PFA
by far, making it specially suitable for data exploration in high-dimensional count scenarios. The
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Figure 6.2: Capturing Sparsity Structure. Comparison of the empirical and inferred distribution of the
number of ones per row in the input matrix, using qq-plots.
non-sparse methods present low coherence, as expected.
Sparsity structure. Next, we evaluate the ability of our model to fit the input distribution of coun-
tries’ diversity, i.e., the number of ones per-row in Z. Figure 6.2 presents a comparison of our
3RBeP-PFA model with the standard BeP-PFA, the sBeP-PFA model, and a simple binomial model
described in [82]. The latest one assumes binary matrices Z and B, a finite number of capabilities
K, and uniform activation probabilities pcc and pcp for all country-capability and capability-product
combinations3. We measure the “proximity” of the empirical and predicted distribution of the num-
ber of ones per row for all models through a qq-plot. The sBeP-PFA underfits the distribution for
higher values, e.g., it predicts a lower number of countries with high number of exports, in contrast
to the 3RBeP-PFA model4.
3Parameters in this baseline model are chosen to best fit the diversity input histogram.
4The horizontal line for the 3RBeP-PFA corresponds to countries only having the bias term F0.
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Qualitative Evaluation
Interpretability Table 6.3 compares two similar latent features (capabilities) inferred by our 3RBeP-
PFA model and using a standard singular value decomposition (SVD). In each case, we report a sorted
list of products and their corresponding factor weights. We only include those products whose weight
is large enough (at most 30% lower than the maximum weight). Compared to SVD, our model is able
to give much shorter and concise descriptions, as weights decrease at a faster pace and the largest
weights are larger. Moreover, products in the SVD list come from a mixture of farming and techno-
logical elements, whereas the 3RBeP-PFA list is more homogeneous. We conclude that our approach
enhances interpretability of the latent factors in terms of both conciseness and precision.
Top Products with weights > 30% Bkd
Bovine 0.49
Misc. Refrigeration Equipment 0.43
Radioactive Chemicals 0.41
Blocks of Iron and Steel 0.41
Rape Seeds 0.40
Animal meat, misc 0.39
Refined Sugars 0.38
Misc. Tire Parts 0.38
Leather Accessories 0.38
Liquor 0.38
Bovine meat 0.38
Embroidery 0.37
Unmilled Barley 0.37
Dried Vegetables 0.36
Textile Fabrics Clothing Accessories 0.36
Horse Meat 0.35
Iron Bars and Rods 0.35
Analog Navigation Devices 0.35
(a) SVD
Top Products with weights > 30% Bkd
Misc. Animal Oils 0.78
Bovine and Equine Entrails 0.72
Bovine meat 0.68
Preserved Milk 0.63
Equine 0.62
Butter 0.58
Misc. Animal Origin Materials 0.57
Glues 0.56
(b) 3RBeP-PFA
Table 6.3: Qualitative comparison for a similar latent feature for SVD and 3RBeP-PFA.
Table 6.4 presents a complete list of all capabilities inferred by our model. For each capabil-
ity k, we report the averaged number of countries m¯k that have it, the top-5 products with highest
weights Bkd and a representative country, which we define as the country that has the least number
of capabilities among those that possess capability k. We also report the average number of active
capabilities J¯n for each representative country n. Clearly, our model is highly interpretable in the
sense that it is able to differentiate capabilities according to the elements required in the production
of products. For instance, we can clearly associate capability F2 to the presence of animals and farm-
ing, or capability F7 to the elements required in the production of automotive parts. Furthermore,
capabilities for which the corresponding representative countries have a high number of active capa-
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Id m¯k Top-5 products with sorted highest weights (Bkd) associated Repr. countries (J¯n)
F1 18.27 Misc. Animal Oils (0.78), Bovine and Equine Entrails (0.72), Bovine meat (0.68), Preserved Milk (0.63), Equine (0.62) Paraguay (2.00)
F2 21.39
Synthetic Woven Fabrics (0.74), Non-retail Synthetic Yarn (0.60), Woven Fabric of less than 85% Discontinuous Synthetic Fibres
(0.60), Woven Fabrics of More Than 85% Discontinuous Synthetic Fiber (0.58), Yarn of Less Than 85% Synthetic Fibers (0.53)
United Arab Emirates
(2.82)
F3 14.87
Parts of Metalworking Machine Tools (0.74), Interchangeable Tool Parts (0.72), Polishing Stones (0.69), Tool Holders (0.66),
Misc. Metalworking Machine-Tools (0.54) Israel (5.97)
F4 18.67
Aldehyde, Ketone and Quinone-Function Compounds (0.68), Glycosides and Vaccines (0.67), Medicaments (0.65), Inorganic
Esters (0.64), Cyclic Alcohols (0.62) Ireland (4.34)
F5 11.04 Synthetic Rubber (0.87), Acrylic Polymers (0.85), Silicones (0.76), Misc. Polymerization Products (0.71), Tinned Sheets (0.65) North Korea (3.99)
F6 21.95
Measuring Controlling Instruments (0.61), Mathematical Calculation Instruments (0.59), Misc. Electrical Instruments (0.57),
Misc. Heating and Cooling Equipment (0.51), Parts of Office Machines (0.49) Malaysia (3.00)
F7 31.14 Vehicles Parts and Accessories (0.59), Cars (0.58), Iron Wire (0.53), Trucks and Vans (0.53), Air Pumps and Compressors (0.50) Belarus (4.20)
F8 33.00
Improved Wood (0.71), Mineral Wool (0.62), Central Heating Equipment (0.62), Aluminium Structures (0.62), Harvesting
Machines (0.60) Belarus (4.20)
F9 16.53
Misc. Electrical Machinery (0.76), Vehicles Stereos (0.72), Misc. Data Processing Equipment (0.64), Video and Sound Recorders
(0.57), Calculating Machines (0.55) Malaysia (3.00)
F10 45.93
Baked Goods (0.67), Metal Containers (0.62), Misc. Edibles (0.59), Misc. Articles of Paper (0.59), Misc. Organic Surfactants
(0.58) Costa Rica (2.06)
F11 33.23
Misc. Articles of Iron (0.65), Carpentry Wood (0.61), Misc. Manufactured Wood Articles (0.60), Sawn Wood Less Than 5mm
Thick (0.56), Electric Current (0.51) Russia (2.93)
F12 38.67 Vegetables (0.60), Fruit or Vegetable Juices (0.54), Misc. Fruit (0.50), Frozen Vegetables (0.48), Apples (0.47) Peru (2.00)
F13 23.29
Misc. Pumps (0.51), Ash and Residues (0.45), Chemical Wood Pulp of sulphite (0.44), Rolls of Paper (0.43), Worked Nickel
(0.43) Russia (2.93)
F14 46.11
Synthetic Knitted Undergarments (0.76), Misc. Feminine Outerwear (0.74), Misc. Knitted Outerwear (0.73), Men’s Shirts (0.70),
Blouses (0.67) Sri Lanka (2.00)
F15 32.12
Misc. Rotating Electric Plant Parts (0.66), Control Instruments of Gas or Liquid (0.58), Valves (0.57), Misc. Rubber (0.56), Misc.
Articles of Plastic (0.55) Philippines (4.01)
Table 6.4: Complete list of latent features found by the 3RBeP-PFA model. From left to right, m¯k is the
averaged number of countries having latent feature k active, we list the top-5 products with highest weights
Bkd; a representative country is the country that has the least number of active features among those possessing
feature k. J¯n is the averaged number of active features for each representative country n.
bilities J¯n, are also present in less countries, i.e. m¯k is low. This observation is in line with methods
proposed in [87, 196], as it suggests that capabilities have different degrees of complexity, which
plays an important role in the production of goods and services.
Table 6.6 provides a qualitative comparison of our 3RBeP-PFA model against the BeP-PFA and
sBeP-PFA models in terms of interpretability strength. For each method to be compared against, we
chose the most similar feature across the 10-folds in terms of the Jaccard index. We report the top-25
products and their corresponding factor weights. Compared to all other methods, our model is able
to give much shorter and concise descriptions, as weights decrease at a faster pace and the largest
weights are significantly larger. Moreover, products in the BeP-PFA list are very heterogeneous. The
list for the sBeP-PFA model includes items from a mixture of farming and technological elements,
whereas the 3RBeP-PFA list is more homogeneous. All these remarks apply for all the other latent
features that are listed in Table 6.4, other comparative tables can be found in the appendix of this
chapter. We conclude that our approach enhances interpretability of the latent factors in terms of
both conciseness and precision.
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Id Top-5 products with sorted highest weights (Bkd) associated
F1 Misc. Non-Ferrous Ores (0.40), Petroleum Gases (0.40), Misc. Textile Articles (0.37), Zinc Ore (0.32), Misc. Bituminous Mixtures (0.31)
F2 Sound Recording Media (0.38), Asbestos Products (0.38), Potatoes (0.37), Silver (0.35), Pig Meat (0.32)
F3 Thin Iron Sheets (0.42), Misc. Food-Processing Machinery (0.41), Baked Goods (0.41), Misc. Animal Entrails (0.34), Basketwork (0.34)
F4 Perfumery and Cosmetics (0.45), Misc. Gas Turbines (0.38), Cut Paper (0.35), Misc. Cereal Grains (0.33), Herbicides (0.32)
F5 Bovine (0.49), Misc. Refrigeration Equipment (0.43), Radioactive Chemicals (0.41), Blocks of Iron and Steel (0.41), Rape Seeds (0.40)
F6 Wheat Flour (0.34), Iron and Steel Forging (0.29), Printing Ink (0.29), Waste Paper (0.28), Aluminum (0.26)
F7 Misc. Oil Seeds and Fruits (0.47), Bones, Ivory and Horns (0.44), Temporarily Preserved Fruit (0.43), Cotton Seed Oil (0.42), Inorganic Bases (0.39)
F8 Prepared Explosives (0.48), Confectionary Sugar (0.39), Cigarretes (0.38), Coke (0.37), Misc. Hides and Skins (0.34)
F9 Fish, preserved (0.44), Fresh Fish (0.43), Misc. Animal Origin Materials (0.40), Oranges (0.37), Sheep and Goat Meat (0.37)
F10 Wood and Animal Hair Waste (0.46), Misc. Carpets (0.42), Wool Carpets (0.41), Wool Yarn (0.40), Degreased Sheep Wool (0.38)
F11 Tin (0.41), Vehicles Stereos (0.40), Copper (0.36), Misc. Articles of Paper (0.36), Petroleum Gases (0.36)
F12 Gypsum and Other Calcareous Stone (0.42), Sausage (0.34), Special Products of Textile (0.32), Movie Cameras and Equipment (0.30), Iron Shapes (0.29)
F13 Cigarretes (0.50), Worked Tin and Alloys (0.43), Aluminum (0.38), Bicycles (0.38), Raw Sheep Skin without Wool (0.38)
F14 Precious Metal Ores (0.50), Gold (0.48), Diamonds (0.47), Unmounted Precious Stones (0.43), Electrical Transformers (0.38)
F15 Sulphur (0.40), Fuel Wood and Charcoal (0.34), Misc. Unmilled Cereals (0.33), Household Refrigeration (0.33), Decorative Wood (0.33)
Table 6.5: Top-15 latent features inferred using the SVD.
BeP-PFA SBeP-PFA 3RBeP-PFA
Confectionary Sugar (0.45) Bovine (0.53) Miscellaneous Animal Oils (0.78)
Plastic Storage Containers (0.43) Improved Wood (0.51) Bovine and Equine Entrails (0.72)
Baked Goods (0.41) Miscellaneous Vegetable Oils (0.50) Bovine meat (0.68)
Tissue Paper (0.40) Butter (0.50) Preserved Milk (0.63)
Metal Containers (0.39) Rape Seeds (0.47) Equine (0.62)
Soaps (0.39) Miscellaneous Wheat (0.45) Butter (0.58)
Waste of Man-Made Fibres (0.38) Pulpwood (0.45) Misc. Animal Origin Mate. (0.57)
Misc. Organic Surfactants (0.35) Harvesting Machines (0.45) Glues (0.56)
Misc. Non-Iron Waste (0.35) Soil Preparation Machinery (0.44) Pig Meat (0.53)
Notebooks (0.34) Misc. Prepared Meats (0.43) Horse Meat (0.52)
Hydrogenated Oils (0.34) Bovine meat (0.43) Malt Extract (0.44)
Iron Structures (0.34) Coniferous Wood (0.42) Hay (0.43)
Household Refrigeration (0.34) Preserved Milk (0.42) Meat and fish extract (0.35)
Synthetic Knitted Undergarments (0.34) Misc. Animal Oils (0.41) Misc. Wheat (0.34)
Chocolate (0.33) Malt (0.41) Tractor Units (0.31)
Table 6.6: Qualitative Evaluation of Topic Interpretability. We compare the BeP-PFA, sBeP-PFA, and
3RBeP-PFA model. Comparison for any other feature can be found in the Supplementary.
Features correlation. In order to analyze the existing correlations between the inferred factors,
we apply our 3RBeP-PFA on the inferred matrix Z as input data. Such a deep structure, i.e. using
two-layer IBP, has already been explored in [40]. As before, we use a bias term, denoted by M-
F0, which is active for all countries. In addition to M-F0, our approach extracts another meta-
feature, M-F1, which is active for 46.19 countries on average (the list of countries can be found
in Table 6.9). The countries with an active M-F1 are those that have more active features in the
original model and a larger gross domestic product (GDP). Table 6.8 shows both meta-features, M-
F0 and M-F1, which assign different weights to each latent feature from the first layer. For the
reader’s convenience, we reproduce a compressed version of Table 6.4 in Table 6.7. M-F1 can be
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interpreted as the meta-feature that distinguishes between developed countries and developing ones
(see Figure 6.3), resulting in a sharp division of the world in terms of capabilities. More importantly
these two meta-features divide the features from the original model into three disjoint sets.
The first set contains the latent features whose weight is either zero or insignificant in M-F1: F0,
F1, F2, F9, F12 and F14 (highlighted in red). These are the features that define countries with least
capabilities, dealing with less complex products like farming or textile (see Table 6.4). It makes sense
that more developed countries do not have stronger weights than developing ones for these features.
Developed countries might have a non-zero RCA, but they are not exploiting such capabilities better
than developing ones.
The second set is composed by F10 (in green), which has a high value in both meta-features.
This feature is traded by both developing and developed countries. But the developed countries do
trade them more efficiently than developing ones. We can understand these products as those in the
capability frontier. We should expect that, as developing countries improve in the future, the weight
for F10 would drop towards zero in M-F1.
The last set includes the remaining features (in black). In this case, their weights in M-F0 are
negligible compared to their weights in M-F1. These features contain products like chemicals and
complex machinery, which are only traded by developed countries. Developing countries have not
acquired such capabilities to trade them yet, or they are in the process to do so but are still far behind.
Such sharp division among features suggests the existence of a “poverty” or “quiescence trap” in the
spirit of [82], a trap of development stasis in which some countries get stuck due to the inability to
“acquire” capabilities associated with the production of more complex products.
6.5.2 Time-varying Scenario
To give a further intuition of the interpretability of our time-varying approach, here we apply the
dBeP-PFA model to the aggregated SITC database between 1964 and 2010. We consider 92 coun-
tries, 501 products, and 47 timestamps. To speed up mixing, we initialize the latent features to the
values obtained from a preliminary training with the 2010 data, listed in Table 6.4, and learn the
feature activation values for all years.
Quantitative Evaluation
We first evaluate the predictive performance and topic interpretability of dBeP-PFA compared to
three alternative methods: Poisson Gamma dynamical system (PGDS), thinned Gamma process
Poisson factor analysis (tGaP-PFA), and BeP-PFA. The recently introduced PGDS model puts a
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Id Top-3 products with highest weights
F0 non-coniferous wood, cereal residues, non-iron waste
F1 misc. animal oils, bovine Entails, bovine meat
F2 synthetic woven, synth. yarn, woven < 85% synth.
F3 parts metalworking, tool parts, polishing stones
F4 Aldehyde–Ketone, glycosides–vaccines, medicaments
F5 synthetic rubber, acrylic polymers, silicones
F6 measuring instruments, math inst., electrical inst.
F7 vehicles parts, cars, iron wire
F8 improved wood, mineral wool, heating equipment
F9 elect. machinery, vehicles stereos, data processing eq.
F10 baked goods, metal containers, misc. edibles
F11 misc. articles of iron, carpentry wood, wood articles
F12 vegetables, fruit–vegetable juices, misc. fruit
F13 misc. pumps, ash–residues, chemical wood pulp
F14 synth. undergarments, feminine outerwear, men’s shirts
F15 misc. rotating, electric plant parts, control inst. of gas
Table 6.7: Averaged features learned by the 3RBeP-PFA
model. We list the top-3 products with higher weights for
each averaged feature.
Id B′1k
F0 1.00
F14 0.37
F12 0.32
F10 0.17
F2 0.16
F1 0.14
F9 0.13
F13 0.05
F6 0.04
F5 0.04
F4 0.04
F15 0.04
F7 0.03
F8 0.03
F11 0.02
F3 0.02
(a) M-F0
Id B′1k
F8 0.69
F11 0.68
F15 0.60
F10 0.59
F7 0.52
F6 0.34
F13 0.32
F4 0.31
F3 0.31
F5 0.14
F1 0.05
F9 0.02
F2 0.01
F14 0.00
F0 0.00
F12 0.00
(b) M-F1
Table 6.8: Averaged meta-features. These
are inferred by applying our S3R-IBP model
to Z as input.
MF-0 MF-1 List of Countries for each activation pattern of the meta-features
1 0
Pakistan, Syria, Chile, Kyrgyzstan, Zimbabwe, Albania, Tanzania, Bahrain, Laos, Botswana, Bolivia,
Bangladesh, Kazakhstan, Senegal, Cuba, Zambia, Namibia, Oman, Turkmenistan, Mongolia, Ethiopia,
Mozambique, Iran, Ghana, Cote d”Ivoire, Papua New Guinea, Saudi Arabia, Yemen, Sudan, Trinidad and
Tobago, Cameroon, Mauritania, Venezuela, Guinea, Azerbaijan, Algeria, Republic of the Congo, Kuwait,
Nigeria, Qatar, Gabon, Libya, Iraq, Angola
1 1
Germany, Italy, United States, Japan, France, China, Austria, Czech Republic, Spain, United Kingdom, Belgium,
Sweden, Netherlands, Switzerland, Poland, Denmark, Portugal, Hong Kong, India, Slovenia, Finland, Hungary,
Thailand, Israel, Turkey, South Korea, Slovakia, Bulgaria, Romania, Croatia, Estonia, Serbia, Canada, Lithuania,
Singapore, Mexico, Panama, Ukraine, Latvia, Malaysia, Brazil, Indonesia, Greece, Bosnia and Herzegovina,
Tunisia, Lebanon, Ireland, Vietnam, Philippines, Argentina, Belarus, Egypt, South Africa, North Korea, New
Zealand, Russia, Uruguay, El Salvador, United Arab Emirates, Norway, Morocco, Sri Lanka, Moldova,
Macedonia, Jordan, Colombia, Australia, Kenya, Mauritius, Peru, Guatemala, Uzbekistan, Dominican Republic,
Paraguay, Madagascar, Costa Rica, Honduras, Georgia, Ecuador, Nicaragua, Cambodia, Burma
Table 6.9: Clustering of countries based on our two-layer 3RBeP-PFA model. We observe a sharp division
of the world in two groups, which aligns with the “quiescence trap” hypothesis [82].
Markovian structure over the dictionary instead of the activation of the features [184]. To run PGDS
on our data, we flatten our X ∈ N ×D × T matrix X into a ND × T matrix. tGaP-PFA is another
Bayesian nonparametric model that learns a smooth underlying parametric function for the activation
probability of the features: for certain timestamps t, some features are “thinned” (de-activated) from
the underlying random measure. This model follows the same spirit as the dependent IBP in [219],
where a Gaussian process (GP) is used to tie the activation of each latent feature over time5. BeP-
PFA refers to the static model described in Section 6.3 using an IBP prior. In this case, we need to
5Inference for the dependent IBP is computationally expensive, and has only been proposed for a Gaussian likelihood.
The tGaP-PFA works for Poisson likelihood.
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Figure 6.3: World heat map according to the presence of features associated with meta feature M-F1.
Darker shade indicates presence of more capabilities that are associated with M-F1. Countries with the lightest
blue shade only have M-F0 capabilities, whereas there is no data for the countries in white shade.
flatten our input data X into a NT × D matrix. The static BeP-PFA model assumes a shared set
of latent features over the years, and independent feature activation vectors for each year, e.g., USA
in 1965 would be counted as a different country from USA in 1986. Both BeP-PFA and dBeP-PFA
assume a bias term (one feature that is active for all countries) to capture global mean effects. For
each model, we ran the MCMC inference procedure during 10.000 iterations for ten different splits
of the data with 90-10% of the observations in the train and test sets.
Metric PGDS tGaP-PFA BeP-PFA dBeP-PFA
Log Perplexity 1.912± 0.002 1.428± 0.001 1.382± 0.003 1.419± 0.005
Coherence - −469.11± 9.562 −506.29± 13.470 −403.70± 31.725
Table 6.10: Quantitative Evaluation of Accuracy and Interpretability for dBeP-PFA. We compare the
following models: PGDS, tGaP-PFA, BeP-PFA and dBeP-PFA in terms of mean and standard error of the test
log-perplexities, and topic coherence.
Table 6.10 shows the averaged test log perplexity for each model. Although BeP-PFA is the best
model in terms of predictive accuracy, both dBeP-PFA and tGaP-PFA present very close predictive
strength. dBeP-PFA is better than BeP-PFA since it imposes more constraints in the solution space
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through the Markovian structure. In terms of topic coherence, dBeP-PFA clearly outperforms all the
other models, which makes it the best choice to perform a data exploratory analysis of this dataset.
Qualitative Evaluation
Table 6.11 shows the list of inferred latent features using the dBeP-PFA. Compared to the static case,
we get less features related to machinery, and more specialized features regarding types of plantations
(coffee and sugar are captured by F12 whereas cotton is accounted for by F15). Similar to the static
scenario, the induced sparsity in matrix B makes each latent feature easy to interpret (for instance,
F1: objects from a hardware store, F2: chemical products, F3: iron processing, etc...).
Id m¯k Top-5 products with highest weights
F0 92 (bias) crude petroleum (0.23), crustaceans (0.18), cereals (0.15), cement (0.14), bones–ivory–horns (0.13)
F1 16.85
light fixtures (0.53), locksmith hardw. (0.46), misc. ceramic ornaments (0.45), bicycles (0.44), misc.
manufactured wood articles (0.42)
F2 15.19
inorganic esters (0.54), transmission belts (0.47), chemical products (0.45), nitrogen compounds (0.42), aldehyde
compounds (0.42), hormones (0.41)
F3 18.36 iron sheets (0.55), iron wire (0.51), thin iron sheets (0.50), metal cables (0.50), uninsulated steel wire (0.49)
F4 16.89
misc. elect. machinery (0.53), typewriters (0.37), misc. office equipment (0.36), cameras (0.36), calculating
machines (0.35)
F5 23.19 soaps (0.53), confectionary sugar (0.44), baked goods (0.42), margarine (0.40), floor polishes (0.35)
F6 18.91
bovine – equine entrails (0.57), bovine meat (0.56), misc. prepared meats (0.51), misc. animal oils (0.48), poultry
meat (0.47)
F7 28.89
knit clothing accessories (0.44), linens (0.41), leather accessor (0.40), textile bags (0.39), unbleached cotton
woven fabrics (0.36)
F8 15.87
glazes (0.57), textiles fabrics for machinery (0.54), mineral wool (0.53), paper office containers (0.51), misc.
mineral materials (0.51)
F9 24.94 misc. vegetables (0.52), grapes and raisins (0.49), misc. fruit (0.48), oranges (0.44), misc. citrus (0.43)
F10 24.77
inorganic bases (0.50), nitrogenous fertilizers (0.44), lubricating petrol. oils (0.40), aluminium (0.34), chemical
elements (0.29)
F11 16.09
imitation jewellery (0.53), embroidery (0.46), synth. precious stones (0.44), textile fabrics clothing accessories
(0.44), eyewear (0.43)
F12 33.64 coffee (0.71), non-coniferous worked wood (0.42), cane sugar (0.41), cocoa beans (0.37), molasses (0.35)
F13 19.40 copper ores (0.43), chemical wood pulp (0.41), misc. non-ferrous ores (0.40), copper (0.37), zinc ore (0.35)
F14 7.00
pepper (0.69), vegetable plaiting materials (0.68), natural rubber (0.66), unwrought tin and allows (0.58), misc.
veg. textile fibres (0.53)
F15 29.94
raw cotton (0.45), cotton linters (0.37), green groundnuts (0.36), misc. animal origin materials (0.34), legumes
(0.34)
Table 6.11: Complete list of latent features found by the dBeP-PFA model. m¯k is the averaged number
of countries having feature k active across timestamps, we list the top-5 products with highest weights Bkd.
Orange color corresponds to the latent features represented in Figure 6.5a.
Temporal dynamics. Figure 6.4 shows the feature activation dynamics for four particular exam-
ples: Chile, Indonesia, Egypt, and United Kingdom. The three first countries were all able to increase
their number of active features over the years, although their dynamics can be attributed to differ-
ent economic factors. The latent features uncover the internal situation of the countries’ economic
system at different timestamps. In particular, Chile’s main strengths rely on natural resources (F9:
140
CHAPTER 6. FLEXIBLE IBP-BASED MODELS FOR INTERNATIONAL TRADE
1965 1975 1985 1995 2005
0
0.5
1
F6
Always active: F9, F13
(a) Chile
1965 1975 1985 1995 2005
0
0.5
1 F1
F4
F7
F10
F13
(b) Indonesia
1965 1975 1985 1995 2005
0
0.5
1
F3
F5
F7
F10
Always active:
F9, F15
(c) Egypt
1965 1975 1985 1995 2005
0
0.5
1
F1
F3
F11
F15
Always active:
F2, F4, F5, F8, F10
(d) United Kingdom
Figure 6.4: Probability of features activation over time using the dynamic dBeP-PFA model. We have
selected four random examples among all countries. We only depict features that are active at some point in
time.
vegetables and fruits, F13: ores, ...) and more recently farming industry (acquisition of F6 in the
90s), whereas the growth of Indonesia is mainly due to acquisition of features related to clothing and
electronic products. Interestingly, Chile is a well known natural resource producer [83], while the
start of Indonesia’s growth coincides with the period when the country opened its economy and got
an influx of foreign direct investments[133].
Egypt is a country that has very unique dynamics, as shown in Figure 6.4c. There is a sudden
fall in the activity of feature F7 (associated to clothing) at the end of the 1970s, after which the
number of active features remained steady at its minimum, until 1985 and the beginning of the
1990s. The 80s correspond to years of political and economic unstability [24]. In that period, the
country lost most of its export RCA. At the beginning of the second growth, which corresponds
to a period of political reforms that made Egypt a more open economy, the country regained the
activity in F7, and gradually incorporated F10 (simple chemicals), F5 (basic manufacturing) and F3
(iron processing). The diffusion after the recovery is in accordance with the conclusions from [88]
where it was discovered that a country’s export basket diffuses over time from only comprising basic
products, such as natural resources and clothing products, to also including technology-driven items.
Finally, United Kingdom (UK) is a developed country which has a diversified export portfolio,
including chemicals (F2, F10), machinery (F4), and manufacturing (F5, F8) among others. Starting
in the 80s, UK loses feature F11 (imitation jewellery, make-up and accessories) and F1 (hardware
store items) as a consequence of the de-industrialisation process and structural unemployment during
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2
2
4
10
5
1
4
4
1.F0
2. F0+F12
3. F0+F12+F7 4. F0+F12+F5
5. F0+F12+F7+F5
(a) Subset of the transition model
Transitions Country Years
1→ 2 Congo 1996-1997
2→ 1 Angola 1976-1977
2→ 3 Colombia 1977-1978
2→ 4 Cote D’Ivoire 1998-1999
2→ 4 Cameroon 1970-1971
2→ 4 Ecuador 1992-1993
2→ 4 Honduras 1998-1999
2→ 5 El Salvador 1985-1986
3→ 2 Cambodia 1996-1997
3→ 5 Costa Rica 1998-1999
4→ 2 Cote D’Ivoire 1983-1984
4→ 2 Cameroon 1975-1976
4→ 2 Honduras 1997-1998
4→ 2 Nicaragua 1982-1983
4→ 5 Honduras 1999-2000
5→ 3 Guatemala 1983-1984
5→ 4 Costa Rica 1999-2000
(b) Transition examples
Figure 6.5: Transition Model induced by dBeP-PFA. (a) Subset of the transition model; the label of each
node corresponds to the set of active features at this state; edges are weighted by the corresponding number of
inferred transition in Z. (b) Transition examples between the nodes depicted in (a).
the Thatcher era [7]. Later in the 2000s, UK also loses F3, corresponding to the delocalization of
iron processing industries.
In addition to monitoring the temporal dynamics of each individual country, it is also interesting
to study the feature transitions globally, as a simple transition model. This is possible given the
discrete nature of the feature weights, as features can be either active or inactive. In fact, Z(t)n• can be
interpreted as the latent state of country n at timestamp t, which indicates the set of features that are
active for country n at time t.
Let G = {M, E} be a hidden network, whereM denotes all possible latent states (all possible
values for vector Z(t)n•) and E refers to all directed edges connecting any two elements belonging to
M (full network). For each country n, the sequence [Z(1)n• ,Z(2)n• , . . . ,Z(T )n• ] corresponds to a certain
path within such network. By monitoring which are the most common nodes and most visited edges
in the network, we can gain new insights on the developing mechanisms of countries.
Figure 6.5a shows a subset of the transition model induced by the dBeP-PFA model, correspond-
ing to the first steps in countries’ development. Node 1 corresponds to the state in which only the bias
term is active (no other capabilities), where 16% of the countries are placed each year on average.
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From that state, the easiest path is to acquire F12 (coffee, sugar and wood plantations), after which
countries might get F7 (basic manufacturing), F5 (clothing) or both. Table 6.5b lists some transition
examples corresponding to that particular sub-network. For instance, Honduras is a country with a
traditional focus on coffee exports. Based on our model, Honduras manages to diversify its export
portfolio by the acquisition of feature F5 and F7 in the 1998-1999 period [25].
6.6 Summary
This chapter presents two extensions of BeP-PFA in order to deal with more flexible structures in
the latent space, including structure sparsity and time-dependency. In the static scenario, we have
combined the beta-stable process with the R-IBP framework for creating a flexible sparse latent
variable prior. We have used this prior together with an additional sparse prior for the weights of
the latent features, giving rise to our 3RBeP-PFA model. Our model is a non-negative sparse latent
variable model particularly suitable for data exploratory analysis of high-dimensional count data,
given its flexibility and interpretability properties. In the time-dependent scenario, we use an mIBP to
extend the BeP-PFA. The resulting dBeP-PFA model assumes Markovian structures in the activation
of the latent features, which can be interpreted as capabilities required for producing products that a
country might acquire or loose over time.
We used these models to explain trade data in a static and time-varying scenarios, e.g., consid-
ering the 1964-2010 temporal span. The obtained factors are compact, easy to interpret and show
that the number of active capabilities is highly correlated with the diversification and the level of
development of an economy. Based on the dynamic approach, we are able to extract a finite state
machine of latent patterns that allow us to understand the typical evolution paths of developing coun-
tries. The presented approaches are general enough to be directly applicable to any other count-data
scenario where data exploration takes precedence over exclusive accuracy, including analysis of gene
expression data, topic modeling, or recommendation systems.
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7
Conclusions
7.1 Summary
In this thesis, we have constructed tailored Bayesian nonparametric (BNP) models specially suitable
for data exploration tasks. We have addressed each new problem from a multidisciplinary point of
view, which has been crucial for an appropriate design of the models and their subsequent validation.
Globally speaking, the contributions of this thesis can be classified in three key aspects:
1. We have improved model interpretability via prior and likelihood design, by including ad-
equate assumptions into the model to better fit reality, using age-gender additive factors in
Chapter 3, treatment-specific latent features in Chapter 4, cancer-specific activation weights in
Chapter 5, or structured sparsity within the solutions in Chapter 6.
2. We have increased model flexibility regarding information sharing across observations by in-
corporating dependency via Gaussian processes (GPs) in Chapter 3, hierarchical model con-
structions of Dirichlet processes (DPs), Bernoulli processes (BePs), or Beta processes (BPs) in
Chapters 3, 4, and 5, as well as Markovian structures in Chapter 6.
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3. We have addressed the issue of result replicability by combining Bayesian models with statis-
tical methods, even in small sample size scenarios. We have incorporated significance assess-
ment and multiple hypothesis testing to our approaches, as described in Chapters 4 and 5. The
idea of running an unsupervised approach to learn an appropriate latent space for the observa-
tions, and then performing statistically significant variable selection for each basis or partition
of this latent space is a powerful and novel approach that could bring new insights in a vast
amount of applications in medicine, pharmacology, biology or sociology.
More precisely, this doctoral thesis brings actual BNP solutions to non-standard applications
in three different scientific fields. Within sport sciences, we have developed the atom-dependent
Dirichlet process (ADDP) model, a dependent infinite mixture model for density estimation that was
applied on marathon running time data, as explained in Chapter 3. By combining a DP with multiple
GPs, we were able to study the impact of age, gender and environment on runner performance [159].
A further analysis based on the hierarchical Dirichlet process (HDP) revealed the most common run-
ning patterns along time for the New York City marathon. A direct application of this work results
in a fair grading system that is able to compare all runners regardless of their gender or age; such
system could be adopted right away in any athletic competition to standardize entry requirements or
to grant appropriate rewards among athletes. We also highlighted the existing link of the proposed
model with the literature of infinite mixture of experts (IMoE), and thus, we reformulated it as a flex-
ible approach to non-linear regression in general settings with heteroscedastic noise, non-Gaussian
likelihoods, or multi-modal distributions.
In the context of cancer research, we have developed BNP approaches with shared and specific
components for biomarker discovery and clinico-genetic association in Chapters 4 and 5 respectively.
These works have brought novel insights on cancer, and shed light on the mechanisms of action of
Codrituzumab, a promising immunotherapy treatment for patients with hepatocellular carcinoma
(HCC). An attractive property of the proposed models refers to their capacity to deal with patient
heterogeneity, which makes it possible to uncover novel information that previous studies were not
able to deliver. The case-control Indian buffet process (C-IBP) or hierarchical Poisson factor analysis
(H-PFA) models can be directly applied to any other clinical trial data or genetic association study,
respectively. Also, in order to facilitate data exploratory analyses of such kind, we have released
open source software, namely the general latent feature model (GLFM) software package that is able
to deal with different types of data jointly, together with noise and missing observations. The code
is user-friendly, fast, and well documented, such that it can be used straightforwardly by researchers
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from other disciplines.
Finally, in the context of international trade, we have proposed two novel doubly-sparse Poisson
factor analysis (PFA) models specially suitable for high-dimensional count data. We have investi-
gated the empirical gain of incorporating enhanced prior distributions over the latent observations. In
the static scenario, by incorporating the stable-BP within the restricted Indian buffet process (R-IBP),
we have allowed for a broader spectrum of sparse solutions that reflect different types of reality. In
the dynamic scenario, we have introduced Markovian dynamics in the activation of the latent features
based on multiple Markov Indian buffet processes (mIBPs). The obtained time-varying features can
be directly interpreted as capabilities necessary for the production of certain products, which coun-
tries might acquire or lose over time. The inclusion of mIBP priors results in much smoother and
robust transitions, opening the door to a better understanding of the available development paths
of countries’ economies over time. The proposed models have allowed us to unfold the productive
structure of countries via the analysis of their export portfolios, and can be directly used for policy
recommendation or future predictions.
Along this thesis, we have developed Markov chain Monte Carlo (MCMC) algorithms based
on Gibbs sampling, Metropolis-Hasting steps, slice sampling, forward-filtering backward-sampling
(FFBS) procedures, and the help of auxiliary variables to handle non-conjugacies arising into the
models. We strongly believe in reproducible research, and thus, code related to most projects has
been made publicly available online,1 including the GLFM toolbox which can be downloaded from
Github.2
7.2 Future Work
Despite their appealing properties, the impact of BNP models has remained limited so far mostly
due to inadequate model assumptions that do not fit reality, or due to unfeasible inference scenarios
(e.g., non-conjugate models, slow mixing, multi-modal settings with prohibitive computational cost).
Replicability guarantees for Bayesian models are lacking to some extent, particularly in more chal-
lenging situations such as very high-dimensional settings and/or small sample size scenarios. Also,
understanding the requirements of a particular application and being able to translate them into ap-
propriate model assumptions remains more of an art than a science, but it is nonetheless unavoidable
in order to get the utmost out of data. If we manage to alleviate such limitations, there is an incredible
1See www.melaniefpradier.work
2https://github.com/ivaleraM/GLFM
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opportunity to boost mankind’s knowledge in most scientific disciplines, by squeezing huge amounts
of available data into more substantial information.
This thesis begets more questions than answers. Our work suggests several paths for further
research, both in the technical and application sides. The future lines of research considered herein
can be classified in the following categories:
• increasing the flexibility of BNP models to handle more general assumptions or types of data
(time-varying streams of data, non-exchangeable observations, complex structures like trees
or graphs, etc). In this regard, deep models are promising to address limited likelihood expres-
sivity [170].
• improving inference methods to either better explore the posterior distribution, or scale infer-
ence in terms of memory and speed, to allow learning in very high-dimensional or large sample
size datasets [11].
• investigating model validation strategies for data exploration tasks and defining appropriate
proxies or metrics to better assess model utility in addition to predictive accuracy [41]. On top
of empirical evidence, further theoretical analyses are imperatively required in the future.
We provide below a concrete list of ideas for future lines of research.
Generalized ADDP model. The ADDP model of Chapter 3 could be generalized in several ways:
• multi-dimensional covariates: we could incorporate an arbitrary number of covariates (na-
tionality, weight, occupation, city, etc), together with an automatic way to select the most
promising characteristics. This could be done by using an automatic relevant discrimination
(ARD) kernel in the GP.
• multi-output scenarios: More output variables could be considered (e.g., intermediate running
times, triathlon metrics, etc.). This extension is challenging due to the curse of dimensional-
ity. Some starting points would be the linear model of coregionalization (LMC) or intrinsic
coregionalization model [23, 8].
• other density estimation applications requiring fairness constraints: the ADDP model could
be directly applied to many other comparative studies, such as salary distribution in male
and female populations across working sectors, or evolution of height and weight in infants
to derive well-calibrated curves for pediatrics. Other applications arise in epidemiological
studies, such as monitoring the distribution of scientific output (e.g., number of citations) with
respect to age, gender, field of research, etc.
148
CHAPTER 7. CONCLUSIONS
Atom-dependent latent feature model. A promising line of research would be to extend the
ADDP model of Chapter 3 to a latent factor scenario, leading to an atom-dependent Indian buffet
process model. Dependency could be introduced by assuming a GP prior over each time-varying
latent feature. This would allow us to capture elements in a video record that move along time, in the
same spirit as in [189]. Inference might suffer from slow mixing, so we might want to consider split
and merge moves or gradient-based strategies, such as Hamiltonian Monte Carlo [45, 217].
Another motivating example arises from the clinical trial for Codrituzumab described in Chap-
ter 4: in that study, patients reached different degrees of drug exposurewn (i.e., this can be interpreted
as how much the drug was “absorbed” by each patient n). It would thus be interesting to incorporate
dependencies in the features based on the reached level of drug exposure, as follows:
xnd ∼ N (Zn•B•d(wn), σ2x), where Bkd(wn) = akdwn + ckd, (7.1)
where the coefficient akd would encode the direction of change for biomarker d and feature k de-
pending on the drug exposure wn. Such model would potentially output stronger statistical findings,
and could be understood as “correcting” for drug exposure as a confounder effect.
Atom-dependency could also be combined with Markovian structures. For instance, the dynamic
Bernoulli process Poisson factor analysis (dBeP-PFA) from Chapter 6 could be improved by addi-
tionally allowing a small variation of the latent features over time. Such time-varying drift of the
capabilities could be interpreted as historical evolution of export strategies or technologies. For in-
stance, a high-tech capability would present increasing weights for laptops and cellphones in the 90s.
In this particular case, we could use the recently introduced Gamma-Poisson auto-regressive chains,
which allow for tractable inference in Gamma-distributed Markov chains [3].
Supervised latent feature model. Concerning the C-IBP or the GLFM described in Chapter 4,
it would be interesting to include some supervised component to guide the data exploration task in
the same spirit as in [163]. Specially in high-dimensional scenarios, there might be multiple local
minima with similar predictive performance, but not all the solutions might be as informative with
respect to some patient metric. As an example, the latent features could be forced to both explain the
observed attributes of patients while being discriminant for progression free survival (PFS).
Efficient approximate inference methods for scalable BNP models. Current BNP models are
limited to a moderate number of observations. Recent advances in both MCMC and variational
inference methods work with subsets of data in each iteration, which allows scaling up the algorithms
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at the expense of a certain accuracy loss in the posterior approximation [11]. A clear promising
research path concerns the implementation of efficient Bayesian nonparametric models for big data
scenarios. Smart data-driven proposals and efficient moves to speed-up mixing will certainly be
needed. BNP models will be much more useful in the future if we manage to develop new inference
methods to explore the posterior distribution more efficiently. This research would benefit healthcare
applications enormously, since it would render the exploration of vast amounts of electronic health
records (EHRs) possible. For example, the considered models in Chapter 5 for genetic association
studies would be most useful if these could scale to the hundreds of thousands of dimensions. We
could envisage a hybrid variational-MCMC inference scheme, or formulate a black-box variational
inference algorithm where non-conjugacy is not problematic anymore [169]. The discrete nature
of all the latent variables renders such task particularly challenging in that application, prone to
be stuck in local minima. Also, in Chapter 6, the proposed FFBS to infer each Markov chain is
relatively slow. Mixing of the MCMC chain could be improved by incorporating a particle Gibbs
with ancestor sampling (PGAS) scheme [119]. A starting point could be the work in [212], where
the authors propose a dynamic latent feature model using PGAS with Gaussian-distributed latent
features. Adapting such model to the Poisson-gamma likelihood-prior case would be useful for data
exploratory analyses in count data (because of the non-negativity of the latent features).
Non-linear BNP models for high-dimensional data. Let us imagine a scenario in which the num-
ber of dimensions D is orders of magnitude bigger than the number of observations N . To analyze
such data, it is a common practice to either select a subset of dimensions, or eventually apply a simple
dimensionality reduction scheme as a pre-processing step. A motivating application lies in the field
of population genetics where we seek to identify main populations of individuals (centro-european,
african, caucasian, etc.) based on vast amounts of genetic variants. A typical scenario would in-
volve thousand of individuals, each of them defined by half a million of genetic variants. Population
structure is a serious problem in genome-wide association study (GWAS) that can lead to high false
discovery rate (FDR) if not modeled properly. In the future, we plan to extend BNP models to an-
alyze data in scenarios where D  N . This could be achieved by combining a standard Chinese
restaurant process (CRP) or Indian buffet process (IBP) with a non-linear Bayesian dimensionality
reduction method such as Gaussian process latent variable model [34]. Such a model would jointly
learn the best dimensionality for the reduced space together with the potentially unbounded number
of clusters or features in such transformed space.
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Nonparametric processes via flexible random measures. Another promising area concerns non-
exchangeable priors for dependent Bayesian nonparametric models [54]. So far in this thesis, de-
pendency has been included in the models via smooth variation of the atom locations in the stick-
breaking representation in Chapter 3, convex combinations of multiple random measures 4, or hi-
erarchical structures (e.g., Chapter 6), but incorporating dependency at the random measure level is
a promising recent area of interest. In fact, novel non-exchangeable BNP models can be obtained
by understanding the fundamental properties of the underlying random measures [106, 105]. New
completely random measure representations and connections might bring light into improved infer-
ence algorithms [146, 118]. Models such as correlated random measures [168] or dependent beta
processes [189] illustrate the potential of this line of research. In particular, it would be interesting
to introduce dependency over the atom weights in the stick breaking representation, leading to a
powerful infinite mixture of GP experts whose weights are input-dependent.
7.3 Discussion
In the last decade, machine learning (ML) systems have become more ubiquitous in complex appli-
cations that directly impacts our everyday life. So far, most of these systems have been evaluated
in terms of accuracy (e.g., maximization of the log likelihood, minimization of a risk or loss func-
tion, etc), but depending on the application at hand, accuracy exclusively might not reflect the actual
needs or desired performance of the system. Given the current predominance of accuracy metrics
for evaluation in the ML community, the risk exists that we might be “optimizing too much for the
wrong things3”.
Nowadays, ML systems are expected not only to have high predictive accuracy, but also to match
important criteria such as safety, fairness, or scientific understanding. However, in contrast to mea-
sures of performance accuracy, these criteria often cannot be completely quantified, and thus rely on
the so-called criterion of interpretability: if the system can explain its reasoning, we then can verify
whether that reasoning is sound with respect to these auxiliary criteria [41]. “Interpret” means to
explain or to present in understandable terms. In the context of ML systems, interpretability refers
to the ability to explain or to present in understandable terms to a human (this can be a patient or
an expert in the field). Actually, the need for interpretable models is urgent: recent European Union
regulation will require algorithms that make decisions based on user-level predictors which “signif-
icantly affect” users to provide explanations by 2018, which is commonly refer to as the “right to
3F. Doshi-Velez in Talks at Google (April 25th, 2017): “Roadmap for the Rigorous Science of Interpretability”.
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explanation” [66].
The following question arises: can interpretability be somehow automatized in ML systems?
Despite the huge need for interpretable models, data exploration remains quicksand land for the ML
community due to a lack of rigorous definitions, evaluation metrics and benchmarks for comparisons.
An effort to formalize model assumptions behind each study is needed if we want to speed up data
exploratory analyses. Also, translating the requirements from the domain knowledge experts into
actual model elements needs special care. Multidisciplinary research efforts will certainly remain
crucial, but if we are able to build an encyclopedia of interpretability requirements and model as-
sumptions, we might be able to identify similar aspects across applications that might help accelerate
and automatize certain types of data exploration.
Current evaluation of interpretability falls in two categories, either application-driven or via a
quantifiable-proxy such as sparsity. In either way, we need to put more attention on which assump-
tions are the most sensitive for each problem at hand, since applications might have different inter-
pretability needs. As stated in [41], the “need for interpretability stems from an incompleteness in the
problem formalization, creating a fundamental barrier to optimization and evaluation.” For exam-
ple, there might be different kinds of sparsity, each of them suitable for a specific kind of application.
Thus, many open questions remain:
• Should a model be sparse in feature weights or sparse in dictionary elements? Should we have
sparsity in input or output dimensions?
• Do all applications have the same interpretability needs?
• Where is the fundamental incompleteness in each particular application?
• How can we incorporate human domain-expert knowledge into the model?
• Is there a trade-off between interpretability and accuracy?
In order to enhance model interpretability, we should encode appropriately our assumptions con-
cerning three aspects: the prior, the generative process (likelihood), and the desired output or sys-
tems’ utility, i.e., in which sense the obtained information will be useful. The assumptions should be
as simple as possible (following Occam’s Razor principle), and be aligned with reality, e.g., predic-
tions should be consistent with data. Given two modelsA andB with similar predictive accuracy, we
should pick up that one with lower entropy (or minimum description length [73]), or that one which
better aligns with expert knowledge. In general, a model will be more interpretable if it contains sim-
ple functional components (for instance, additive effects), a clear dependency graph of the involved
latent variables which might be identified with specific elements from reality, and a meaningful out-
put design, i.e., clear encoding of the type of information that we seek.
152
CHAPTER 7. CONCLUSIONS
Marathon
(Chapter 3)
Clinical Trial
(Chapter 4)
Genetic Associa-
tions (Chapter 5)
International Trade
(Chapter 6)
How to set up the
input (priors)
expert knowledge
(humans cannot run a
marathon in less than 2h)
normalization +
standardized priors
sample hyperparameters + appropriate support
(Poisson for count data)
Assumption
underlying the
generative
process
(likelihood)
assume shared mixture
weights at shifting
locations
learn patient subspace
and additional latent
dimensions linked to
treatment
shared and specific
associations across
cancer types
(hierarchical or
partitioned basis)
flexible sparsity
assumptions on the
latent features
(power-law, restricted,
time-varying)
Output format
(predictive or
marginals)
offsets associated to age,
gender; race-dependent
multiplicative factor
statistical significance, effect size and direction
for each clinico-genetic association or biomarker
sparse latent features,
i.e., list of countries
capabilities
Usability knowledge + athletic fairgrading system
knowledge useful for oncologists and clinicians
to improve diagnosis and personalize treatment
knowledge + policy
recommendations,
future export predictions
Table 7.1: Model design for interpretability. Overview of models’ elements within this thesis having an
impact on interpretability.
Based on these general elements, Table 7.1 gives a final overview of the different mechanisms
that we have used to improve interpretability in each model presented within this thesis. To conclude,
this doctoral thesis is an attempt to advance the research of BNP models for data exploratory tasks. In
the same way that computers have accelerated scientific progress, it is our belief that models for data
exploration which are flexible, interpretable, and robust, might lead to an explosion of life-changing
scientific discoveries.
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8
Inference Details for Poisson Factor
Analysis Models and Extensions
8.1 Poisson Factor Analysis
Poisson factorization models have been successfully applied for recommendation systems [68], topic
modeling [67], and analysis of Electronic Health Records among others [84]. Let X ∈ NN×D be a
sparse matrix of count-data observations with N samples and D dimensions. The generative process
for each single observation xnd in the standard parametric Poisson factor analysis (PFA) is as follows
xnd|θn•,B•d ∼ Poisson(θn•B•d) (8.1)
θnk ∼ Gamma(a, b), Bkd ∼ Gamma(c, d), (8.2)
where θ is an N × K matrix of weights, and B is a K × D matrix of hidden factors (sometimes
called dictionary). A direct non-parametric extension can be obtained by putting a Gamma process
prior over θ [207].
155
CHAPTER 8. INFERENCE DETAILS FOR PFA MODELS AND EXTENSIONS
Inference Algorithm
Direct inference in such models is intractable, but we can easily solve the problem using Markov
chain Monte Carlo (MCMC) techniques. For each observation xnd, we introduce the auxiliary
variables x
′
nd,1, . . . , x
′
nd,K such that xnd =
∑K
k=1 x
′
nd,k, and x
′
nd,k ∼ Poisson(θnkBkd) for k =
1, . . . ,K. Each Poisson count is separated in a sum of Poisson contributions corresponding to each
latent factor. Given such auxiliary variables, the model is conditionally conjugate, and a Gibbs sam-
pler can be derived straightforwardly. In particular, we use the following theorem:
Theorem 1 Let Y1, . . . , Yn be Poisson distributed random variables with rates λ1, . . . , λn respec-
tively. Let us define S =
∑N
n=1 Yn. Then,
{Y1, . . . , Yn}|S ∼ Multinomial
({
λi∑N
n=1 λn
}
i
, S
)
. (8.3)
Using Theorem 1, x
′
nd,• can be sampled from a Multinomial given xnd, θn• and B•d. The
equations for the complete conditional distributions are as follows:
p(θnk|x′n•,k,Bk•) ∝ Gamma
(
a+
D∑
d=1
x
′
nd,k, b+
D∑
d=1
Bkd
)
(8.4)
p(Bkd|x′•d,k,θ•k) ∝ Gamma
(
c+
N∑
n=1
x
′
nd,k, d+
N∑
n=1
θnk
)
(8.5)
p(x
′
nd,•|xnd,θn•,B•d) ∝ Multinomial
({
θniBid∑K
k=1 θnkBkd
}
i
, xnd
)
. (8.6)
Based on the conditional distributions, a variational inference scheme can also be derived, since exact
expectations can be computed in closed-form due to the Poisson-Gamma conjugacy [67].
8.2 Bernoulli Process Poisson Factor Analysis
The generative model for the Bernoulli process Poisson factor analysis (BeP-PFA) is given by:
xnd ∼ Poisson(Zn•B•d) (8.7)
Z ∼ IBP(α) (8.8)
Bkd ∼ Gamma
(
αB,
µB
αB
)
, (8.9)
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where Z is aN×K matrix of binary weights, and B is aK×Dmatrix of non-negative hidden factors.
In the following, we propose two MCMC algorithms: a collapsed Gibbs sampler where matrix B is
marginalized out using a Laplace approximation, and an uncollapsed slice sampler version which
allows for parallel sampling of both the elements in Z and B given the auxiliary variables described
in Section 8.1.
8.2.1 Collapsed Gibbs Sampler
We first propose a collapsed Gibbs sampler where matrix B is marginalized out, and we only need
to sample the elements of matrix Z. We need to compute its posterior distribution:
p(znk|X,Z¬nk) ∝ p(znk|Z¬nk)p(X|Z)
∝ p(znk|Z¬nk)
∫
p(X|Z,B)p(B)dB (8.10)
∝ p(znk|Z¬nk)
D∏
d=1
∫ ( N∏
n=1
p(xnd|Zn•,B•d)
)
p(B•d)dB•d (8.11)
In order to approximate the integral in (8.11), we resort to a Laplace approximation, which
assumes that: ∫
eψ(B•d)dB•d (8.12)
has a peak at a certain value of BMAP•d . The idea is to Taylor-expand the un-normalized log-posterior
of B•d and approximate eψ(B•d) by an unnormalized Gaussian. The integral thus corresponds to the
normalizing constant of this Gaussian, in our case:∫ ( N∏
n=1
p(xnd|Zn•,B•d)
)
p(B•d)dB•d = eψ(B
MAP
•d )
√
(2pi)K
| − ∇∇ψ(BMAP•d )|
(8.13)
Equations to find maximum a posteriori BMAP•d . Let us define ψ(B•d) as the un-normalized
log-posterior of B•d, i.e,
ψ(B•d) =
N∑
n=1
log p(xnd|Zn•,B•d) + log p(B•d) (8.14)
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ψ(B•d) =
N∑
n=1
xnd log(Zn•B•d)−
N∑
n=1
Zn•B•d +
K∑
k=1
(αB − 1) log Bkd − αB
µB
K∑
k=1
Bkd +R
(8.15)
where R = −
N∑
n=1
log xnd!−K
(
αB log
µB
αB
+ log Γ(αB)
)
(8.16)
∇ψ(B•d) =
N∑
n=1
xnd
Zn•
Zn•B•d
−
N∑
Zn• + (αB − 1) 1
B•d
− αB
µB
(8.17)
∇∇ψ(B•d) = −
N∑
n=1
xnd
Zn•ZTn•
(Zn•B•d)2
− (αB − 1
B2•d
)T I (8.18)
In order to find the maximum value BMAP•d , we can use either Newton’s method or gradient
descent. Where applicable, Newton’s method might converge faster towards a local maximum or
minimum than gradient descent. Newton’s method is an iterative method for optimization where
each value B(t)•d at iteration t is computed as:
B
(t)
•d = B
(t−1)
•d + γ[∇∇ψ(B(t−1)•d )]−1∇ψ(B(t−1)•d ) (8.19)
where γ ∈ (0, 1] is the step-size of the algorithm. Note that for the Laplace approximation to work
properly,−∇∇ψ(B•d) should be a positive semi-definite matrix. This is guaranteed only if αB > 1,
so the collapsed Gibbs sampler will only work for shape parameters bigger than one, resulting in
non-sparse B matrices.
8.2.2 Uncollapsed Gibbs Sampler
Inference for the BeP-PFA model can be performed using an uncollapsed Gibbs sampler together
with a slice sampler for semi-ordered stick-breaking representation of the Indian buffet process
(IBP) [202]. For the sake of completeness, the slice sampling procedure for matrix Z is described in
Algorithm 7. Using the auxiliary random variables described in Section 8.1, the complete condition-
als can be easily derived as follows:
p(Bkd|Z•k,x′•d,k) ∝ Gamma
(
c+
N∑
n=1
x
′
nd,k, d+
N∑
n=1
znk
)
(8.20)
p(x
′
nd,•|xnd,B•d) ∝ Multinomial
({
zniBid∑K
k=1 znkBkd
}K
i=1
, xnd
)
(8.21)
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Algorithm 7 Slice sampler for the semi-ordered stick-breaking representation of the IBP [202].
1: Sample auxiliary slice variable s for the creation of new sticks, if s < µ(K?), create new sticks
using adaptive rejection sampling [65], and sample corresponding feature parameters from prior.
2: Sample Z matrix. Given the stick weights, each row can be sampled independently and in
parallel:
p(znk|rest) ∝ µ(k) ·
D∏
p(x
′
nd,k|znk, θnk, Bkd). (8.22)
3: Remove inactive features.
4: Sample sticks
p(µ(k)|rest) ∼ Beta(m•,k, 1 +N −m•,k), (8.23)
where m•,k =
∑N
i=1 znk.
log p(znk = 1|Z¬nk,Bk•, pik) = 1
1 + e−unk
, (8.24)
where unk =
D∑
d=1
xndlog
(∑
j 6=k znjBjd +Bkd∑
j 6=k znjBjd
)
−
D∑
d=1
Bkd + log
pik
1− pik . (8.25)
8.2.3 Variational Inference
Variational inference is a good option to deal with big and high dimensional scenarios, since it can be
scaled up with stochastic extensions, and it has shown good mixing properties in the literature, that
allows for a better exploration of the latent space [42]. For the sake of simplicity, we here consider a
variational approach that uses a finite Beta-Bernoulli approximation to the IBP.
Let X be our observations, and Φ be the set of hidden variables in the model. The idea behind
variational inference is to turn approximate posterior computation into an optimization problem. For
that, we choose an easy to handle variational distribution q(Φ|λ) over the set of latent variables
Φ and optimize its variational free parameters λ to approximate the posterior distribution p(Φ|X).
The objective is to find a variational distribution q∗(·) that minimizes the KL divergence between
both distributions, which is equivalent to maximizing the Evidence Lower Bound (ELBO) over the
marginal likelihood,
q∗(·) = argmaxq∈QE[log p(X,Φ)− log q(Φ|λ)] (8.26)
In our case, we have Φ = {Z,β,θ,pi}. Based on the complete conditional distributions derived
in Section 8.4.1, exact update equations can be derived for pi, θ, and β. In particular,
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Latent Var Type Complete Cond.
Variational
Param
pik Beta
g +
∑N znk;
h+N −∑N znk τ˜k1; τ˜k2
znk Bernoulli 1/
(
1− exp−unk) ν˜nk
θnk Gamma
a+ znk
∑D x′nd,k;
b+ znk
∑D βkd
θ˜shpnk ;
θ˜rtenk
βkd Gamma
c+
∑N znkx′nd,k;
d+
∑N znkθnk
β˜shpkd ;
β˜rtekd
x
′
nd,· Multinomial
log (znkθnkβkd),
0 < k < K
φ˜nd,·
Table 8.1: Summary and notation for the variational inference procedure in the BeP-PFA.
τ˜k1 = g +
N∑
ν˜nk (8.27)
τ˜k2 = h+N −
N∑
ν˜nk (8.28)
θ˜shpnk = a+ ν˜nk
D∑
xndφ˜nd,k (8.29)
θ˜rtenk = b+ ν˜nk
D∑ β˜shpnd
β˜rtend
(8.30)
β˜shpkd = c+
N∑
ν˜nkxndφ˜nd,k (8.31)
β˜rtekd = d+
N∑
ν˜nk
θ˜shpnk
θ˜rtenk
(8.32)
Update equations for Z and x
′
nd,· cannot be derived analytically. Instead, we compute a noisy
gradient step based on a black-box procedure [169].
Black-box Variational Inference
Our objective is find the parameters λ that maximize the ELBO L (λ):
L (λ) = Eq[log p (X,Φ)− log q (Φ|λ)] (8.33)
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The general form for the ELBO derivative with respect to the free parameters λ is given as:
∇λL = Eq[∇λ log q(Φ|λ)
(
log p(X,Φ)− log q(Φ|λ))] (8.34)
Let Φ = {Z,β,θ,pi} be the set of all latent variables in our model, and λ all the free parameters
to characterize the variational distribution q (Φ|λ). The joint distribution is given as:
log p (X,Φ) =
N∑ D∑
log Poisson
(
xnd;
K∑
znkθnkβkd
)
+
K∑ D∑
log Gamma (βkd; aβ, bβ)
+
N∑ K∑
log Bernoulli (znk;pik)
+
N∑ K∑
log Gamma (θnk; aθ, bθ)
+
K∑
log Beta (pik; api, bpi) (8.35)
Using a mean-field approximation, the whole variational distribution q(Φ|λ) factorizes as
log q (Φ|λ) =
N∑ D∑
log Multinomial(x
′
nd,·|xnd, φ˜nd)
+
K∑ D∑
log Gamma(βkd; β˜
shp
kd , β˜
rte
kd )
+
N∑ K∑(
log Gamma(θnk; θ˜
shp
nk , θ˜
rte
nk )
+ log Bernoulli (znk; ν˜nk)
)
+
K∑
log Beta (pik; τ˜k1, τ˜k2) (8.36)
The idea of Black-box Variational Inference is to update each variational free parameter λi fol-
lowing a step in the direction of the noisy gradient of the ELBO,
λ
(t)
i = λ
(t−1)
i + ρt∇λiL(λ) (8.37)
To reduce the variance of the gradient estimator, we perform rao-blackwellization for each vari-
able, as explained in [169]. Each component of the gradient can then be written as
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∇λiL(λ) = Eq
[
∇λi log q(Φi|λi)
(
log p(X,Φi)− log q(Φi|λi)
)]
(8.38)
where Φi is the set of latent variables in the Markov blanket of φi, and φi is the latent variable
whose variational distribution includes λi.
Derivation of noisy gradients
• Equations for φ˜nd,·
log q(x′nd,·|φ˜nd, xnd) =
K∑
x′nd,k log φ˜nd,k + log(xnd!)−
K∑
log(x′nd,k!) (8.39)
∇
φ˜nd,k
log q(x′nd,·|φ˜nd, xnd) =
x
′
nd,k
φ˜nd,k
(8.40)
Technical note: Since φ˜nd,· are the variational parameters of a multinomial distribution, we
need to satisfy
∑K
k=1 φ˜nd,k = 1. For this purpose, we use the softmax function P(x)j =
exj∑K exk to transform the original unconstrained variational parameters. The equations should
be properly modified using the chain rule, as follows:
log q(x′nd,·|φ˜nd, xnd) =
K∑
x′nd,k logP(φ˜nd,k)
+ log(xnd!)−
K∑
log(x′nd,k!) (8.41)
∇
φ˜nd,k
log q(x′nd,·|φ˜nd, xnd) =
−
∑
j 6=k
x
′
nd,j
P(φ˜nd,·)j
eφ˜nd,jeφ˜nd,k
(
∑K
r=1 e
φ˜nd,r)2
+
x
′
nd,k
P(φ˜nd,·)k
eφ˜nd,k
∑K
r=1 e
φ˜nd,r − e2φ˜nd,k
(
∑K
r=1 e
φ˜nd,r)2
(8.42)
Finally, the Markov blanket of each variable x
′
nd,k isM[x
′
nd,k] = {x
′
nd,k,x
′
nd,¬k, zn·,θn·,β·d}
and their corresponding probability distribution is given by
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log p
(M[x′nd,k]) =
log Mult
(
x
′
nd,·|xnd, (zn·  θn·)β·d
)
+
K∑(
log Bernoulli
(
znk|pik
)
+ log Gamma
(
θnk|αθ, µθ
αθ
)
+ log Gamma
(
βkd|αβ, µβ
αβ
))
(8.43)
The gradient coordinates for each free parameter φ˜nd,k is computed by plugging in eq. (8.41), (8.42),
and (8.43) into (8.38).
• Equations for Z:
log q(znk|ν˜nk) = znk log ν˜nk + (1− znk) log(1− ν˜nk) (8.44)
∇ν˜nk log q(znk|ν˜nk) =
znk
ν˜nk
− 1− znk
1− ν˜nk (8.45)
Technical note: ν˜nk is the variational parameter of a Bernoulli distribution, so it should belong
to the interval [0, 1]. We use the sigmoid transformation function F(x) = 1
1+e−x . The new
equations are the following:
log q(znk|ν˜nk) = znk logF(ν˜nk)
+ (1− znk) log
(
1−F(ν˜nk)
)
(8.46)
∇ν˜nk log q(znk|ν˜nk) = F
′
(ν˜nk)
(
znk
F(ν˜nk) −
1− znk
1−F(ν˜nk)
)
(8.47)
where F ′(ν˜nk) = e−x(1+e−x)2 .
The markov blanket for each variable znk is M[znk] = {znk, pik, x′nd,k, θnk, βkd} and their
corresponding probability distribution is given by
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log p
(M[znk]) = log Beta(pik|api, bpi)+ log Bernoulli(znk|pik)
+ log Gamma
(
θnk|αθ, µθ
αθ
)
+
D∑
log Gamma
(
βkd|αβ, µβ
αβ
)
+
D∑
log Poisson
(
x
′
nd,k|znkθnkβkd
)
(8.48)
The gradient estimator is computed by plugging in eqs. (8.46), (8.47), and (8.48) into (8.38).
If we run the algorithm with these equations, all variational parameters for Z might tend to
zero. One explanation for this might be the strong correlation between Z and X
′
. To solve it,
we use the probability of the Markov blanketM[znk] after collapsing the auxiliary variables
X
′
. The new joint probability is
log p
(M[znk]) = log Beta(pik|api, bpi)
+
K∑(
log Bernoulli
(
znk|pik
)
+ log Gamma
(
θnk|αθ, µθ
αθ
))
+
K∑ D∑
log Gamma
(
βkd|αβ, µβ
αβ
)
+
D∑
log Poisson
(
xnd|(zn·  θn·)β·d
)
(8.49)
8.3 Spike and Slab Bernoulli Process Poisson Factor Analysis
To get even sparser topics, we may use a spike and slab prior on each element of B by incorporating
a binary matrix Θd that works as a selection mask on the feature matrix B•d. The generative model
in this case is given by:
xnd ∼ Poisson
(
Zn•
(
Θd B•d
) )
(8.50)
Z ∼ IBP (α) (8.51)
Bkd ∼ Gamma
(
αB,
µB
αB
)
(8.52)
Θ ∼ IBP(αβ, cβ, σβ). (8.53)
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An equivalent formulation can be written as:
xnd ∼ Poisson(Zn•B•d) (8.54)
Z ∼ IBP(α) (8.55)
Bkd|θkd ∼ Gamma
(
αB,
µB
αB
)θkd
+ δ
(1−θkd)
0 (8.56)
Θ ∼ IBP(αβ, cβ, σβ), (8.57)
where Bkd = Bkd · θkd, and Bkd follows a spike and slab distribution where θkd selects between
the Gamma distribution (slab) or a delta probability mass at zero. A third way to write down the
generative model would be as follows:
xnd ∼ Poisson(Zn•B•d) (8.58)
Z ∼ IBP(α) (8.59)
BT•d|Θd ∼ SGP(αB, µB,Θd) (8.60)
Θ ∼ IBP(αβ, cβ, σβ), (8.61)
where each column of matrix B is a draw from a spike and slab Gamma process. Such process is
defined as the multiplication of a Gamma process together with a Bernoulli process. We call such
process IBP compound Gamma process. This approach is very similar in spirit to [13], where they use
a tree-parameter Indian buffet process (3P-IBP) over the feature matrix in a Dirichlet-Multinomial
topic model. We present here its counterpart with a Poisson-Gamma formulation. Regarding infer-
ence, the model is not conjugate anymore because of the spike component in the features, e.g., the
binary matrix Θd. We thus derive a collapsed Gibbs sampler where matrix B is marginalized out1.
8.3.1 Collapsed Gibbs Sampler
Since the spike and slab BeP-PFA is not conjugate anymore, we propose a collapsed Gibbs sampler
where we integrate matrix B and only need to sample the two binary matrices Z and Θ. For that, we
will need to compute the conditional probabilities p(znk|X,Z¬nk,Θ) and p(θkd|X,Θ¬k,d,Z).
1Variational inference in this setting becomes tedious due to the discrete nature of the latent space, resulting in multiple
local minima.
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Sampling elements of Z given Θ
p(znk|X,Z¬nk,Θ) ∝ p(znk|Z¬nk)p(X|Z,Θ)
∝ p(znk|Z¬nk)
∫
p(X|Z,B,Θ)p(B)dB (8.62)
∝ p(znk|Z¬nk)
∫
p(X|Z,β)p(β)dβ (8.63)
∝ p(znk|Z¬nk)
D∏
d=1
∫ ( N∏
n=1
p(xnd|Zn•,βd)
)
p(βd)dβd, (8.64)
where p(znk = 1|Z¬nk) = mkN , mk = |{n | znk = 1}|, and the marginal likelihood p(X|Z,Θ) can
be computed using Laplace approximation, since the function to optimize is always log-concave for
αB > 1. Sparsity in the features is obtained through the binary mask Θ.
In order to sample new features, we follow the approach described in [72]. In particular, there
are an infinite number of remaining columns which contain all zeros. For any particular feature
k > K, the probability of activation of any element is zero. Nonetheless, we can sample the number
of columns that become nonzero, knew, according to
p(knew) ∝ Poisson
(
knew;
α
N
)
p(X|Znew), (8.65)
where Znew is the feature assignment matrix with knew additional columns set to one for observation
n, and zero otherwise. We compute these probabilities for knew = 0, . . . ,Kmax for some Kmax,
normalize and sample from the resulting multinomial.
Sampling elements of Θ given Z
p(θkd|X,Θ¬k,d,Z) ∝ p(θkd|Θ¬kd)p(Xd|Z,Θd)
∝ p(θkd|Θ¬k,d)
∫
p(Xd|Z,βd)p(βd)dβd (8.66)
∝ p(θkd|Θ¬k,d)
∫ ( N∏
n=1
p(xnd|Zn•,βd)
)
p(βd)dβd, (8.67)
where p(θkd = 1|Θ¬kd) = rk−σβD−1+cβ and rk = |{d | θkd = 1}|. Here again, in order to approximate
the marginal likelihood p(Xd|Z,Θd), we resort to Laplace approximation.
Similar as before, we can sample the number of new features knew that should be activated for
observation n as:
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p(knew) ∝ Poisson(knew; ) · p(X|Znew), (8.68)
where  = αβ
Γ(1 + cβ)Γ(D − 1 + cβ + σβ)
Γ(D + cβ)Γ(cβ + σβ)
. (8.69)
8.4 Dynamic Bernoulli Process Poisson Factor Analysis
For the sake of completeness, we state here again the equations describing the dynamic Bernoulli
process Poisson factor analysis (dBeP-PFA) model:
x
(t)
nd ∼ Poisson
(
Z
(t)
n•B•d
)
(8.70)
Z
(•)
n• ∼ mIBP(α) (8.71)
Bkd ∼ Gamma
(
αB,
µB
αB
)
, (8.72)
where the Markov Indian buffet process (mIBP) prior is equivalent to the following parametric con-
struction as K →∞:
ak ∼ Beta( α
K
, 1), (8.73)
bk ∼ Beta(γ, δ), (8.74)
z
(t)
nk |ak, bk ∼ Bernoulli
(
a
1−z(t−1)nk
k b
z
(t−1)
nk
k
)
. (8.75)
The variables αB , hypmuB, α, γ, and δ are the model hyperparameters.
8.4.1 MCMC Inference
The complete conditionals in this case are:
p(Bkd|Z(•)•k , r(•)•d,k) ∝ Gamma
(
αB +
N∑
n=1
T∑
t=1
r
(t)
nd,k,
µB
αB
+
N∑
n=1
T∑
t=1
z
(t)
nk
)
(8.76)
p(r
(t)
nd,.|x(t)nd,Z(t)n•,B•d) ∝ Multinomial
({
z
(t)
ni Bid∑K
k=1 z
(t)
nkBkd
}
i=1,...,K+
, x
(t)
nd
)
(8.77)
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The most challenging part is how to sample p(Z|X,B). For each country n and latent feature k, we
can write:
p(X
(1:t)
n• , z
(t)
nk |−) = p(X(t)n•|z(t)nk ,−) p(X(1:t−1)n• , z(t)nk |−) (8.78)
= p(X
(t)
n•|z(t)nk ,−)
∑
z
(t−1)
nk
p(X
(1:t−1)
n• , z
(t)
nk , z
(t−1)
nk |−) (8.79)
= p(X
(t)
n•|z(t)nk ,−)
∑
z
(t−1)
nk
p(X
(1:t−1)
n• , z
(t−1)
nk |−)p(z(t)nk |z(t−1)nk ). (8.80)
We perform a forward-filtering backward-sampling (FFBS) procedure in order to get samples from
the posterior of the time-dependent matrix Z.
Forward step. First, we compute the forward factors f [z(t)nk ] = p(z
(t)
nk = 1|X(1:t)n• ,Z(t)n,¬k,B) and
(1− f [z(t)nk ]) = p(z(t)nk = 0|X(1:t)n• ,Z(t)n,¬k,B) for each country n and timestep t:
p(z
(t)
nk |X(1:t)n• ,Z(t)n,¬k,B) ∝ p(X(t)n•|Z(t)n•,B)·∑
z
(t−1)
nk
p(z
(t−1)
nk |X(1:t−1)n• ,Z(t)n,¬k)p(z(t)nk |z(t−1)nk ), (8.81)
f [z
(t)
nk ] = p(z
(t)
nk = 1|X(1:t)n• ,Z(t)n,¬k,B) =
1
1 + e−u
(t)
nk
, (8.82)
where u
(t)
nk =
D∑
d=1
x
(t)
nd log
(∑
j 6=k z
(t)
njBjd +Bkd∑
j 6=k z
(t)
njBjd
)
−
D∑
d=1
Bkd
+ log
ak(1− f [z(t−1)nk ]) + bkf [z(t−1)nk ]
(1− ak)(1− f [z(t−1)nk ]) + (1− bk)f [z(t−1)nk ]
, (8.83)
Backward step. Next, we iteratively sample from:
p(z
(t)
nk |z(t+1)nk ,X(1:t)n• ,Z(t)n,¬k,B) ∝ p(z(t)nk |X(1:t)n• ,Z(t)n,¬k,B)p(z(t+1)nk |z(t)nk) (8.84)
168
CHAPTER 8. INFERENCE DETAILS FOR PFA MODELS AND EXTENSIONS
p(z
(t)
nk = 1|z(t+1)nk ,X(1:t)n• ,Z(t)n,¬k,B) =
1
1 + e−g
(t)
nk
, (8.85)
where g
(t)
nk = log
f [z
(t)
nk ]
1− f [z(t)nk ]
+ z
(t+1)
nk log
bk
ak
+ (1− z(t+1)nk ) log
1− bk
1− ak , (8.86)
Finally, we sample the activation probability ak using a slice sampler, and persistence parameter
bk of each transition matrix:
p(ak|−) ∝ p(Z(•)•k |X, µ,a, b) p(ak)
∝
N∏ T∏
∀n,t|z(t−1)nk =0
p(z
(t)
nk |ak) p(ak)
∝ Beta
 N∑ T∑
∀n,t|z(t−1)nk =0
z
(t)
nk , 1 +m
0
k −
N∑ T∑
∀n,t|z(t−1)nk =0
z
(t)
nk
 (8.87)
p(bk|−) ∝ p(Z(•)•k |X, µ,a, b) p(bk)
∝
N∏ T∏
∀n,t|z(t−1)nk =1
p(z
(t)
nk |bk) p(bk)
∝ Beta
γ + N∑ T∑
∀n,t|z(t−1)nk =1
z
(t)
nk , δ +m
1
k −
N∑ T∑
∀n,t|z(t−1)nk =1
z
(t)
nk
 (8.88)
where m0k =
∑N∑T 1{z(t−1)nk = 0} and m1k = 1{∑N∑T z(t−1)nk = 1}.
The stick-breaking representation for the mIBP of [56] turns out to be very useful for inference
purposes, as it allows us to use a combination of slice sampling and dynamic programming. The
corresponding equations are the following:
a1 ∝ Beta(α, 1) (8.89)
p(ak|ak−1) = αa−αk−1aα−1k 1(0 ≤ ak ≤ ak−1) (8.90)
On the other hand, variables bk are all independent of the number of latent features K, and are
obtained as draws from a Beta(γ, δ) distribution. The central idea behind the slice sampler lies on
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introducing an auxiliary slice variable µ with the following distribution:
µ ∼ Uniform(0, min
k:∃t,Z(t)•k=1
ak) (8.91)
If we marginalize out the distribution p(µ,a, b,Z) = p(µ|a,Z)p(a, b,Z) with respect to µ, it is
clear that we recover the original joint distribution p(a, b,Z). However, if we condition on µ, we
get:
p(Z|X, µ,a, b) ∝ p(Z|X,a, b)
1(0 ≤ µ ≤ min
k:∃t,Z(t)•k=1
ak)
min
k:∃t,Z(t)•k=1
ak
(8.92)
which forces all columns of X for which ak < µ to be all zero. Note that there can only be a finite
number of weights ak > µ, such that we only need to sample a finite (bounded) number of columns
of Z.
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